

**On approval of classifications, reference books and nomenclature in the field of digital healthcare**

***Unofficial translation***

Order of the Acting Minister of Healthcare of the Republic of Kazakhstan dated February 4, 2021 № ҚР-ДСМ-14. Registered with the Ministry of Justice of the Republic of Kazakhstan on February 8, 2021 № 22166.

      Unofficial translation

      Footnote. The title is in the wording of the order of the Minister of Healthcare of the Republic of Kazakhstan dated 13.08.2024 № 61 (shall be enforced upon expiry of ten calendar days after the day of its first official publication).

      Pursuant to subparagraph 87) of Article 7 of the Code of the Republic of Kazakhstan “On Public Health and Healthcare System” **I ORDER**:

      Footnote. Preamble as amended by the order of the Minister of Health of the Republic of Kazakhstan dated 29.09.2022 № KR DSM-104 (enacted ten calendar days after the date of its first official publication).

      1. To approve classifications, reference books and nomenclature in the field of digital healthcare in accordance with the Appendix to this order.

      Footnote. Paragraph 1 is in the wording of the order of the Minister of Healthcare of the Republic of Kazakhstan dated 13.08.2024 № 61 (shall be enforced upon expiry of ten calendar days after the day of its first official publication).

      2. Heads of local government bodies for healthcare in regions, cities of national significance and the capital, heads of healthcare organizations of national significance shall ensure the implementation and use of classifications, reference books and nomenclature in the field of digital healthcare.

      Footnote. Paragraph 2 is in the wording of the order of the Minister of Healthcare of the Republic of Kazakhstan dated 13.08.2024 № 61 (shall be enforced upon expiry of ten calendar days after the day of its first official publication).

      3. The Department of Development of Digital Healthcare of the Ministry of Healthcare of the Republic of Kazakhstan shall ensure:

      1) state registration of this order with the Ministry of Justice of the Republic of Kazakhstan;

      2) posting this order on the Internet resource of the Ministry of Healthcare of the Republic of Kazakhstan after its official publication;

      3) within ten working days after the state registration of this order with the Ministry of Justice of the Republic of Kazakhstan, submission of information to the Legal Department of the Ministry of Healthcare of the Republic of Kazakhstan on implementation of measures, set forth in subclauses 1) and 2) of this clause.

      4. Control over execution of this order shall be entrusted to the supervising Vice Minister of Healthcare of the Republic of Kazakhstan.

      5. This order shall be enforced upon expiry of ten calendar days after the date of its first official publication.

|  |
| --- |
| *Acting Minister of Healthcare* |
| *of the Republic of Kazakhstan* | *M. Shoranov* |

      “APPROVED”

Ministry of Labor and Social Protection

of Population of the Republic of Kazakhstan

      “APPROVED”

Ministry of Digital Development,

Innovations and Aerospace Industry

of the Republic of Kazakhstan

|  |  |
| --- | --- |
|  | Appendix to the order  of the Acting Minister of Healthcare  of the Republic of Kazakhstan  dated February 4, 2021 № ҚР-ДСМ-14 |

**Classification, reference books and nomenclature in the field of digital healthcare**

      Footnote. Appendix is in the wording of order of the Minister of Healthcare of the Republic of Kazakhstan dated 13.08.2024 № 61 (shall be enforced upon expiry of ten calendar days after the day of its first official publication).

|  |  |  |  |
| --- | --- | --- | --- |
| Item № | | Code of the object identifier of the reference book | Name of reference books, classifications |
| Administrative reference books | | | |
| 1. | | 1.2.398.7.1.4.2.1.1 | Gender |
| 2. | | 1.2.398.7.1.4.2.1.2 | Race type |
| 3. | | 1.2.398.7.1.4.2.1.3 | Language of communication |
| 4. | | 1.2.398.7.1.4.2.1.4 | City/village resident |
| 5. | | 1.2.398.7.1.4.2.1.5 | Education |
| 6. | | 1.2.398.7.1.4.2.1.6 | Marital status |
| 7. | | 1.2.398.7.1.4.2.1.7 | Disability group |
| 8. | | 1.2.398.7.1.4.2.1.8 | Type of sanatorium organization |
| 9. | | 1.2.398.7.1.4.2.1.9 | Sanatorium profile |
| 10. | | 1.2.398.7.1.4.2.1.10 | Employment of positions |
| 11. | | 1.2.398.7.1.4.2.1.11 | Source of funding |
| 12. | | 1.2.398.7.1.4.2.1.12 | Qualification category |
| 13. | | 1.2.398.7.1.4.2.1.13 | Type of day hospital |
| 14. | | 1.2.398.7.1.4.2.1.14 | Types of mobile units |
| 15. | | 1.2.398.7.1.4.2.1.15 | Place of care provision |
| 16. | | 1.2.398.7.1.4.2.1.16 | Type of medical care |
| 17. | | 1.2.398.7.1.4.2.1.17 | Type of payment |
| 18. | | 1.2.398.7.1.4.2.1.18 | Category of payer in the compulsory social health insurance system |
| 19. | | 1.2.398.7.1.4.2.1.19 | Social status |
| 20. | | 1.2.398.7.1.4.2.1.20 | Type of visit |
| 21. | | 1.2.398.7.1.4.2.1.21 | Outcome of stay |
| 22. | | 1.2.398.7.1.4.2.1.22 | Hospitalized with caregiver |
| 23. | | 1.2.398.7.1.4.2.1.23 | Bed profile |
| 24. | | 1.2.398.7.1.4.2.1.24 | Method of payment for prescription |
| 25. | | 1.2.398.7.1.4.2.1.25 | Type of screening |
| 26. | | 1.2.398.7.1.4.2.1.26 | Place of residence/stay of the person at the time of examination by medical and social expertise |
| 27. | | 1.2.398.7.1.4.2.1.27 | Screening not performed due to |
| 28. | | 1.2.398.7.1.4.2.1.28 | Purpose of referral for medical and social expertise |
| 29. | | 1.2.398.7.1.4.2.1.29 | Status of medical death certificate |
| 30. | | 1.2.398.7.1.4.2.1.30 | Target group of vaccination |
| 31. | | 1.2.398.7.1.4.2.1.31 | Type of vaccination |
| 32. | | 1.2.398.7.1.4.2.1.32 | Reason for placement for dynamic observation |
| 33. | | 1.2.398.7.1.4.2.1.33 | Type of ambulance transport |
| 34. | | 1.2.398.7.1.4.2.1.34 | Profile of ambulance teams |
| 35. | | 1.2.398.7.1.4.2.1.35 | Contingent of children subject to examination |
| 36. | | 1.2.398.7.1.4.2.1.36 | Reasons for non-immunization |
| 37. | | 1.2.398.7.1.4.2.1.37 | Type of hospital |
| 38. | | 1.2.398.7.1.4.2.1.38 | Medical workers |
| 39. | | 1.2.398.7.1.4.2.1.39 | Dispensary group |
| 40. | | 1.2.398.7.1.4.2.1.40 | Dispensary observation group of patients diagnosed with tuberculosis |
| 41. | | 1.2.398.7.1.4.2.1.41 | Dynamic observation group of patients with suspected and confirmed diagnosis of malignant neoplasms |
| 42. | | 1.2.398.7.1.4.2.1.42 | Child health group |
| 43. | | 1.2.398.7.1.4.2.1.43 | Dynamic observation group of women of childbearing age |
| General clinical reference books | | | |
| 44. | | 1.2.398.7.1.4.2.2.1 | Risk of falls |
| 45. | | 1.2.398.7.1.4.2.2.2 | Pain scale |
| 46. | | 1.2.398.7.1.4.2.2.3 | Symptoms of allergic reactions |
| 47. | | 1.2.398.7.1.4.2.2.4 | Regimen |
| 48. | | 1.2.398.7.1.4.2.2.5 | Diet |
| 49. | | 1.2.398.7.1.4.2.2.6 | Severity of the patient's condition |
| 50. | | 1.2.398.7.1.4.2.2.7 | Errors in clinical diagnosis |
| 51. | | 1.2.398.7.1.4.2.2.8 | Reasons for discrepancies in diagnoses |
| 52. | | 1.2.398.7.1.4.2.2.9 | Reason for termination of dynamic observation |
| 53. | | 1.2.398.7.1.4.2.2.10 | Mental mood and emotions |
| 54. | | 1.2.398.7.1.4.2.2.11 | Mental state, thinking, memory, speech |
| 55. | | 1.2.398.7.1.4.2.2.12 | Mental state, somatovegetative disorders |
| 56. | | 1.2.398.7.1.4.2.2.13 | Additional symptoms of mental state |
| 57. | | 1.2.398.7.1.4.2.2.14 | Type of diagnosis |
| 58. | | 1.2.398.7.1.4.2.2.15 | Clinical classification of hearing loss according to the World Health Organization |
| 59. | | 1.2.398.7.1.4.2.2.16 | Type of hearing aid conductivity |
| 60. | | 1.2.398.7.1.4.2.2.17 | Localization of the implanted system |
| 61. | | 1.2.398.7.1.4.2.2.18 | Degree of hearing loss |
| 62. | | 1.2.398.7.1.4.2.2.19 | Result of audiological screening |
| 63. | | 1.2.398.7.1.4.2.2.20 | Character of breathing of a newborn in intensive care |
| 64. | | 1.2.398.7.1.4.2.2.21 | Skin color |
| 65. | | 1.2.398.7.1.4.2.2.22 | Continuous positive pressure ventilation mode |
| 66. | | 1.2.398.7.1.4.2.2.23 | Artificial ventilation |
| 67. | | 1.2.398.7.1.4.2.2.24 | Type of anesthesia |
| 68. | | 1.2.398.7.1.4.2.2.25 | Signs of infectious pathology |
| 69. | | 1.2.398.7.1.4.2.2.26 | Growth centile corridor |
| 70. | | 1.2.398.7.1.4.2.2.27 | Body weight centile corridor |
| 71. | | 1.2.398.7.1.4.2.2.28 | Warning signs during examination of a child in a primary health and social care organization |
| 72. | | 1.2.398.7.1.4.2.2.29 | Assessment of neuropsychic development |
| 73. | | 1.2.398.7.1.4.2.2.30 | Conclusion of a puberty test |
| 74. | | 1.2.398.7.1.4.2.2.31 | Indications for ophthalmological screening of premature infants |
| 75. | | 1.2.398.7.1.4.2.2.32 | Environment in which the organs are placed |
| 76. | | 1.2.398.7.1.4.2.2.33 | Status of newly diagnosed condition |
| 77. | | 1.2.398.7.1.4.2.2.34 | Diagnosis status |
| 78. | | 1.2.398.7.1.4.2.2.35 | Adverse reaction or adverse event |
| 79. | | 1.2.398.7.1.4.2.2.36 | Head and chest volume measurement (children under 3 years) |
| 80. | | 1.2.398.7.1.4.2.2.37 | Assessment of psychophysical development according to scales of neuropsychic development of children |
| 81. | | 1.2.398.7.1.4.2.2.38 | Type of diagnosis |
| 82. | | 1.2.398.7.1.4.2.2.39 | Nature of diagnosis |
| 83. | | 1.2.398.7.1.4.2.2.40 | Type of injury |
| 84. | | 1.2.398.7.1.4.2.2.41 | Purpose of hospitalization |
| 85. | | 1.2.398.7.1.4.2.2.42 | Treatment outcome |
| 86. | | 1.2.398.7.1.4.2.2.43 | Circumstances of the woman's death |
| 87. | | 1.2.398.7.1.4.2.2.44 | Place of death |
| 88. | | 1.2.398.7.1.4.2.2.45 | Patient management conditions |
| 89. | | 1.2.398.7.1.4.2.2.46 | Basis for declaring death |
| 90. | | 1.2.398.7.1.4.2.2.47 | Richmond agitation-sedation scale |
| 91. | | 1.2.398.7.1.4.2.2.48 | X-ray examination |
| 92. | | 1.2.398.7.1.4.2.2.49 | Ultrasound examination |
| 93. | | 1.2.398.7.1.4.2.2.50 | Triage (sorting) |
| 94. | | 1.2.398.7.1.4.2.2.51 | Emergency (hospitalizations, operations, type of examination order) |
| 95. | | 1.2.398.7.1.4.2.2.52 | Frequency (hospitalizations, examinations, transfusions) |
| 96. | | 1.2.398.7.1.4.2.2.53 | Type of hospital transportation |
| 97. | | 1.2.398.7.1.4.2.2.54 | Type of endoscopic examinations |
| 98. | | 1.2.398.7.1.4.2.2.55 | Risk factors for acute cerebrovascular accident |
| 99. | | 1.2.398.7.1.4.2.2.56 | Rankine scale |
| 100. | | 1.2.398.7.1.4.2.2.57 | Reason for contacting a primary health care organization |
| 101. | | 1.2.398.7.1.4.2.2.58 | Pre-hospital primary health care for a patient |
| Reference books of phthisiology service | | | |
| 102. | | 1.2.398.7.1.4.2.3.1 | Method of detecting tuberculosis |
| 103. | | 1.2.398.7.1.4.2.3.2 | Contingent for phthisiatric service |
| 104. | | 1.2.398.7.1.4.2.3.3 | Type of phthisiatric contingent |
| 105. | | 1.2.398.7.1.4.2.3.4 | Type of phthisiatric patient |
| 106. | | 1.2.398.7.1.4.2.3.5 | Reasons for removing a phthisiatric patient from dispensary registration |
| 107. | | 1.2.398.7.1.4.2.3.6 | Reasons for removing a TB patient with active bacterial excretion from the register |
| 108. | | 1.2.398.7.1.4.2.3.7 | Treatment outcomes of a TB patient |
| 109. | | 1.2.398.7.1.4.2.3.8 | Improvement of a TB patient |
| 110. | | 1.2.398.7.1.4.2.3.9 | Risk factors for tuberculosis |
| 111. | | 1.2.398.7.1.4.2.3.10 | Localization of tuberculosis |
| 112. | | 1.2.398.7.1.4.2.3.11 | Presence of drug resistance to anti-TB drugs |
| 113. | | 1.2.398.7.1.4.2.3.12 | Method of diagnostics of drug resistance |
| 114. | | 1.2.398.7.1.4.2.3.13 | Result of drug susceptibility test |
| 115. | | 1.2.398.7.1.4.2.3.14 | Anti-TB drugs |
| 116. | | 1.2.398.7.1.4.2.3.15 | Category of TB patient |
| 117. | | 1.2.398.7.1.4.2.3.16 | Purpose of examination of a phthisiological patient |
| 118. | | 1.2.398.7.1.4.2.3.17 | Course of treatment |
| 119. | | 1.2.398.7.1.4.2.3.18 | Group of focus |
| 120. | | 1.2.398.7.1.4.2.3.19 | Reason for removal from the group of focus |
| Transfusion care reference books | | | |
| 121. | | 1.2.398.7.1.4.2.4.1 | The purpose of issuing a blood product |
| 122. | | 1.2.398.7.1.4.2.4.2 | The reason for the write-off of the blood product |
| 123. | | 1.2.398.7.1.4.2.4.3 | Method of disposal of blood product |
| 124. | | 1.2.398.7.1.4.2.4.4 | The outcome of the transfusion |
| 125. | | 1.2.398.7.1.4.2.4.5 | Blood type |
| 126. | | 1.2.398.7.1.4.2.4.6 | The Rh factor |
| 127. | | 1.2.398.7.1.4.2.4.7 | Transfusion tactics |
| 128. | | 1.2.398.7.1.4.2.4.8 | Indications for individual selection of blood cells |
| 129. | | 1.2.398.7.1.4.2.4.9 | Blood transfusion rate |
| 130. | | 1.2.398.7.1.4.2.4.10 | Transfusion history |
| 131. | | 1.2.398.7.1.4.2.4.11 | Obstetric history before transfusion |
| 132. | | 1.2.398.7.1.4.2.4.12 | The presence of irregular immune anti-erythrocyte antibodies |
| 133. | | 1.2.398.7.1.4.2.4.13 | Indications for the use of blood and its components |
| 134. | | 1.2.398.7.1.4.2.4.14 | Clinical signs of deficiency of blood coagulation cells/factors |
| 135. | | 1.2.398.7.1.4.2.4.15 | Status of transfusion therapy |
| 136. | | 1.2.398.7.1.4.2.4.16 | Adverse effects of blood transfusion and its components |
| 137. | | 1.2.398.7.1.4.2.4.17 | The method of laboratory testing for individual compatibility |
| 138. | | 1.2.398.7.1.4.2.4.18 | The result and interpretation of the laboratory test for individual compatibility |
| 139. | | 1.2.398.7.1.4.2.4.19 | Measures for the treatment of the adverse effects of transfusion |
| 140. | | 1.2.398.7.1.4.2.4.20 | Transfusion media |
| 141. | | 1.2.398.7.1.4.2.4.21 | Blood and its components for transfusion |
| 142. | | 1.2.398.7.1.4.2.4.22 | Laboratory indicators confirming the deficiency of cells/coagulation factors |
| Pregnancy and Childbirth reference books | | | |
| 143. | | 1.2.398.7.1.4.2.5.1 | Level of delivery |
| 144. | | 1.2.398.7.1.4.2.5.2 | Place of delivery |
| 145. | | 1.2.398.7.1.4.2.5.3 | Position of the fetus |
| 146. | | 1.2.398.7.1.4.2.5.4 | Position and type of the fetus |
| 147. | | 1.2.398.7.1.4.2.5.5 | Presenting part of the fetus |
| 148. | | 1.2.398.7.1.4.2.5.6 | Labor activity |
| 149. | | 1.2.398.7.1.4.2.5.7 | Labor period |
| 150. | | 1.2.398.7.1.4.2.5.8 | Criterion of live birth |
| 151. | | 1.2.398.7.1.4.2.5.9 | Assessment according to the Apgar scale |
| 152. | | 1.2.398.7.1.4.2.5.10 | The child was born |
| 153. | | 1.2.398.7.1.4.2.5.11 | Information about the timing of delivery |
| 154. | | 1.2.398.7.1.4.2.5.12 | Pregnancy outcome |
| 155. | | 1.2.398.7.1.4.2.5.13 | Delivery accepted |
| 156. | | 1.2.398.7.1.4.2.5.14 | Gestational age at first visit to the obstetrician (midwife) |
| 157. | | 1.2.398.7.1.4.2.5.15 | Nature of amniotic fluid |
| 158. | | 1.2.398.7.1.4.2.5.16 | Stillbirth |
| 159. | | 1.2.398.7.1.4.2.5.17 | Type of contraception |
| Laboratory service reference books | | | |
| 160. | | 1.2.398.7.1.4.2.6.1 | Type of biomaterial |
| 161. | | 1.2.398.7.1.4.2.6.2 | Urine color |
| 162. | | 1.2.398.7.1.4.2.6.3 | People tested for human immunodeficiency virus |
| 163. | | 1.2.398.7.1.4.2.6.4 | Active substance (allergens) |
| 164. | | 1.2.398.7.1.4.2.6.5 | Food and household allergens |
| 165. | | 1.2.398.7.1.4.2.6.6 | Type of laboratory tests |
| Medicinal reference books | | | |
| 166. | | 1.2.398.7.1.4.2.7.1 | Route of administration |
| 167. | | 1.2.398.7.1.4.2.7.2 | Frequency of administration |
| 168. | | 1.2.398.7.1.4.2.7.3 | List of diseases against which the vaccine is used |
| Dialysis service reference books | | | |
| 169. | | 1.2.398.7.1.4.2.8.1 | Dialyzer capacity |
| 170. | | 1.2.398.7.1.4.2.8.2 | Ultrafiltration profile (hemodialysis) |
| 171. | | 1.2.398.7.1.4.2.8.3 | Vascular access (hemodialysis) |
| 172. | | 1.2.398.7.1.4.2.8.4 | Renal replacement therapy method |
| 173. | | 1.2.398.7.1.4.2.8.5 | Plasma replacement solution |
| 174. | | 1.2.398.7.1.4.2.8.6 | Peritoneal dialysis program |
| 175. | | 1.2.398.7.1.4.2.8.7 | Anticoagulation during the procedure |
| 176. | | 1.2.398.7.1.4.2.8.8 | Transfusion frequency |
| 177. | | 1.2.398.7.1.4.2.8.9 | Procedures for renal replacement therapy |
| 178. | | 1.2.398.7.1.4.2.8.10 | Sorbent |
| 179. | | 1.2.398.7.1.4.2.8.11 | Technical complications of dialysis |
| 180. | | 1.2.398.7.1.4.2.8.12 | Clinical complications of dialysis |
| 181. | | 1.2.398.7.1.4.2.8.13 | Hemodialysis method |
| 182. | | 1.2.398.7.1.4.2.8.14 | Peritoneal equilibrium test, solution |
| Reference books used in providing surgical care | | | |
| 183. | | 1.2.398.7.1.4.2.9.1 | Type of surgery |
| 184. | | 1.2.398.7.1.4.2.9.2 | Post-surgery regimen, chemotherapy, etc. |
| 185. | | 1.2.398.7.1.4.2.9.3 | Surgery outcome |
| 186. | | 1.2.398.7.1.4.2.9.4 | Post-surgery instructions |
| Reference books of ambulance and air ambulance services | | | |
| 187. | | 1.2.398.7.1.4.2.10.1 | Fracture shape |
| 188. | | 1.2.398.7.1.4.2.10.2 | Direction of fracture lines |
| 189. | | 1.2.398.7.1.4.2.10.3 | Form of damage |
| 190. | | 1.2.398.7.1.4.2.10.4 | Direction of physical damage |
| 191. | | 1.2.398.7.1.4.2.10.5 | Condition of the bottom or covering crust |
| 192. | | 1.2.398.7.1.4.2.10.6 | Features of the surrounding soft tissues |
| 193. | | 1.2.398.7.1.4.2.10.7 | Color of the bruise |
| 194. | | 1.2.398.7.1.4.2.10.8 | Shape and size of the wound with gaping and convergence of the edges |
| 195. | | 1.2.398.7.1.4.2.10.9 | Features of the edges of the wound |
| 196. | | 1.2.398.7.1.4.2.10.10 | Relief of the walls bevel of the wound |
| 197. | | 1.2.398.7.1.4.2.10.11 | Features of the wound bottom |
| 198. | | 1.2.398.7.1.4.2.10.12 | Features of hair damage in the wound area |
| 199. | | 1.2.398.7.1.4.2.10.13 | Features of the microrelief on the plane of the cut, incision, sawing of cartilage, bone |
| 200. | | 1.2.398.7.1.4.2.10.14 | Behavior |
| 201. | | 1.2.398.7.1.4.2.10.15 | Reason for calling an ambulance team |
| 202. | | 1.2.398.7.1.4.2.10.16 | Category of the ambulance call |
| 203. | | 1.2.398.7.1.4.2.10.17 | Orientation in space |
| 204. | | 1.2.398.7.1.4.2.10.18 | Result of the ambulance call |
| 205. | | 1.2.398.7.1.4.2.10.19 | Pulse |
| 206. | | 1.2.398.7.1.4.2.10.20 | Chest excursion |
| 207. | | 1.2.398.7.1.4.2.10.21 | Percussion sound |
| 208. | | 1.2.398.7.1.4.2.10.22 | Breathing auscultative |
| 209. | | 1.2.398.7.1.4.2.10.23 | Wheezing |
| 210. | | 1.2.398.7.1.4.2.10.24 | Shortness of breath |
|  | 211. | 1.2.398.7.1.4.2.10.25 | Meningeal symptoms |
|  | 212. | 1.2.398.7.1.4.2.10.26 | Eyeballs |
|  | 213. | 1.2.398.7.1.4.2.10.27 | Maxillo-cerebral nerves |
|  | 214. | 1.2.398.7.1.4.2.10.28 | Tendon reflexes |
|  | 215. | 1.2.398.7.1.4.2.10.29 | Motor sphere |
|  | 216. | 1.2.398.7.1.4.2.10.30 | Pain sensitivity |
|  | 217. | 1.2.398.7.1.4.2.10.31 | Aphasia |
|  | 218. | 1.2.398.7.1.4.2.10.32 | Babinski's symptom |
|  | 219. | 1.2.398.7.1.4.2.10.33 | Oppenheim's symptom |
|  | 220. | 1.2.398.7.1.4.2.10.34 | Pharynx |
|  | 221. | 1.2.398.7.1.4.2.10.35 | Tonsils |
|  | 222. | 1.2.398.7.1.4.2.10.36 | Tongue |
|  | 223. | 1.2.398.7.1.4.2.10.37 | Abdomen condition |
|  | 224. | 1.2.398.7.1.4.2.10.38 | Density of parenchymatous organs |
|  | 225. | 1.2.398.7.1.4.2.10.39 | Urination |
|  | 226. | 1.2.398.7.1.4.2.10.40 | Abdomen shape |
|  | 227. | 1.2.398.7.1.4.2.10.41 | Uterine tone |
|  | 228. | 1.2.398.7.1.4.2.10.42 | Peripheral edema |
|  | 229. | 1.2.398.7.1.4.2.10.43 | Menstrual cycle |
|  | 230. | 1.2.398.7.1.4.2.10.44 | Body type |
|  | 231. | 1.2.398.7.1.4.2.10.45 | Consciousness |
|  | 232. | 1.2.398.7.1.4.2.10.46 | Glasgow scale |
|  | 233. | 1.2.398.7.1.4.2.10.47 | Pupils |
|  | 234. | 1.2.398.7.1.4.2.10.48 | Reaction to light |
|  | 235. | 1.2.398.7.1.4.2.10.49 | Heart sounds |
|  | 236. | 1.2.398.7.1.4.2.10.50 | Heart murmurs |
|  | Reference books of the rehabilitation service | | |
|  | 237. | 1.2.398.7.1.4.2.11.1 | Rehabilitation route scale |
|  | 238. | 1.2.398.7.1.4.2.11.2 | Rehabilitation potential assessment scale |
|  | 239. | 1.2.398.7.1.4.2.11.3 | Rehabilitation stage |
|  | 240. | 1.2.398.7.1.4.2.11.4 | Rehabilitation plan |
|  | 241. | 1.2.398.7.1.4.2.11.5 | Patient rehabilitation profile |
|  | 242. | 1.2.398.7.1.4.2.11.6 | Efficiency of medical rehabilitation |
|  | 243. | 1.2.398.7.1.4.2.11.7 | Achieving the rehabilitation goal of the current treatment |
|  | 244. | 1.2.398.7.1.4.2.11.8 | Rehabilitation prognosis |
|  | 245. | 1.2.398.7.1.4.2.11.9 | Level of rehabilitation |
|  | 246. | 1.2.398.7.1.4.2.11.10 | Type of rehabilitation |
|  | 247. | 1.2.398.7.1.4.2.11.11 | Evaluation of the results of medical rehabilitation |
|  | 248. | 1.2.398.7.1.4.2.11.12 | Rehabilitation potential |
|  | Reference books of cancer service | | |
|  | 249. | 1.2.398.7.1.4.2.12.1 | Method of detecting malignant neoplasms |
|  | 250. | 1.2.398.7.1.4.2.12.2 | Oncology stage |
|  | 251. | 1.2.398.7.1.4.2.12.3 | Special treatment methods |
|  | Classification in the field of digital healthcare | | |
|  | 252. | 1.2.398.7.1.4.3.1 | Classification of body parts |

**Reference books in the field of digital healthcare Administrative reference books**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| № s/n | Code of object identifier of the reference book | Name of the reference book | Code of object identifier of the reference book value | Contents |
| 1. | 1.2.398.7.1.4.2.1.1 | Gender | 1.2.398.7.1.4.2.1.1.1 | Male |
| 1.2.398.7.1.4.2.1.1.2 | Female |
| 2. | 1.2.398.7.1.4.2.1.2 | Race type | 1.2.398.7.1.4.2.1.2.1 | Caucasian |
| 1.2.398.7.1.4.2.1.2.2 | Negroid |
| 1.2.398.7.1.4.2.1.2.3 | Mongoloid |
| 3. | 1.2.398.7.1.4.2.1.3 | Language of communication | 1.2.398.7.1.4.2.1.3.1 | Kazakh |
| 1.2.398.7.1.4.2.1.3.2 | Russian |
| 1.2.398.7.1.4.2.1.3.3 | English |
| 4. | 1.2.398.7.1.4.2.1.4 | City/village resident | 1.2.398.7.1.4.2.1.4.1 | Urban |
| 1.2.398.7.1.4.2.1.4.2 | Rural |
| 5. | 1.2.398.7.1.4.2.1.5 | Education | 1.2.398.7.1.4.2.1.5.1 | Not available |
| 1.2.398.7.1.4.2.1.5.2 | Primary |
| 1.2.398.7.1.4.2.1.5.3 | Basic secondary |
| 1.2.398.7.1.4.2.1.5.4 | General secondary |
| 1.2.398.7.1.4.2.1.5.5 | Secondary special |
| 1.2.398.7.1.4.2.1.5.6 | Incomplete higher |
| 1.2.398.7.1.4.2.1.5.7 | Higher |
| 1.2.398.7.1.4.2.1.5.8 | Unknown |
| 6. | 1.2.398.7.1.4.2.1.6 | Marital status | 1.2.398.7.1.4.2.1.6.1 | Never been married |
| 1.2.398.7.1.4.2.1.6.2 | Married |
| 1.2.398.7.1.4.2.1.6.3 | Widow/Widower |
| 1.2.398.7.1.4.2.1.6.4 | Divorced |
| 1.2.398.7.1.4.2.1.6.5 | Unknown |
| 7. | 1.2.398.7.1.4.2.1.7 | Disability group | 1.2.398.7.1.4.2.1.7.1 | First group of disability |
| 1.2.398.7.1.4.2.1.7.2 | Second group of disability |
| 1.2.398.7.1.4.2.1.7.3 | Third group of disability |
| 1.2.398.7.1.4.2.1.7.4 | Child with disability (0-7 years) |
| 1.2.398.7.1.4.2.1.7.5 | Child with first group of disability (7-18 years) |
| 1.2.398.7.1.4.2.1.7.6 | Child with second group of disability (7-18 years) |
| 1.2.398.7.1.4.2.1.7.7 | Child with third group of disability (7-18 years) |
| 8. | 1.2.398.7.1.4.2.1.8 | Type of sanatorium organization | 1.2.398.7.1.4.2.1.8.1 | Sanatorium group |
| 1.2.398.7.1.4.2.1.8.2 | Sanatorium kindergarten |
| 1.2.398.7.1.4.2.1.8.3 | Sanatorium boarding school |
| 1.2.398.7.1.4.2.1.8.4 | Tuberculosis sanatorium |
| 9. | 1.2.398.7.1.4.2.1.9 | Profile of the sanatorium | 1.2.398.7.1.4.2.1.9.1 | Sanatoriums for adults |
| 1.2.398.7.1.4.2.1.9.2 | Sanatoriums for children |
| 1.2.398.7.1.4.2.1.9.3 | For patients with tuberculosis (for adults) |
| 1.2.398.7.1.4.2.1.9.4 | For patients with tuberculosis (for children) |
| 1.2.398.7.1.4.2.1.9.5 | For patients with bone tuberculosis (for adults) |
| 1.2.398.7.1.4.2.1.9.6 | For patients with bone tuberculosis (for children) |
| 1.2.398.7.1.4.2.1.9.7 | With diseases of the respiratory system |
| 1.2.398.7.1.4.2.1.9.8 | With diseases of the digestive system |
| 1.2.398.7.1.4.2.1.9.9 | With diseases of the musculoskeletal system |
| 1.2.398.7.1.4.2.1.9.10 | With diseases of the nervous system and cerebral palsy |
| 1.2.398.7.1.4.2.1.9.11 | With diseases of the genitourinary organs |
| 1.2.398.7.1.4.2.1.9.12 | Others |
| 10. | 1.2.398.7.1.4.2.1.10 | Positions occupied | 1.2.398.7.1.4.2.1.10.1 | Full-time |
| 1.2.398.7.1.4.2.1.10.2 | Employed |
| 1.2.398.7.1.4.2.1.10.3 | Individuals, key workers in occupied positions |
| 1.2.398.7.1.4.2.1.10.4 | Vacant |
| 11. | 1.2.398.7.1.4.2.1.11 | Source of funding | 1.2.398.7.1.4.2.1.11.1 | Paid |
| 1.2.398.7.1.4.2.1.11.2 | Guaranteed volume of free medical care |
| 1.2.398.7.1.4.2.1.11.3 | Compulsory social health insurance |
| 12. | 1.2.398.7.1.4.2.1.12 | Qualification category | 1.2.398.7.1.4.2.1.12.1 | Higher |
| 1.2.398.7.1.4.2.1.12.2 | First |
| 1.2.398.7.1.4.2.1.12.3 | Second |
| 1.2.398.7.1.4.2.1.12.4 | Without a category |
| 13. | 1.2.398.7.1.4.2.1.13 | Type of day hospital | 1.2.398.7.1.4.2.1.13.1 | Day hospital at organizations providing outpatient care (independent and part of) |
| 1.2.398.7.1.4.2.1.13.2 | Day hospital in organizations providing inpatient care |
| 1.2.398.7.1.4.2.1.13.3 | Day hospital at home |
| 14. | 1.2.398.7.1.4.2.1.14 | Types of mobile units | 1.2.398.7.1.4.2.1.14.1 | Mobile medical complexes |
| 1.2.398.7.1.4.2.1.14.2 | Dental installations |
| 1.2.398.7.1.4.2.1.14.3 | Fluorographic installations |
| 1.2.398.7.1.4.2.1.14.4 | Clinical and diagnostic laboratories |
| 15. | 1.2.398.7.1.4.2.1.15 | Place of assistance | 1.2.398.7.1.4.2.1.15.1 | In a healthcare organization |
| 1.2.398.7.1.4.2.1.15.2 | At home |
| 1.2.398.7.1.4.2.1.15.3 | Others |
| 16. | 1.2.398.7.1.4.2.1.16 | Type of assistance | 1.2.398.7.1.4.2.1.16.1 | Consultations |
| 1.2.398.7.1.4.2.1.16.2 | Operations |
| 1.2.398.7.1.4.2.1.16.3 | Researches |
| 1.2.398.7.1.4.2.1.16.4 | Procedures and manipulations |
| 17. | 1.2.398.7.1.4.2.1.17 | Payment type | 1.2.398.7.1.4.2.1.17.1 | Payment by clinical cost group |
| 1.2.398.7.1.4.2.1.17.2 | Payment by bed-days |
| 1.2.398.7.1.4.2.1.17.3 | Payment by cases |
| 1.2.398.7.1.4.2.1.17.4 | Payment by actual costs |
| 1.2.398.7.1.4.2.1.17.5 | Payment by medical-economic tariff |
| 1.2.398.7.1.4.2.1.17.6 | Payment according to per capita standards |
| 1.2.398.7.1.4.2.1.17.7 | Payment according to complex tariffs |
| 1.2.398.7.1.4.2.1.17.8 | Payment for the departure of mobile teams |
| 1.2.398.7.1.4.2.1.17.9 | Payment for the services of mobile medical complexes per person based on a medical train |
| 1.2.398.7.1.4.2.1.17.10 | Payment for consultative and diagnostic services |
| 1.2.398.7.1.4.2.1.17.11 | Payment for blood component testing and tissue immunotyping services (HLA testing) |
| 1.2.398.7.1.4.2.1.17.12 | Payment for reference testing in the blood service |
| 1.2.398.7.1.4.2.1.17.13 | Payment for the isolation of hematopoietic stem cells from placental blood |
| 1.2.398.7.1.4.2.1.17.14 | Payment for the production of donor blood components |
| 1.2.398.7.1.4.2.1.17.15 | Payment according to tariffs for the service rendered |
| 18. | 1.2.398.7.1.4.2.1.18 | Payer category in the compulsory social health insurance system | 1.2.398.7.1.4.2.1.18.1 | Preferential |
| 1.2.398.7.1.4.2.1.18.2 | Employee |
| 1.2.398.7.1.4.2.1.18.3 | Payer of a single aggregate payment |
| 1.2.398.7.1.4.2.1.18.4 | Individual entrepreneur/private entrepreneur (individual entrepreneur or person engaged in private practice) |
| 1.2.398.7.1.4.2.1.18.5 | Independent payer |
| 1.2.398.7.1.4.2.1.18.6 | Civil law contract (individuals receiving incomes under contracts). |
| 19. | 1.2.398.7.1.4.2.1.19 | Social status | 1.2.398.7.1.4.2.1.19.1 | Children up to and including 18 years of age |
| 1.2.398.7.1.4.2.1.19.2 | Persons registered as unemployed |
| 1.2.398.7.1.4.2.1.19.3 | Unemployed pregnant women |
| 1.2.398.7.1.4.2.1.19.4 | Unemployed person (one of the child's legal representatives) bringing up a child (children) until he (they) reaches the age of three years, with the exception of persons on leave in connection with pregnancy and childbirth, adoption of a newborn child (children), for caring for a child (children) until he (they) reaches the age of three years |
| 1.2.398.7.1.4.2.1.19.5 | Persons on maternity leave, adoption of a newborn child (children), or child care leave until the child (children) reaches the age of three |
| 1.2.398.7.1.4.2.1.19.6 | Non-working persons caring for a child with a disability |
| 1.2.398.7.1.4.2.1.19.7 | Non-working persons caring for a person with a first-group disability |
| 1.2.398.7.1.4.2.1.19.8 | Recipients of pension payments, including veterans of the Great Patriotic War |
| 1.2.398.7.1.4.2.1.19.9 | Persons serving a sentence under a court sentence in institutions of the penal system (except for minimum security institutions) |
| 1.2.398.7.1.4.2.1.19.10 | Persons held in pre-trial detention centres, as well as unemployed persons to whom a preventive measure in the form of house arrest has been applied |
| 1.2.398.7.1.4.2.1.19.11 | Unemployed fellow countrymen |
| 1.2.398.7.1.4.2.1.19.12 | Mothers of many children, awarded with the pendants "Altyn alka", "Kumis alka" or previously received the title "Mother Heroine", as well as awarded with the orders "Maternal Glory" of the 1st and 2nd degrees |
| 1.2.398.7.1.4.2.1.19.13 | Persons with disabilities |
| 1.2.398.7.1.4.2.1.19.14 | Persons studying full-time in secondary, technical and vocational, post-secondary, higher education institutions, as well as postgraduate education institutions |
| 1.2.398.7.1.4.2.1.19.15 | Non-working recipients of state targeted social assistance |
| 20. | 1.2.398.7.1.4.2.1.20 | Type of treatment | 1.2.398.7.1.4.2.1.20.1 | Ambulance |
| 1.2.398.7.1.4.2.1.20.2 | Self-referral |
| 1.2.398.7.1.4.2.1.20.3 | By referral |
| 1.2.398.7.1.4.2.1.20.4 | Other |
| 21. | 1.2.398.7.1.4.2.1.21 | Outcome of stay | 1.2.398.7.1.4.2.1.21.1 | Discharged |
| 1.2.398.7.1.4.2.1.21.2 | Death |
| 1.2.398.7.1.4.2.1.21.3 | Transferred to another healthcare organization |
| 1.2.398.7.1.4.2.1.21.4 | Written refusal of treatment |
| 1.2.398.7.1.4.2.1.21.5 | Violation of internal regulations |
| 22. | 1.2.398.7.1.4.2.1.22 | Hospitalized with caregiver | 1.2.398.7.1.4.2.1.22.1 | Without accompanying person |
| 1.2.398.7.1.4.2.1.22.2 | With accompanying person |
| 1.2.398.7.1.4.2.1.22.3 | With nursing mother of a child under 1 year of age |
| 23. | 1.2.398.7.1.4.2.1.23 | Bed profile | 1.2.398.7.1.4.2.1.23.1 | General |
| 1.2.398.7.1.4.2.1.23.2 | Therapeutic |
| 1.2.398.7.1.4.2.1.23.3 | Surgical |
| 1.2.398.7.1.4.2.1.23.4 | Pediatric |
| 1.2.398.7.1.4.2.1.23.5 | Obstetrics and Gynecology |
| 1.2.398.7.1.4.2.1.23.6 | Cardiology for adults |
| 1.2.398.7.1.4.2.1.23.7 | Cardiology for children |
| 1.2.398.7.1.4.2.1.23.8 | Gastroenterology for adults |
| 1.2.398.7.1.4.2.1.23.9 | Gastroenterology for children |
| 1.2.398.7.1.4.2.1.23.10 | Allergological for adults |
| 1.2.398.7.1.4.2.1.23.11 | Allergological for children |
| 1.2.398.7.1.4.2.1.23.12 | Endocrinological for adults |
| 1.2.398.7.1.4.2.1.23.13 | Endocrinological for children |
| 1.2.398.7.1.4.2.1.23.14 | Infectious for adults |
| 1.2.398.7.1.4.2.1.23.15 | Infectious for children |
| 1.2.398.7.1.4.2.1.23.16 | Hematological for adults |
| 1.2.398.7.1.4.2.1.23.17 | Hematological for children |
| 1.2.398.7.1.4.2.1.23.18 | Nephrological for adults |
| 1.2.398.7.1.4.2.1.23.19 | Nephrological for children |
| 1.2.398.7.1.4.2.1.23.20 | Surgical for adults |
| 1.2.398.7.1.4.2.1.23.21 | Surgical for children |
| 1.2.398.7.1.4.2.1.23.22 | Neurosurgery for adults |
| 1.2.398.7.1.4.2.1.23.23 | Neurosurgery for children |
| 1.2.398.7.1.4.2.1.23.24 | Thoracic surgery for adults |
| 1.2.398.7.1.4.2.1.23.25 | Thoracic surgery for children |
| 1.2.398.7.1.4.2.1.23.26 | Traumatology for adults |
| 1.2.398.7.1.4.2.1.23.27 | Traumatology for children |
| 1.2.398.7.1.4.2.1.23.28 | Orthopedic for adults |
| 1.2.398.7.1.4.2.1.23.29 | Orthopedic for children |
| 1.2.398.7.1.4.2.1.23.30 | Urological for adults |
| 1.2.398.7.1.4.2.1.23.31 | Urological for children |
| 1.2.398.7.1.4.2.1.23.32 | Dental for adults |
| 1.2.398.7.1.4.2.1.23.33 | Dental for children |
| 1.2.398.7.1.4.2.1.23.34 | Oncological for adults |
| 1.2.398.7.1.4.2.1.23.35 | Oncological for children |
| 1.2.398.7.1.4.2.1.23.36 | For pregnant women and women in labor (except for pregnancy pathology) |
| 1.2.398.7.1.4.2.1.23.37 | Pregnancy pathology |
| 1.2.398.7.1.4.2.1.23.38 | Gynecological for adults, including for abortions |
| 1.2.398.7.1.4.2.1.23.39 | Gynecological for children, including for abortions |
| 1.2.398.7.1.4.2.1.23.40 | Tuberculosis for patients with drug-resistant tuberculosis |
| 1.2.398.7.1.4.2.1.23.41 | Tuberculosis for adult patients with extrapulmonary, including osteoarticular, tuberculosis |
| 1.2.398.7.1.4.2.1.23.42 | For compulsory treatment of tuberculosis patients |
| 1.2.398.7.1.4.2.1.23.43 | Tuberculosis for children |
| 1.2.398.7.1.4.2.1.23.44 | Tuberculosis for sick children with extrapulmonary, including osteoarticular, tuberculosis |
| 1.2.398.7.1.4.2.1.23.45 | Neurological for adults |
| 1.2.398.7.1.4.2.1.23.46 | Neurological for children |
| 1.2.398.7.1.4.2.1.23.47 | Psychiatric (psychoneurological) for adults |
| 1.2.398.7.1.4.2.1.23.48 | Psychiatric (psychoneurological) for children |
| 1.2.398.7.1.4.2.1.23.49 | Psychosomatic |
| 1.2.398.7.1.4.2.1.23.50 | Narcological for adults |
| 1.2.398.7.1.4.2.1.23.51 | For those involved in work at industrial enterprises, construction, agriculture |
| 1.2.398.7.1.4.2.1.23.52 | For compulsory treatment of patients with severe concomitant diseases |
| 1.2.398.7.1.4.2.1.23.53 | Ophthalmological for adults |
| 1.2.398.7.1.4.2.1.23.54 | Ophthalmological for children |
| 1.2.398.7.1.4.2.1.23.55 | Otolaryngological for adults |
| 1.2.398.7.1.4.2.1.23.56 | Otolaryngological for children |
| 1.2.398.7.1.4.2.1.23.57 | Dermatovenereological for adults |
| 1.2.398.7.1.4.2.1.23.58 | Dermatovenereological for children |
| 1.2.398.7.1.4.2.1.23.59 | Radiological |
| 1.2.398.7.1.4.2.1.23.60 | Pathology of newborns and nursing of premature babies |
| 1.2.398.7.1.4.2.1.23.61 | For infants |
| 1.2.398.7.1.4.2.1.23.62 | Proctological |
| 1.2.398.7.1.4.2.1.23.63 | Rheumatology for adults |
| 1.2.398.7.1.4.2.1.23.64 | Rheumatology for children |
| 1.2.398.7.1.4.2.1.23.65 | Purulent surgical for adults |
| 1.2.398.7.1.4.2.1.23.66 | Purulent surgical for children |
| 1.2.398.7.1.4.2.1.23.67 | Pulmonology for adults |
| 1.2.398.7.1.4.2.1.23.68 | Pulmonology for children |
| 1.2.398.7.1.4.2.1.23.69 | Other for adults |
| 1.2.398.7.1.4.2.1.23.70 | Other for children |
| 1.2.398.7.1.4.2.1.23.71 | Intensive care cardiac surgery for adults |
| 1.2.398.7.1.4.2.1.23.72 | Vascular surgery |
| 1.2.398.7.1.4.2.1.23.73 | Burn (combustological) for adults |
| 1.2.398.7.1.4.2.1.23.74 | Toxicological for adults |
| 1.2.398.7.1.4.2.1.23.75 | Sanatorium |
| 1.2.398.7.1.4.2.1.23.76 | Maxillofacial surgery for adults |
| 1.2.398.7.1.4.2.1.23.77 | Day hospital bed |
| 1.2.398.7.1.4.2.1.23.78 | Hemodialysis |
| 1.2.398.7.1.4.2.1.23.79 | Reception and diagnostic |
| 1.2.398.7.1.4.2.1.23.80 | Regional chemotherapy department |
| 1.2.398.7.1.4.2.1.23.81 | Infarction |
| 1.2.398.7.1.4.2.1.23.82 | Neurovascular |
| 1.2.398.7.1.4.2.1.23.83 | Cerebral palsy |
| 1.2.398.7.1.4.2.1.23.84 | Chemo-radiation |
| 1.2.398.7.1.4.2.1.23.85 | Chemotherapy |
| 1.2.398.7.1.4.2.1.23.86 | Tuberculosis |
| 1.2.398.7.1.4.2.1.23.87 | Hospice |
| 1.2.398.7.1.4.2.1.23.88 | Occupational pathology quota |
| 1.2.398.7.1.4.2.1.23.89 | Mammology |
| 1.2.398.7.1.4.2.1.23.90 | Specialized treatment and prevention department |
| 1.2.398.7.1.4.2.1.23.91 | Burn (cambustiology) for children |
| 1.2.398.7.1.4.2.1.23.92 | Resuscitation for children |
| 1.2.398.7.1.4.2.1.23.93 | Rehabilitation and medical rehabilitation for adults |
| 1.2.398.7.1.4.2.1.23.94 | Rehabilitation and medical rehabilitation for children |
| 1.2.398.7.1.4.2.1.23.95 | Rehabilitation and medical rehabilitation, cardiology for adults |
| 1.2.398.7.1.4.2.1.23.96 | Rehabilitation and medical rehabilitation, cardiology for children |
| 1.2.398.7.1.4.2.1.23.97 | Rehabilitation and medical rehabilitation, cardiac surgery for adults |
| 1.2.398.7.1.4.2.1.23.98 | Rehabilitation and medical rehabilitation, cardiac surgery for children |
| 1.2.398.7.1.4.2.1.23.99 | Rehabilitation and medical rehabilitation, neurological for adults |
| 1.2.398.7.1.4.2.1.23.100 | Rehabilitation and medical rehabilitation, neurological for children |
| 1.2.398.7.1.4.2.1.23.101 | Rehabilitation and medical rehabilitation, neurosurgical for adults |
| 1.2.398.7.1.4.2.1.23.102 | Rehabilitation and medical rehabilitation, neurosurgical for children |
| 1.2.398.7.1.4.2.1.23.103 | Rehabilitation and medical rehabilitation, traumatological for adults |
| 1.2.398.7.1.4.2.1.23.104 | Rehabilitation and medical rehabilitation, traumatological for children |
| 1.2.398.7.1.4.2.1.23.105 | Rehabilitation and medical rehabilitation, orthopedic for adults |
| 1.2.398.7.1.4.2.1.23.106 | Rehabilitation and medical rehabilitation, orthopedic for children |
| 1.2.398.7.1.4.2.1.23.107 | Rehabilitation and medical rehabilitation, general |
| 1.2.398.7.1.4.2.1.23.108 | Rehabilitation and medical rehabilitation, endocrinological for children |
| 1.2.398.7.1.4.2.1.23.109 | Cardiac surgery for children |
| 1.2.398.7.1.4.2.1.23.110 | Gynecological for children, including for abortions |
| 1.2.398.7.1.4.2.1.23.111 | Tuberculosis for adults, for compulsory treatment of patients with tuberculosis |
| 1.2.398.7.1.4.2.1.23.112 | Tuberculosis for adults, for patients with drug-resistant tuberculosis |
| 1.2.398.7.1.4.2.1.23.113 | Psychotherapeutic for children |
| 1.2.398.7.1.4.2.1.23.114 | Narcological for children |
| 1.2.398.7.1.4.2.1.23.115 | Toxicological for children |
| 1.2.398.7.1.4.2.1.23.116 | Maxillofacial surgery (dental) for children |
| 1.2.398.7.1.4.2.1.23.117 | Transplantology for adults |
| 1.2.398.7.1.4.2.1.23.118 | Transplantology for children |
| 1.2.398.7.1.4.2.1.23.119 | Serological |
| 1.2.398.7.1.4.2.1.23.120 | Diagnostic (emergency room) for adults |
| 1.2.398.7.1.4.2.1.23.121 | Diagnostic (emergency room) for children |
| 1.2.398.7.1.4.2.1.23.122 | Intensive care for adults |
| 1.2.398.7.1.4.2.1.23.123 | Intensive care for children |
| 1.2.398.7.1.4.2.1.23.124 | Nursing |
| 1.2.398.7.1.4.2.1.23.125 | Palliative care |
| 1.2.398.7.1.4.2.1.23.126 | Surgical for newborns |
| 1.2.398.7.1.4.2.1.23.127 | Maxillofacial surgery (dental) for adults |
| 1.2.398.7.1.4.2.1.23.128 | For nursing with nutrition |
| 1.2.398.7.1.4.2.1.23.129 | For nursing without nutrition |
| 1.2.398.7.1.4.2.1.23.130 | Tuberculosis surgical |
| 1.2.398.7.1.4.2.1.23.131 | Psychotherapeutic for adults |
| 1.2.398.7.1.4.2.1.23.132 | Narcological for compulsory treatment |
| 1.2.398.7.1.4.2.1.23.133 | Stroke |
| 1.2.398.7.1.4.2.1.23.134 | Coronavirus infection, infectious |
| 1.2.398.7.1.4.2.1.23.135 | Coronavirus infection, provisional |
| 1.2.398.7.1.4.2.1.23.136 | Coronavirus infection, quarantine |
| 1.2.398.7.1.4.2.1.23.137 | Palliative care |
| 1.2.398.7.1.4.2.1.23.138 | Coronavirus infection, infectious (reserve) |
| 1.2.398.7.1.4.2.1.23.139 | For restorative treatment and medical rehabilitation, pulmonary for adults |
| 1.2.398.7.1.4.2.1.23.140 | For restorative treatment and medical rehabilitation, pulmonary for children |
| 24. | 1.2.398.7.1.4.2.1.24 | Method of payment for the prescription | 1.2.398.7.1.4.2.1.24.1 | Paid |
| 1.2.398.7.1.4.2.1.24.2 | Free |
| 25. | 1.2.398.7.1.4.2.1.25 | Type of screening | 1.2.398.7.1.4.2.1.25.1 | Prenatal |
| 1.2.398.7.1.4.2.1.25.2 | Neonatal;  audiological screening of young children |
| 1.2.398.7.1.4.2.1.25.3 | Screening of psychophysical development of young children |
| 1.2.398.7.1.4.2.1.25.4 | Ophthalmological screening of premature newborns |
| 1.2.398.7.1.4.2.1.25.5 | For early detection of arterial hypertension, ischemic heart disease, diabetes mellitus, glaucoma and behavioral risk factors |
| 1.2.398.7.1.4.2.1.25.6 | For early detection of cervical cancer |
| 1.2.398.7.1.4.2.1.25.7 | For early detection of breast cancer |
| 1.2.398.7.1.4.2.1.25.8 | For early detection of colorectal cancer |
| 1.2.398.7.1.4.2.1.25.9 | For early detection of viral hepatitis B and C (2 stages) |
| 1.2.398.7.1.4.2.1.25.10 | For early detection of viral hepatitis B and C (1 stage) |
| 1.2.398.7.1.4.2.1.25.11 | For early detection of behavioral risk factors, arterial hypertension,  ischemic heart disease (for rural population) |
| 1.2.398.7.1.4.2.1.25.12 | For early detection of diabetes mellitus (for rural population) |
| 1.2.398.7.1.4.2.1.25.13 | For early detection of glaucoma (for rural population) |
| 1.2.398.7.1.4.2.1.25.14 | For early detection of gastrointestinal diseases (for rural population) |
| 1.2.398.7.1.4.2.1.25.15 | For early detection of chronic kidney diseases (for rural population) |
| 1.2.398.7.1.4.2.1.25.16 | For early detection of respiratory diseases (for rural population) |
| 1.2.398.7.1.4.2.1.25.17 | For early detection of prostate cancer (for rural population) |
| 26. | 1.2.398.7.1.4.2.1.26 | The place of residence/stay of the person at the time of the medical and social examination | 1.2.398.7.1.4.2.1.26.1 | In a children's home, boarding school, specialized organizations for children |
| 1.2.398.7.1.4.2.1.26.2 | In medical and social institutions (organizations) of social protection |
| 1.2.398.7.1.4.2.1.26.3 | In institutions of the penal (penitentiary) system |
| 1.2.398.7.1.4.2.1.26.4 | At home |
| 1.2.398.7.1.4.2.1.26.5 | In a hospital |
| 1.2.398.7.1.4.2.1.26.6 | In absentia |
| 27. | 1.2.398.7.1.4.2.1.27 | Screening was not performed due to | 1.2.398.7.1.4.2.1.27.1 | Completion of screening |
| 1.2.398.7.1.4.2.1.27.2 | Refusal at the patient's request |
| 1.2.398.7.1.4.2.1.27.3 | Refusal by indications |
| 1.2.398.7.1.4.2.1.27.4 | Expiration of the term |
| 1.2.398.7.1.4.2.1.27.5 | Patient's death |
| 1.2.398.7.1.4.2.1.27.6 | Erroneous opening of screening |
| 1.2.398.7.1.4.2.1.27.7 | Patient's re-attachment |
| 1.2.398.7.1.4.2.1.27.8 | Other |
| 28. | 1.2.398.7.1.4.2.1.28 | Purpose of referral for medical and social examination | 1.2.398.7.1.4.2.1.28.1 | Disability determination |
| 1.2.398.7.1.4.2.1.28.2 | Re-examination |
| 1.2.398.7.1.4.2.1.28.3 | Early re-examination |
| 1.2.398.7.1.4.2.1.28.4 | Determination of the degree of loss of general working capacity, primary |
| 1.2.398.7.1.4.2.1.28.5 | Determination of the degree of loss of general working capacity, repeated |
| 1.2.398.7.1.4.2.1.28.6 | Determination of the degree of loss of professional working capacity, primary |
| 1.2.398.7.1.4.2.1.28.7 | Determination of the degree of loss of professional ability to work, repeatedly |
| 1.2.398.7.1.4.2.1.28.8 | Causes of disability |
| 1.2.398.7.1.4.2.1.28.9 | Formation or correction of an individual rehabilitation plan |
| 1.2.398.7.1.4.2.1.28.10 | Need to issue a conclusion on the need of the injured worker for additional types of assistance and care |
| 29. | 1.2.398.7.1.4.2.1.29 | The status of the medical death certificate | 1.2.398.7.1.4.2.1.29.1 | Preliminary |
| 1.2.398.7.1.4.2.1.29.2 | Final |
| 1.2.398.7.1.4.2.1.29.3 | Instead of the preliminary |
| 1.2.398.7.1.4.2.1.29.4 | Instead of the final one |
| 30. | 1.2.398.7.1.4.2.1.30 | Vaccination target group | 1.2.398.7.1.4.2.1.30.1 | Persons by age in accordance with the established deadlines for mandatory preventive vaccinations |
| 1.2.398.7.1.4.2.1.30.2 | The population living and working in natural foci of infectious diseases (spring-summer tick-borne encephalitis, anthrax, tularemia, plague) |
| 1.2.398.7.1.4.2.1.30.3 | Persons belonging to risk groups due to their professional activities |
| 1.2.398.7.1.4.2.1.30.3.1 | healthcare workers (viral hepatitis B, flu) |
| 1.2.398.7.1.4.2.1.30.3.2 | workers in sewerage and treatment facilities (typhoid fever) |
| 1.2.398.7.1.4.2.1.30.4 | Persons belonging to risk groups due to their health status: |
| 1.2.398.7.1.4.2.1.30.4.1 | received blood transfusions (viral hepatitis B) |
| 1.2.398.7.1.4.2.1.30.4.2 | children registered with a medical organization (flu) |
| 1.2.398.7.1.4.2.1.30.4.3 | persons who have been bitten or licked by any animal (rabies) |
| 1.2.398.7.1.4.2.1.30.4.4 | persons who have received injuries or wounds with damage to the integrity of the skin and mucous membranes (tetanus) |
| 1.2.398.7.1.4.2.1.30.4.5 | persons who have a high risk of infection according to epidemiological indications (viral hepatitis A, influenza, measles, rubella, mumps, coronavirus infection) |
| 31. | 1.2.398.7.1.4.2.1.31 | Type of vaccination | 1.2.398.7.1.4.2.1.31.1 | Vaccination |
| 1.2.398.7.1.4.2.1.31.2 | Revaccination |
| 1.2.398.7.1.4.2.1.31.3 | Mantoux test |
| 32. | 1.2.398.7.1.4.2.1.32 | Reason for placement under dynamic observation | 1.2.398.7.1.4.2.1.32.1 | Conclusion of a primary health care physician |
| 1.2.398.7.1.4.2.1.32.2 | Advisory opinion of a specialized specialist |
| 1.2.398.7.1.4.2.1.32.3 | Extract from the medical record of an inpatient |
| 33. | 1.2.398.7.1.4.2.1.33 | Type of ambulance transport | 1.2.398.7.1.4.2.1.33.1 | Airplanes |
| 1.2.398.7.1.4.2.1.33.2 | Helicopters |
| 1.2.398.7.1.4.2.1.33.3 | Ambulance transport |
| 1.2.398.7.1.4.2.1.33.4 | Mobile medical complexes |
| 1.2.398.7.1.4.2.1.33.5 | Treatment and diagnostic trains |
| 34. | 1.2.398.7.1.4.2.1.34 | Profile of ambulance teams | 1.2.398.7.1.4.2.1.34.1 | General medical |
| 1.2.398.7.1.4.2.1.34.2 | General medical, for providing medical care to children |
| 1.2.398.7.1.4.2.1.34.3 | Paramedic |
| 1.2.398.7.1.4.2.1.34.4 | Specialized |
| 1.2.398.7.1.4.2.1.34.5 | Specialized, cardioreanimation |
| 1.2.398.7.1.4.2.1.34.6 | Specialized, intensive care |
| 1.2.398.7.1.4.2.1.34.7 | Others |
| 35. | 1.2.398.7.1.4.2.1.35 | Contingent of children subject to examination | 1.2.398.7.1.4.2.1.35.1 | Up to and including 14 years of age |
| 1.2.398.7.1.4.2.1.35.2 | Preschool age |
| 1.2.398.7.1.4.2.1.35.3 | Schoolchildren (0-9 grades) |
| 1.2.398.7.1.4.2.1.35.4 | Passed screening examinations up to 3 years |
| 1.2.398.7.1.4.2.1.35.5 | Sent for psycho-medical-pedagogical correction |
| 1.2.398.7.1.4.2.1.35.6 | Children transferred for observation to the adolescent office |
| 36. | 1.2.398.7.1.4.2.1.36 | Reasons for non-immunization | 1.2.398.7.1.4.2.1.36.1 | Temporary contraindications |
| 1.2.398.7.1.4.2.1.36.2 | Permanent contraindications |
| 1.2.398.7.1.4.2.1.36.3 | Due to the fault of health workers |
| 1.2.398.7.1.4.2.1.36.4 | Lack of vaccine |
| 1.2.398.7.1.4.2.1.36.5 | Refusal of vaccinations |
| 37. | 1.2.398.7.1.4.2.1.37 | Type of hospital | 1.2.398.7.1.4.2.1.37.1 | Day hospitals (departments, wards) in organizations providing inpatient care |
| 1.2.398.7.1.4.2.1.37.2 | Day hospitals in organizations providing outpatient care |
| 1.2.398.7.1.4.2.1.37.3 | Home hospitals |
| 1.2.398.7.1.4.2.1.37.4 | 24-hour hospital |
| 38. | 1.2.398.7.1.4.2.1.38 | Medical workers | 1.2.398.7.1.4.2.1.38.1 | Doctors |
| 1.2.398.7.1.4.2.1.38.2 | Nursing specialists with higher education |
| 1.2.398.7.1.4.2.1.38.3 | Medical workers |
| 1.2.398.7.1.4.2.1.38.4 | Specialists with higher pharmaceutical education |
| 1.2.398.7.1.4.2.1.38.5 | Specialists with secondary pharmaceutical education |
| 39. | 1.2.398.7.1.4.2.1.39 | Outpatient group | 1.2.398.7.1.4.2.1.39.1 | D-I healthy - individuals who do not present any complaints and who have no chronic diseases or dysfunctions of individual organs or systems in their medical history or during examination; these include individuals with so-called "borderline" conditions who require observation (individuals who have minor deviations from the established normal limits in blood pressure values ​​and other physiological characteristics that do not affect the functional activity of the body). |
| 1.2.398.7.1.4.2.1.39.2 | D-II practically healthy - persons with a history of acute and chronic disease without exacerbations over the past several years |
| 1.2.398.7.1.4.2.1.39.3 | D-III patients - persons in need of treatment |
| 40. | 1.2.398.7.1.4.2.1.40 | Group of dispensary observation of patients diagnosed with tuberculosis | 1.2.398.7.1.4.2.1.40.1 | 0 |
| 1.2.398.7.1.4.2.1.40.2 | IА |
| 1.2.398.7.1.4.2.1.40.3 | IВ |
| 1.2.398.7.1.4.2.1.40.4 | IГ |
| 1.2.398.7.1.4.2.1.40.5 | II |
| 1.2.398.7.1.4.2.1.40.6 | IIIА |
| 1.2.398.7.1.4.2.1.40.7 | IIIБ |
| 1.2.398.7.1.4.2.1.40.8 | IIIВ |
| 41. | 1.2.398.7.1.4.2.1.41 | Dynamic observation group of patients with suspected and confirmed diagnosis of malignant neoplasms | 1.2.398.7.1.4.2.1.41.1 | Group Ia – patients with disease suspected of being malignant |
| 1.2.398.7.1.4.2.1.41.2 | Group Ib – patients with precancerous diseases |
| 1.2.398.7.1.4.2.1.41.3 | Group II – patients with malignant neoplasms subject to special treatment (surgery, chemotherapy, radiation therapy, immune cell therapy) |
| 1.2.398.7.1.4.2.1.41.4 | Group IIa – patients with early forms of malignant neoplasms subject to radical treatment |
| 1.2.398.7.1.4.2.1.41.5 | Group III – patients after radical treatment of malignant tumors (practically healthy individuals) |
| 1.2.398.7.1.4.2.1.41.6 | Group IV – patients with widespread forms of malignant neoplasms subject to palliative or symptomatic treatment |
| 42. | 1.2.398.7.1.4.2.1.42 | Child health group | 1.2.398.7.1.4.2.1.42.1 | 1 |
| 1.2.398.7.1.4.2.1.42.2 | 2 |
| 1.2.398.7.1.4.2.1.42.3 | 3 |
| 1.2.398.7.1.4.2.1.42.4 | 4 |
| 1.2.398.7.1.4.2.1.42.5 | 5 |
| 43. | 1.2.398.7.1.4.2.1.43 | Dynamic observation group for women of childbearing age | 1.2.398.7.1.4.2.1.43.1 | Healthy women |
| 1.2.398.7.1.4.2.1.43.2 | With extragenital pathology |
| 1.2.398.7.1.4.2.1.43.3 | With gynecological pathology |
| 1.2.398.7.1.4.2.1.43.4 | With extragenital and gynecological pathology |
| 1.2.398.7.1.4.2.1.43.5 | Social risk group |

**General clinical reference books**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| № s/n | Object identifier code of the reference book | Name of the reference book | Object identifier code of the reference book | Contents |
| 1. | 1.2.398.7.1.4.2.2.1 | Fall risk | 1.2.398.7.1.4.2.2.1.1 | No risk (Morse) |
| 1.2.398.7.1.4.2.2.1.2 | Low risk |
| 1.2.398.7.1.4.2.2.1.3 | High risk |
| 2. | 1.2.398.7.1.4.2.2.2 | Pain scale | 1.2.398.7.1.4.2.2.2.1 | No pain |
| 1.2.398.7.1.4.2.2.2.2 | Mild pain |
| 1.2.398.7.1.4.2.2.2.3 | Moderate pain |
| 1.2.398.7.1.4.2.2.2.4 | Severe pain |
| 1.2.398.7.1.4.2.2.2.5 | Unbearable pain |
| 3. | 1.2.398.7.1.4.2.2.3 | Symptoms of allergic reactions | 1.2.398.7.1.4.2.2.3.1 | Redness |
| 1.2.398.7.1.4.2.2.3.2 | Pain |
| 1.2.398.7.1.4.2.2.3.3 | Shortness of breath |
| 1.2.398.7.1.4.2.2.3.4 | Hearing loss |
| 1.2.398.7.1.4.2.2.3.5 | Swelling |
| 1.2.398.7.1.4.2.2.3.6 | Nausea |
| 1.2.398.7.1.4.2.2.3.7 | Itching |
| 1.2.398.7.1.4.2.2.3.8 | Others |
| 4. | 1.2.398.7.1.4.2.2.4 | Regimen | 1.2.398.7.1.4.2.2.4.1 | Hospitalization |
| 1.2.398.7.1.4.2.2.4.2 | Outpatient treatment |
| 5. | 1.2.398.7.1.4.2.2.5 | Diet | 1.2.398.7.1.4.2.2.5.1 | Diet №1, 1а, 1б |
| 1.2.398.7.1.4.2.2.5.2 | Diet №2 |
| 1.2.398.7.1.4.2.2.5.3 | Diet №3 |
| 1.2.398.7.1.4.2.2.5.4 | Diet №4, 4а, 4б, 4в |
| 1.2.398.7.1.4.2.2.5.5 | Diet №5, 5а |
| 1.2.398.7.1.4.2.2.5.6 | Diet № 6 |
| 1.2.398.7.1.4.2.2.5.7 | Diet №7, 7а, 7б, 7в, 7г |
| 1.2.398.7.1.4.2.2.5.8 | Diet №8 |
| 1.2.398.7.1.4.2.2.5.9 | Diet №9 |
| 1.2.398.7.1.4.2.2.5.10 | Diet №10 |
| 1.2.398.7.1.4.2.2.5.11 | Diet №11 |
| 1.2.398.7.1.4.2.2.5.12 | Diet №12 |
| 1.2.398.7.1.4.2.2.5.13 | Diet №13 |
| 1.2.398.7.1.4.2.2.5.14 | Diet №14 |
| 1.2.398.7.1.4.2.2.5.15 | Diet №15 |
| 6. | 1.2.398.7.1.4.2.2.6 | Severity of the patient's condition | 1.2.398.7.1.4.2.2.6.1 | Satisfactory |
| 1.2.398.7.1.4.2.2.6.2 | Moderate |
| 1.2.398.7.1.4.2.2.6.3 | Severe |
| 1.2.398.7.1.4.2.2.6.4 | Extremely severe |
| 7. | 1.2.398.7.1.4.2.2.7 | Errors in clinical diagnosis | 1.2.398.7.1.4.2.2.7.1 | Discrepancy in diagnoses for the underlying disease |
| 1.2.398.7.1.4.2.2.7.2 | Late diagnosis of the underlying disease |
| 1.2.398.7.1.4.2.2.7.3 | Discrepancy in diagnoses for complications |
| 1.2.398.7.1.4.2.2.7.4 | Discrepancy in diagnoses for concomitant diseases |
| 1.2.398.7.1.4.2.2.7.5 | Others |
| 8. | 1.2.398.7.1.4.2.2.8 | Reasons for discrepancies in diagnoses | 1.2.398.7.1.4.2.2.8.1 | Disease rarity |
| 1.2.398.7.1.4.2.2.8.2 | Overestimation of examination data |
| 1.2.398.7.1.4.2.2.8.3 | Underexamination of the patient |
| 1.2.398.7.1.4.2.2.8.4 | Short-term stay |
| 1.2.398.7.1.4.2.2.8.5 | Objective difficulty of diagnosis |
| 9. | 1.2.398.7.1.4.2.2.9 | Reason for termination of dynamic observation | 1.2.398.7.1.4.2.2.9.1 | Written refusal of the patient |
| 1.2.398.7.1.4.2.2.9.2 | Death of the patient |
| 1.2.398.7.1.4.2.2.9.3 | Recovery, persistent improvement |
| 10. | 1.2.398.7.1.4.2.2.10 | Mental mood and emotions | 1.2.398.7.1.4.2.2.10.1 | Even mood background |
| 1.2.398.7.1.4.2.2.10.2 | Decreased mood background (passivity, despondency, pessimism) |
| 1.2.398.7.1.4.2.2.10.3 | Irritability and (or) anger |
| 1.2.398.7.1.4.2.2.10.4 | Increased mood background (cheerfulness, vigor, optimism) |
| 1.2.398.7.1.4.2.2.10.5 | Fear, anxiety |
| 11. | 1.2.398.7.1.4.2.2.11 | Mental state, thinking, memory, speech | 1.2.398.7.1.4.2.2.11.1 | No abnormalities |
| 1.2.398.7.1.4.2.2.11.2 | Slow thinking, speech |
| 1.2.398.7.1.4.2.2.11.3 | Rapid thinking, speech |
| 1.2.398.7.1.4.2.2.11.4 | Detailed (detailed) thinking, speech |
| 1.2.398.7.1.4.2.2.11.5 | Incoherent thinking |
| 1.2.398.7.1.4.2.2.11.6 | Delusional ideas |
| 1.2.398.7.1.4.2.2.11.7 | Thoughts of death, suicide |
| 1.2.398.7.1.4.2.2.11.8 | Memory impairment |
| 1.2.398.7.1.4.2.2.11.9 | Attention impairment |
| 12. | 1.2.398.7.1.4.2.2.12 | Mental state, somatovegetative disorders | 1.2.398.7.1.4.2.2.12.1 | Rapid or increased heartbeat, discomfort in the heart area |
| 1.2.398.7.1.4.2.2.12.2 | Increased sweating, hot flashes or chills, dry mouth |
| 1.2.398.7.1.4.2.2.12.3 | Tremors in the arms and/or legs and/or body |
| 1.2.398.7.1.4.2.2.12.4 | Muscle tension, inability to relax |
| 1.2.398.7.1.4.2.2.12.5 | Feeling of choking or a lump in the throat, difficulty breathing |
| 1.2.398.7.1.4.2.2.12.6 | Feeling of discomfort or pain in the chest, “heaviness in the chest” |
| 1.2.398.7.1.4.2.2.12.7 | Dizziness, headaches |
| 1.2.398.7.1.4.2.2.12.8 | Feeling of weakness, fatigue |
| 1.2.398.7.1.4.2.2.12.9 | Feeling of numbness and/or tingling |
| 13. | 1.2.398.7.1.4.2.2.13 | Additional symptoms of mental state | 1.2.398.7.1.4.2.2.13.1 | Sleep disturbances |
| 1.2.398.7.1.4.2.2.13.2 | Appetite disturbances |
| 1.2.398.7.1.4.2.2.13.3 | Presence of psychological trauma |
| 1.2.398.7.1.4.2.2.13.4 | Loss of interests |
| 1.2.398.7.1.4.2.2.13.5 | Secrecy, distrust |
| 1.2.398.7.1.4.2.2.13.6 | Reports of alcohol consumption |
| 1.2.398.7.1.4.2.2.13.7 | Feeling of despair |
| 1.2.398.7.1.4.2.2.13.8 | Hallucinations (patient looks around, talks to an invisible interlocutor) |
| 14. | 1.2.398.7.1.4.2.2.14 | Type of diagnosis | 1.2.398.7.1.4.2.2.14.1 | Not specified |
| 1.2.398.7.1.4.2.2.14.2 | Referral |
| 1.2.398.7.1.4.2.2.14.3 | Preliminary |
| 1.2.398.7.1.4.2.2.14.4 | Stage |
| 1.2.398.7.1.4.2.2.14.5 | (Clinical) |
| 1.2.398.7.1.4.2.2.14.6 | Pathological |
| 15. | 1.2.398.7.1.4.2.2.15 | Clinical classification of hearing loss according to the World Health Organization | 1.2.398.7.1.4.2.2.15.1 | Congenital malformations of the outer ear (anomalies of the auricle, atresia of the external auditory canal) |
| 1.2.398.7.1.4.2.2.15.2 | Congenital malformations of the inner ear (anomalies of the cochlea, auditory nerve) |
| 1.2.398.7.1.4.2.2.15.3 | Diseases of the spectrum of auditory (auditory) neuropathies |
| 1.2.398.7.1.4.2.2.15.4 | Sensorineural (or sensorineural) hearing loss |
| 1.2.398.7.1.4.2.2.15.5 | Conductive hearing loss |
| 1.2.398.7.1.4.2.2.15.6 | Mixed (combined) hearing loss |
| 16. | 1.2.398.7.1.4.2.2.16 | Type of hearing aid conductivity | 1.2.398.7.1.4.2.2.16.1 | Air conduction |
| 1.2.398.7.1.4.2.2.16.2 | Bone conduction |
| 17. | 1.2.398.7.1.4.2.2.17 | Location of the implanted system | 1.2.398.7.1.4.2.2.17.1 | Middle ear |
| 1.2.398.7.1.4.2.2.17.2 | Bone conduction |
| 1.2.398.7.1.4.2.2.17.3 | Cochlear implantation |
| 18. | 1.2.398.7.1.4.2.2.18 | Degree of hearing loss | 1.2.398.7.1.4.2.2.18.1 | First |
| 1.2.398.7.1.4.2.2.18.2 | Second |
| 1.2.398.7.1.4.2.2.18.3 | Third |
| 1.2.398.7.1.4.2.2.18.4 | Fourth |
| 1.2.398.7.1.4.2.2.18.5 | Deafness. |
| 19. | 1.2.398.7.1.4.2.2.19 | Result of audiological screening | 1.2.398.7.1.4.2.2.19.1 | Passed |
| 1.2.398.7.1.4.2.2.19.2 | Didn't pass |
| 20. | 1.2.398.7.1.4.2.2.20 | Breathing pattern of a newborn in intensive care | 1.2.398.7.1.4.2.2.20.1 | Absent |
| 1.2.398.7.1.4.2.2.20.2 | Gasping breathing |
| 1.2.398.7.1.4.2.2.20.3 | Irregular |
| 1.2.398.7.1.4.2.2.20.4 | Regular with respiratory disturbances |
| 1.2.398.7.1.4.2.2.20.5 | Regular |
| 21. | 1.2.398.7.1.4.2.2.21 | Skin color | 1.2.398.7.1.4.2.2.21.1 | Pale |
| 1.2.398.7.1.4.2.2.21.2 | Diffuse cyanosis |
| 1.2.398.7.1.4.2.2.21.3 | Acrocyanosis |
| 1.2.398.7.1.4.2.2.21.4 | Pink |
| 22. | 1.2.398.7.1.4.2.2.22 | Artificial ventilation mode with constant positive pressure | 1.2.398.7.1.4.2.2.22.1 | Mask |
| 1.2.398.7.1.4.2.2.22.2 | Nasal cannula |
| 1.2.398.7.1.4.2.2.22.3 | Nasopharyngeal tube |
| 23. | 1.2.398.7.1.4.2.2.23 | Artificial lung ventilation | 1.2.398.7.1.4.2.2.23.1 | Mask |
| 1.2.398.7.1.4.2.2.23.2 | Laryngeal mask |
| 1.2.398.7.1.4.2.2.23.3 | Intubation tube |
| 24. | 1.2.398.7.1.4.2.2.24 | Type of anesthesia | 1.2.398.7.1.4.2.2.24.1 | Intravenous |
| 1.2.398.7.1.4.2.2.24.2 | Intubation |
| 1.2.398.7.1.4.2.2.24.3 | Local |
| 1.2.398.7.1.4.2.2.24.4 | Peridural |
| 1.2.398.7.1.4.2.2.24.5 | Conduction |
| 1.2.398.7.1.4.2.2.24.6 | Spinal |
| 1.2.398.7.1.4.2.2.24.7 | Mask anesthesia |
| 25. | 1.2.398.7.1.4.2.2.25 | Signs of infectious pathology | 1.2.398.7.1.4.2.2.25.1 | Skin rash |
| 1.2.398.7.1.4.2.2.25.2 | Fever |
| 1.2.398.7.1.4.2.2.25.3 | Nasal discharge |
| 1.2.398.7.1.4.2.2.25.4 | Cough |
| 1.2.398.7.1.4.2.2.25.5 | Sore throat |
| 1.2.398.7.1.4.2.2.25.6 | Vomiting |
| 1.2.398.7.1.4.2.2.25.7 | Loose stools |
| 1.2.398.7.1.4.2.2.25.8 | Flatulence |
| 26. | 1.2.398.7.1.4.2.2.26 | Centile growth corridor | 1.2.398.7.1.4.2.2.26.1 | 1 |
| 1.2.398.7.1.4.2.2.26.2 | 2 |
| 1.2.398.7.1.4.2.2.26.3 | 3 |
| 1.2.398.7.1.4.2.2.26.4 | 4 |
| 1.2.398.7.1.4.2.2.26.5 | 5 |
| 1.2.398.7.1.4.2.2.26.6 | 6 |
| 1.2.398.7.1.4.2.2.26.7 | 7 |
| 1.2.398.7.1.4.2.2.26.8 | 8 |
| 27. | 1.2.398.7.1.4.2.2.27 | Body weight centile corridor | 1.2.398.7.1.4.2.2.27.1 | 1 |
| 1.2.398.7.1.4.2.2.27.2 | 2 |
| 1.2.398.7.1.4.2.2.27.3 | 3 |
| 1.2.398.7.1.4.2.2.27.4 | 4 |
| 1.2.398.7.1.4.2.2.27.5 | 5 |
| 1.2.398.7.1.4.2.2.27.6 | 6 |
| 1.2.398.7.1.4.2.2.27.7 | 7 |
| 1.2.398.7.1.4.2.2.27.8 | 8 |
| 28. | 1.2.398.7.1.4.2.2.28 | Warning signs when examining a child in a primary health care organization | 1.2.398.7.1.4.2.2.28.1 | Possible deafness or vision problems, the child does not make contact |
| 1.2.398.7.1.4.2.2.28.2 | Difficulty maintaining balance when walking |
| 1.2.398.7.1.4.2.2.28.3 | Unexplained changes in the child's behavior, signs of physical abuse (especially if the child is under the supervision of others) |
| 1.2.398.7.1.4.2.2.28.4 | Poor appetite |
| 29. | 1.2.398.7.1.4.2.2.29 | Assessment of neuropsychic development | 1.2.398.7.1.4.2.2.29.1 | Normal level of neuropsychic development |
| 1.2.398.7.1.4.2.2.29.2 | Minor deviations in neuropsychic development |
| 1.2.398.7.1.4.2.2.29.3 | Pronounced deviations in neuropsychic development |
| 30. | 1.2.398.7.1.4.2.2.30 | Conclusion of the puberty test | 1.2.398.7.1.4.2.2.30.1 | Norm |
| 1.2.398.7.1.4.2.2.30.2 | Advancement |
| 1.2.398.7.1.4.2.2.30.3 | Lagging |
| 31. | 1.2.398.7.1.4.2.2.31 | Indications for ophthalmologic screening of premature infants | 1.2.398.7.1.4.2.2.31.1 | Birth weight up to 2000 grams |
| 1.2.398.7.1.4.2.2.31.2 | Gestational age at birth less than 34 weeks |
| 1.2.398.7.1.4.2.2.31.3 | Presence of aggravated perinatal history |
| 1.2.398.7.1.4.2.2.31.4 | Presence of an unstable clinical condition of the newborn |
| 32. | 1.2.398.7.1.4.2.2.32 | The environment in which the organs are placed  Indications for ophthalmologic screening of premature infants | 1.2.398.7.1.4.2.2.32.1 | Apparatus for storing and transporting the heart and (or) lungs |
| 1.2.398.7.1.4.2.2.32.2 | Thermal container |
| 1.2.398.7.1.4.2.2.32.3 | Thermal container for kidney |
| 1.2.398.7.1.4.2.2.32.4 | Thermal container for liver |
| 1.2.398.7.1.4.2.2.32.5 | Container for organs of vision with physiological solution, 10 ml |
| 33. | 1.2.398.7.1.4.2.2.33 | Status of newly diagnosed condition | 1.2.398.7.1.4.2.2.33.1 | First identified |
| 1.2.398.7.1.4.2.2.33.2 | Previously known |
| 34. | 1.2.398.7.1.4.2.2.34 | Diagnosis status | 1.2.398.7.1.4.2.2.34.1 | Preliminary |
| 1.2.398.7.1.4.2.2.34.2 | Confirmed |
| 1.2.398.7.1.4.2.2.34.3 | Closed |
| 35. | 1.2.398.7.1.4.2.2.35 | Adverse reaction or adverse event | 1.2.398.7.1.4.2.2.35.1 | Acute extrapyramidal syndrome |
| 1.2.398.7.1.4.2.2.35.2 | Hormonal disorders |
| 1.2.398.7.1.4.2.2.35.3 | Drowsiness |
| 1.2.398.7.1.4.2.2.35.4 | Increased psychotic symptoms |
| 1.2.398.7.1.4.2.2.35.5 | Violation of internal organs |
| 1.2.398.7.1.4.2.2.35.6 | Allergy |
| 1.2.398.7.1.4.2.2.35.7 | Other |
| 36. | 1.2.398.7.1.4.2.2.36 | Measuring the volume of the head and chest (children under 3 years) | 1.2.398.7.1.4.2.2.36.1 | Norm |
| 1.2.398.7.1.4.2.2.36.2 | Deviation |
| 37. | 1.2.398.7.1.4.2.2.37 | Assessment of psychophysical development according to scales of neuropsychic development of children | 1.2.398.7.1.4.2.2.37.1 | Norm |
| 1.2.398.7.1.4.2.2.37.2 | Deviation |
| 38. | 1.2.398.7.1.4.2.2.38 | Type of diagnosis | 1.2.398.7.1.4.2.2.38.1 | Not specified |
| 1.2.398.7.1.4.2.2.38.2 | Main |
| 1.2.398.7.1.4.2.2.38.3 | Accompanying |
| 1.2.398.7.1.4.2.2.38.4 | Complication |
| 1.2.398.7.1.4.2.2.38.5 | Background |
| 1.2.398.7.1.4.2.2.38.6 | Competing |
| 1.2.398.7.1.4.2.2.38.7 | Cause of death |
| 1.2.398.7.1.4.2.2.38.8 | Clarifying |
| 1.2.398.7.1.4.2.2.38.9 | Change in the main |
| 39. | 1.2.398.7.1.4.2.2.39 | Nature of diagnosis | 1.2.398.7.1.4.2.2.39.1 | Acute disease |
| 1.2.398.7.1.4.2.2.39.2 | Chronic in the acute stage |
| 1.2.398.7.1.4.2.2.39.3 | Chronic in the remission stage |
| 1.2.398.7.1.4.2.2.39.4 | Risk factor |
| 40. | 1.2.398.7.1.4.2.2.40 | Type of injury | 1.2.398.7.1.4.2.2.40.1 | Associated with production |
| 1.2.398.7.1.4.2.2.40.1.1 | In industry |
| 1.2.398.7.1.4.2.2.40.1.2 | In agriculture |
| 1.2.398.7.1.4.2.2.40.1.3 | In construction |
| 1.2.398.7.1.4.2.2.40.1.4 | Road transport |
| 1.2.398.7.1.4.2.2.40.2 | Not related to production |
| 1.2.398.7.1.4.2.2.40.2.1 | Household |
| 1.2.398.7.1.4.2.2.40.2.2 | Outdoor |
| 1.2.398.7.1.4.2.2.40.2.3 | Road transport |
| 1.2.398.7.1.4.2.2.40.2.4 | Sports |
| 1.2.398.7.1.4.2.2.40.2.5 | School |
| 1.2.398.7.1.4.2.2.40.2.6 | Childish |
| 41. | 1.2.398.7.1.4.2.2.41 | Purpose of hospitalization | 1.2.398.7.1.4.2.2.41.1 | Treatment |
| 1.2.398.7.1.4.2.2.41.2 | Rehabilitation |
| 1.2.398.7.1.4.2.2.41.3 | Surgery |
| 1.2.398.7.1.4.2.2.41.4 | Diagnosis clarification |
| 42. | 1.2.398.7.1.4.2.2.42 | Outcome of treatment | 1.2.398.7.1.4.2.2.42.1 | Recovery |
| 1.2.398.7.1.4.2.2.42.2 | Improvement |
| 1.2.398.7.1.4.2.2.42.3 | No change |
| 1.2.398.7.1.4.2.2.42.4 | Death |
| 1.2.398.7.1.4.2.2.42.5 | Transferred to another healthcare organization |
| 43. | 1.2.398.7.1.4.2.2.43 | Circumstances of the woman's death | 1.2.398.7.1.4.2.2.43.1 | Died while pregnant (regardless of the duration and location of pregnancy) |
| 1.2.398.7.1.4.2.2.43.2 | During childbirth (abortion) |
| 1.2.398.7.1.4.2.2.43.3 | Within 42 days after childbirth (abortion) |
| 1.2.398.7.1.4.2.2.43.4 | Within 43-365 days after the end of pregnancy, childbirth |
| 44. | 1.2.398.7.1.4.2.2.44 | Place of death | 1.2.398.7.1.4.2.2.44.1 | Hospital |
| 1.2.398.7.1.4.2.2.44.2 | Primary health care |
| 1.2.398.7.1.4.2.2.44.3 | Private clinic |
| 1.2.398.7.1.4.2.2.44.4 | At home |
| 1.2.398.7.1.4.2.2.44.5 | During transportation |
| 1.2.398.7.1.4.2.2.44.6 | At the scene of the accident |
| 1.2.398.7.1.4.2.2.44.7 | Other |
| 45. | 1.2.398.7.1.4.2.2.45 | Patient management conditions | 1.2.398.7.1.4.2.2.45.1 | Observed treatment |
| 1.2.398.7.1.4.2.2.45.2 | Video observed treatment |
| 1.2.398.7.1.4.2.2.45.3 | Hospital at home |
| 46. | 1.2.398.7.1.4.2.2.46 | Basis for death determination | 1.2.398.7.1.4.2.2.46.1 | Examination of the corpse |
| 1.2.398.7.1.4.2.2.46.2 | Medical records |
| 1.2.398.7.1.4.2.2.46.3 | Previous observation of the patient |
| 1.2.398.7.1.4.2.2.46.4 | Autopsy results |
| 47. | 1.2.398.7.1.4.2.2.47 | Richmond Agitation-Sedation Scale | 1.2.398.7.1.4.2.2.47.1 | +4 Aggressive |
| 1.2.398.7.1.4.2.2.47.2 | +3 Extremely agitated |
| 1.2.398.7.1.4.2.2.47.3 | +2 Agitated |
| 1.2.398.7.1.4.2.2.47.4 | 0 |
| 1.2.398.7.1.4.2.2.47.5 | -1 Drowsiness |
| 1.2.398.7.1.4.2.2.47.6 | -2 Light sedation |
| 1.2.398.7.1.4.2.2.47.7 | -3 Moderate sedation |
| 1.2.398.7.1.4.2.2.47.8 | -4 Deep sedation |
| 1.2.398.7.1.4.2.2.47.9 | -5 No awakening |
| 48. | 1.2.398.7.1.4.2.2.48 | X-ray examination | 1.2.398.7.1.4.2.2.48.1 | X-ray studies |
| 1.2.398.7.1.4.2.2.48.2 | Transillumination |
| 1.2.398.7.1.4.2.2.48.3 | X-ray |
| 1.2.398.7.1.4.2.2.48.4 | Electroradiogram |
| 1.2.398.7.1.4.2.2.48.5 | Diagnostic fluorogram |
| 1.2.398.7.1.4.2.2.48.6 | Mammogram |
| 1.2.398.7.1.4.2.2.48.7 | Special studies |
| 1.2.398.7.1.4.2.2.48.8 | Angiography |
| 49. | 1.2.398.7.1.4.2.2.49 | Ultrasound examination | 1.2.398.7.1.4.2.2.49.1 | Cardiovascular examination |
| 1.2.398.7.1.4.2.2.49.2 | Abdominal cavity examination |
| 1.2.398.7.1.4.2.2.49.3 | Breast examination |
| 1.2.398.7.1.4.2.2.49.4 | Thyroid examination |
| 1.2.398.7.1.4.2.2.49.5 | Urogenital system examination |
| 1.2.398.7.1.4.2.2.49.6 | Bone and joint system examination |
| 1.2.398.7.1.4.2.2.49.7 | Female genital organs examination |
| 1.2.398.7.1.4.2.2.49.8 | Doppler examination of peripheral vessels |
| 1.2.398.7.1.4.2.2.49.9 | Brain echo |
| 1.2.398.7.1.4.2.2.49.10 | Ultrasound-guided needle biopsy and drainage |
| 1.2.398.7.1.4.2.2.49.11 | Intraoperative ultrasound examinations |
| 1.2.398.7.1.4.2.2.49.12 | Children under one year old |
| 1.2.398.7.1.4.2.2.49.13 | Other |
| 50. | 1.2.398.7.1.4.2.2.50 | Triage (sorting) | 1.2.398.7.1.4.2.2.50.1 | First group (red zone) |
| 1.2.398.7.1.4.2.2.50.2 | Second group (yellow zone) |
| 1.2.398.7.1.4.2.2.50.3 | Third group (green zone) |
| 51. | 1.2.398.7.1.4.2.2.51 | Urgency (hospitalizations, operations, type of examination order) | 1.2.398.7.1.4.2.2.51.1 | Emergency |
| 1.2.398.7.1.4.2.2.51.2 | Planned |
| 52. | 1.2.398.7.1.4.2.2.52 | Frequency (hospitalizations, examinations, transfusions) | 1.2.398.7.1.4.2.2.52.1 | Primary |
| 1.2.398.7.1.4.2.2.52.2 | Repeated |
| 53. | 1.2.398.7.1.4.2.2.53 | Type of transportation in hospital | 1.2.398.7.1.4.2.2.53.1 | Wheelchair |
| 1.2.398.7.1.4.2.2.53.2 | Stretcher |
| 1.2.398.7.1.4.2.2.53.3 | Hands |
| 1.2.398.7.1.4.2.2.53.4 | Incubator |
| 54. | 1.2.398.7.1.4.2.2.54 | Type of endoscopic examinations | 1.2.398.7.1.4.2.2.54.1 | Esophagogastroduodenoscopy |
| 1.2.398.7.1.4.2.2.54.2 | Colonoscopy |
| 1.2.398.7.1.4.2.2.54.3 | Bronchoscopy |
| 1.2.398.7.1.4.2.2.54.4 | Rectigomoscopy |
| 1.2.398.7.1.4.2.2.54.5 | Fibrolaryngoscopy |
| 1.2.398.7.1.4.2.2.54.6 | Retrograde pancreatic cholangiography |
| 1.2.398.7.1.4.2.2.54.7 | Other |
| 55. | 1.2.398.7.1.4.2.2.55 | Risk factors for acute cerebrovascular accident | 1.2.398.7.1.4.2.2.55.1 | Arterial hypertension |
| 1.2.398.7.1.4.2.2.55.2 | Diabetes mellitus |
| 1.2.398.7.1.4.2.2.55.3 | Blood diseases |
| 1.2.398.7.1.4.2.2.55.4 | Smoking |
| 1.2.398.7.1.4.2.2.55.5 | Alcohol |
| 1.2.398.7.1.4.2.2.55.6 | Overweight |
| 1.2.398.7.1.4.2.2.55.7 | Cases of sudden death in the family |
| 1.2.398.7.1.4.2.2.55.8 | Stenotic changes in the main vessels |
| 1.2.398.7.1.4.2.2.55.9 | Dyslipidemia |
| 1.2.398.7.1.4.2.2.55.10 | Hereditary predisposition |
| 1.2.398.7.1.4.2.2.55.11 | Hormone replacement therapy |
| 1.2.398.7.1.4.2.2.55.12 | Pregnancy |
| 1.2.398.7.1.4.2.2.55.13 | Previous cardiovascular history |
| 1.2.398.7.1.4.2.2.55.14 | Previous diagnosis of stroke |
| 1.2.398.7.1.4.2.2.55.15 | Previous diagnosis of transient ischemic attack |
| 1.2.398.7.1.4.2.2.55.16 | Previous myocardial infarction |
| 1.2.398.7.1.4.2.2.55.17 | Coronary artery bypass grafting/Transcatheter coronary angioplasty |
| 1.2.398.7.1.4.2.2.55.18 | Heart valve disease |
| 1.2.398.7.1.4.2.2.55.19 | Cardiomyopathy |
| 1.2.398.7.1.4.2.2.55.20 | Chronic heart failure |
| 1.2.398.7.1.4.2.2.55.21 | Contraceptives |
| 1.2.398.7.1.4.2.2.55.22 | Coronary artery disease |
| 1.2.398.7.1.4.2.2.55.23 | Coronary artery bypass grafting/Percutaneous coronary interventions |
| 1.2.398.7.1.4.2.2.55.24 | Pacemaker/Implantable cardioverter defibrillators |
| 1.2.398.7.1.4.2.2.55.25 | Atrial fibrillation |
| 1.2.398.7.1.4.2.2.55.26 | Atrial fibrillation |
| 56. | 1.2.398.7.1.4.2.2.56 | Rankin scale | 1.2.398.7.1.4.2.2.56.1 | 1 degree - no signs of disability |
| 1.2.398.7.1.4.2.2.56.2 | 2 degree - presence of mild signs of disability |
| 1.2.398.7.1.4.2.2.56.3 | 3 degree - moderate signs of disability |
| 1.2.398.7.1.4.2.2.56.4 | 4 degree - presence of pronounced signs of disability |
| 1.2.398.7.1.4.2.2.56.5 | 5 degree - severe signs of disability |
| 57. | 1.2.398.7.1.4.2.2.57 | Reason for contacting a primary health care organization | 1.2.398.7.1.4.2.2.57.1 | Disease |
| 1.2.398.7.1.4.2.2.57.1.1 | Emergency conditions |
| 1.2.398.7.1.4.2.2.57.1.2 | Acute disease (condition) and (or) exacerbation of a chronic disease |
| 1.2.398.7.1.4.2.2.57.1.3 | Suspected socially significant disease |
| 1.2.398.7.1.4.2.2.57.1.4 | Active |
| 1.2.398.7.1.4.2.2.57.1.5 | Medical rehabilitation (stage 3) |
| 1.2.398.7.1.4.2.2.57.1.6 | Planned dental care |
| 1.2.398.7.1.4.2.2.57.1.7 | Emergency dental care |
| 1.2.398.7.1.4.2.2.57.1.8 | Orthodontic care for children with congenital pathology of the maxillofacial region |
| 1.2.398.7.1.4.2.2.57.1.9 | Orthodontic care for children from low-income families |
| 1.2.398.7.1.4.2.2.57.1.10 | Services for diseases that pose a danger to others, in which foreigners and stateless persons temporarily staying in the Republic of Kazakhstan, asylum seekers shall have the right to receive a guaranteed amount of free medical care |
| 1.2.398.7.1.4.2.2.57.2 | Injury |
| 1.2.398.7.1.4.2.2.57.2.1 | Acute trauma (emergency room, outpatient clinics) |
| 1.2.398.7.1.4.2.2.57.2.2 | Consequences of injury (outpatient clinics) |
| 1.2.398.7.1.4.2.2.57.2.3 | Consequences of injury (youth health centers) |
| 1.2.398.7.1.4.2.2.57.3 | Prevention |
| 1.2.398.7.1.4.2.2.57.3.1 | Examination of a patient with a previous coronavirus infection |
| 1.2.398.7.1.4.2.2.57.3.2 | Treatment for preventive purposes (except screening) |
| 1.2.398.7.1.4.2.2.57.3.3 | Immunoprophylaxis |
| 1.2.398.7.1.4.2.2.57.3.4 | Screening (Preventive medical examinations) |
| 1.2.398.7.1.4.2.2.57.3.5 | Patronage |
| 1.2.398.7.1.4.2.2.57.3.6 | Family planning services, safe termination of pregnancy, reproductive health care |
| 1.2.398.7.1.4.2.2.57.3.7 | Appointment during antenatal observation |
| 1.2.398.7.1.4.2.2.57.3.8 | Appointment during postnatal observation |
| 1.2.398.7.1.4.2.2.57.3.9 | Student health services (school medicine) |
| 1.2.398.7.1.4.2.2.57.3.10 | Healthy lifestyle activities |
| 1.2.398.7.1.4.2.2.57.3.11 | Paid medical examinations |
| 1.2.398.7.1.4.2.2.57.4 | Dynamic observation |
| 1.2.398.7.1.4.2.2.57.4.1 | Dynamic observation of chronic diseases (including the Disease management program) |
| 1.2.398.7.1.4.2.2.57.4.2 | Dynamic observation of socially significant diseases |
| 1.2.398.7.1.4.2.2.57.4.3 | Dynamic observation of chronic diseases subject to observation by specialized specialists |
| 1.2.398.7.1.4.2.2.57.5 | Medical and social services |
| 1.2.398.7.1.4.2.2.57.5.1 | Medical and social support |
| 1.2.398.7.1.4.2.2.57.5.2 | Psychological assistance |
| 1.2.398.7.1.4.2.2.57.6 | Administrative |
| 1.2.398.7.1.4.2.2.57.6.1 | Administrative |
| 1.2.398.7.1.4.2.2.57.6.2 | Registration of documents for medical and social examination |
| 1.2.398.7.1.4.2.2.57.6.3 | Prescription |
| 1.2.398.7.1.4.2.2.57.7 | Examination for coronavirus infection |
| 1.2.398.7.1.4.2.2.57.7.1 | Suspected coronavirus infection |
| 1.2.398.7.1.4.2.2.57.7.2 | Examination for coronavirus infection during planned hospitalization (pre-hospital examination), including pregnant women for delivery at 37 weeks, patients on hemodialysis |
| 58. | 1.2.398.7.1.4.2.2.58 | Pre-hospital primary health care for the patient | 1.2.398.7.1.4.2.2.58.1 | Appointment: Paramedic |
| 1.2.398.7.1.4.2.2.58.2 | Education of the population on disease prevention: Paramedic |
| 1.2.398.7.1.4.2.2.58.3 | Training the patient in self-management: Paramedic |
| 1.2.398.7.1.4.2.2.58.4 | Pre-medical examination in the examination room: Paramedic |
| 1.2.398.7.1.4.2.2.58.5 | Preventive examination of the oral cavity: Paramedic |
| 1.2.398.7.1.4.2.2.58.6 | Teaching children sanitary and hygienic skills for dental and oral mucosa care: Paramedic |
| 1.2.398.7.1.4.2.2.58.7 | Complex of medical rehabilitation services: Paramedic |
| 1.2.398.7.1.4.2.2.58.8 | Provision of emergency medical care: Paramedic |
| 1.2.398.7.1.4.2.2.58.9 | Appointment: Nurse with higher education |
| 1.2.398.7.1.4.2.2.58.10 | Education of the population on disease prevention: Nurse with higher education |
| 1.2.398.7.1.4.2.2.58.11 | Patient self-management training: Nurse with higher education |
| 1.2.398.7.1.4.2.2.58.12 | Pre-medical examination in the examination room: Nurse with higher education |
| 1.2.398.7.1.4.2.2.58.13 | Preventive examination of the oral cavity: Nurse with higher education |
| 1.2.398.7.1.4.2.2.58.14 | Teaching children sanitary and hygienic skills for caring for teeth and oral mucosa: Nurse with higher education |
| 1.2.398.7.1.4.2.2.58.15 | Complex of medical rehabilitation services: Nurse with higher education |
| 1.2.398.7.1.4.2.2.58.16 | Appointment:Nurse with secondary education |
| 1.2.398.7.1.4.2.2.58.17 | Education of the population on disease prevention: Nurse with secondary education |
| 1.2.398.7.1.4.2.2.58.18 | Teaching patients self-management: Nurse with secondary education |
| 1.2.398.7.1.4.2.2.58.19 | Pre-medical examination in the examination room: Nurse with secondary education |
| 1.2.398.7.1.4.2.2.58.20 | Preventive examination of the oral cavity: Nurse with secondary education |
| 1.2.398.7.1.4.2.2.58.21 | Teaching children sanitary and hygienic skills for caring for teeth and oral mucosa: Nurse with secondary education |
| 1.2.398.7.1.4.2.2.58.22 | Complex of medical rehabilitation services: Nurse with higher education |
| 1.2.398.7.1.4.2.2.58.23 | Appointment: Midwife |
| 1.2.398.7.1.4.2.2.58.24 | Patient self-management training: Midwife |
| 1.2.398.7.1.4.2.2.58.25 | Pre-medical examination in the examination room: Midwife |
| 1.2.398.7.1.4.2.2.58.26 | School of preparation for childbirth of a pregnant woman and family members: Midwife |
| 1.2.398.7.1.4.2.2.58.27 | Determination of urine parameters (pH, leukocytes, erythrocytes, urobilinogen, nitrites, protein) by express method |
| 1.2.398.7.1.4.2.2.58.28 | Determination of total cholesterol in blood serum by express method |
| 1.2.398.7.1.4.2.2.58.29 | Determination of glucose in blood serum by express method |
| 1.2.398.7.1.4.2.2.58.30 | Determination of triglycerides in blood serum by express method |
| 1.2.398.7.1.4.2.2.58.31 | Determination of human chorionic gonadotropin in urine by express method (pregnancy test) |
| 1.2.398.7.1.4.2.2.58.32 | Determination of total antibodies to Human Immunodeficiency Virus -1,2 and p24 antigen by express method |
| 1.2.398.7.1.4.2.2.58.33 | Determination of antibodies to Treponema Pallidum in blood serum by express method (rapid test for syphilis) |
| 1.2.398.7.1.4.2.2.58.34 | Determination of total antibodies to hepatitis C virus in blood serum by express method |
| 1.2.398.7.1.4.2.2.58.35 | Determination of HBsAg in blood serum by express method |
| 1.2.398.7.1.4.2.2.58.36 | Examination of smear for the presence of amniotic fluid by express method |
| 1.2.398.7.1.4.2.2.58.37 | Vein blood sampling |
| 1.2.398.7.1.4.2.2.58.38 | Finger blood sampling |
| 1.2.398.7.1.4.2.2.58.39 | Taking a smear for oncocytology |
| 1.2.398.7.1.4.2.2.58.40 | Taking a smear for vaginal cleanliness |
| 1.2.398.7.1.4.2.2.58.41 | Taking material for microbiological studies |
| 1.2.398.7.1.4.2.2.58.42 | Conducting a Mantoux test |
| 1.2.398.7.1.4.2.2.58.43 | Conducting a Diaskintest |
| 1.2.398.7.1.4.2.2.58.44 | Gastric lavage |
| 1.2.398.7.1.4.2.2.58.45 | Enema |
| 1.2.398.7.1.4.2.2.58.46 | Conducting inhalation |
| 1.2.398.7.1.4.2.2.58.47 | Respiratory tract sanitation with an electric suction |
| 1.2.398.7.1.4.2.2.58.48 | Rinsing out earwax plugs |
| 1.2.398.7.1.4.2.2.58.49 |  |
| 1.2.398.7.1.4.2.2.58.50 | Nasogastric tube placement |
| 1.2.398.7.1.4.2.2.58.51 | Duodenal intubation |
| 1.2.398.7.1.4.2.2.58.52 | Bladder catheterization |
| 1.2.398.7.1.4.2.2.58.53 | Peripheral vein catheterization |
| 1.2.398.7.1.4.2.2.58.54 | Transport immobilization |
| 1.2.398.7.1.4.2.2.58.55 | Vaginal sanitation |
| 1.2.398.7.1.4.2.2.58.56 | Eye lavage (excluding cost of medicines) |
| 1.2.398.7.1.4.2.2.58.57 | Tympanic cavity lavage |
| 1.2.398.7.1.4.2.2.58.58 | Desault dressing application |
| 1.2.398.7.1.4.2.2.58.59 | Subconjunctival injection (excluding the cost of medicines) |
| 1.2.398.7.1.4.2.2.58.60 | Procedures for nursing care of an elderly patient |
| 1.2.398.7.1.4.2.2.58.61 | Training family members of the patient in elements of care and hygiene |
| 1.2.398.7.1.4.2.2.58.62 | Prevention and treatment of bedsores |
| 1.2.398.7.1.4.2.2.58.63 | Dressing |
| 1.2.398.7.1.4.2.2.58.64 | Hair, nail care, shaving of a seriously ill patient |
| 1.2.398.7.1.4.2.2.58.65 | Oral care of a seriously ill patient |
| 1.2.398.7.1.4.2.2.58.66 | Suction of mucus from the oropharynx |
| 1.2.398.7.1.4.2.2.58.67 | Care guide for orostomies, esophagostomies |
| 1.2.398.7.1.4.2.2.58.68 | Care guide for tracheostomy |
| 1.2.398.7.1.4.2.2.58.69 | Nasogastric probe, nasal cannula and catheter care |
| 1.2.398.7.1.4.2.2.58.70 | Suction of mucus from the upper respiratory tract |
| 1.2.398.7.1.4.2.2.58.71 | Sucking mucus out of the nose |
| 1.2.398.7.1.4.2.2.58.72 | Care guide for pharyngostomy |
| 1.2.398.7.1.4.2.2.58.73 | Administration of drugs intranasally |
| 1.2.398.7.1.4.2.2.58.74 | Care guide for gastrostomas |
| 1.2.398.7.1.4.2.2.58.75 | Nasogastric probe care |
| 1.2.398.7.1.4.2.2.58.76 | Feeding a seriously ill patient through gastrostomy |
| 1.2.398.7.1.4.2.2.58.77 | Care guide for ileostomy |
| 1.2.398.7.1.4.2.2.58.78 | Intestinal tube care |
| 1.2.398.7.1.4.2.2.58.79 | Feeding a seriously ill patient through an intestinal tube |
| 1.2.398.7.1.4.2.2.58.80 | Ileostomy care training |
| 1.2.398.7.1.4.2.2.58.81 | Care guide for colon stoma |
| 1.2.398.7.1.4.2.2.58.82 | Colostomy care training |
| 1.2.398.7.1.4.2.2.58.83 | Defecation care guide for a seriously ill patient |
| 1.2.398.7.1.4.2.2.58.84 | Installation of a gas vent tube |
| 1.2.398.7.1.4.2.2.58.85 | Removal of coprolites |
| 1.2.398.7.1.4.2.2.58.86 | Fecal incontinence care guide |
| 1.2.398.7.1.4.2.2.58.87 | Installation of a siphon enema |
| 1.2.398.7.1.4.2.2.58.88 | Insertion and removal of a vaginal support ring (pessary) |
| 1.2.398.7.1.4.2.2.58.89 | Care of the external auditory canal |
| 1.2.398.7.1.4.2.2.58.90 | Care of the eyes of a seriously ill patient |
| 1.2.398.7.1.4.2.2.58.91 | Instillation of medicinal substances into the conjunctival cavity |
| 1.2.398.7.1.4.2.2.58.92 | Care guide for urination of a seriously ill patient |
| 1.2.398.7.1.4.2.2.58.93 | Care of a urinary catheter |
| 1.2.398.7.1.4.2.2.58.94 | Care of a cystostomy and urostomy |
| 1.2.398.7.1.4.2.2.58.95 | Care guide for urinary incontinence |
| 1.2.398.7.1.4.2.2.58.96 | Moving and/or placing a seriously ill patient in bed |
| 1.2.398.7.1.4.2.2.58.97 | Transportation of a seriously ill patient within the institution |
| 1.2.398.7.1.4.2.2.58.98 | Feeding a seriously ill patient by mouth and/or nasogastric tube |
| 1.2.398.7.1.4.2.2.58.99 | Preparing and changing bed linen for a seriously ill patient |
| 1.2.398.7.1.4.2.2.58.100 | Guide to changing bed linen and clothing for a seriously ill patient |
| 1.2.398.7.1.4.2.2.58.101 | Care of the perineum and external genitalia of a seriously ill patient |
| 1.2.398.7.1.4.2.2.58.102 | Care of drainage |
| 1.2.398.7.1.4.2.2.58.103 | Guide to parenteral administration of drugs |
| 1.2.398.7.1.4.2.2.58.104 | Assessing the degree of risk of developing bedsores |
| 1.2.398.7.1.4.2.2.58.105 | Assessing the severity of bedsores |
| 1.2.398.7.1.4.2.2.58.106 | Assessing the intensity of pain |
| 1.2.398.7.1.4.2.2.58.107 | Teaching the patient's family members the technique of moving and (or) placing in bed |
| 1.2.398.7.1.4.2.2.58.108 | Teaching the patient self-help when moving in bed and (or) a chair |
| 1.2.398.7.1.4.2.2.58.109 | Teaching the patient to move on crutches |
| 1.2.398.7.1.4.2.2.58.110 | Teaching the patient self-help when moving with the help of additional support |
| 1.2.398.7.1.4.2.2.58.111 | Vaccination without the cost of the drug |
| 1.2.398.7.1.4.2.2.58.112 | Removing sutures, removing ligatures |
| 1.2.398.7.1.4.2.2.58.113 | Training in preventive rooms, health schools |
| 1.2.398.7.1.4.2.2.58.114 | Teaching patients and their family members self-monitoring, self-help and mutual assistance in accordance with chronic disease management programs |
| 1.2.398.7.1.4.2.2.58.115 | Consultation by phone "Hotline" |
| 1.2.398.7.1.4.2.2.58.116 | Intramuscular injection (excluding the cost of drugs) |
| 1.2.398.7.1.4.2.2.58.117 | Intravenous injection (excluding the cost of drugs) |
| 1.2.398.7.1.4.2.2.58.118 | Subcutaneous injection (excluding the cost of drugs) |

**Reference books of phthisiology service**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| № s/n | Object identifier code of the reference book | Name of the reference book | Object identifier code of the value | Contents |
| 1. | 1.2.398.7.1.4.2.3.1 | Method of detecting tuberculosis | 1.2.398.7.1.4.2.3.1.1 | Visit |
| 1.2.398.7.1.4.2.3.1.2 | Medical examination |
| 1.2.398.7.1.4.2.3.1.3 | Post-mortem |
| 2.2. | 1.2.398.7.1.4.2.3.2 | Contingent for phthisiology service | 1.2.398.7.1.4.2.3.2.1 | Risk group |
| 1.2.398.7.1.4.2.3.2.2 | Mandatory contingent |
| 1.2.398.7.1.4.2.3.2.3 | Other |
| 3. | 1.2.398.7.1.4.2.3.3 | Type of tuberculous contingent | 1.2.398.7.1.4.2.3.3.1 | Tuberculosis of dubious activity |
| 1.2.398.7.1.4.2.3.3.2 | Active tuberculosis |
| 1.2.398.7.1.4.2.3.3.3 | Inactive tuberculosis |
| 1.2.398.7.1.4.2.3.3.4 | Contact with drug-resistant tuberculosis (Mycobacterium tuberculosis (+) |
| 1.2.398.7.1.4.2.3.3.5 | Inactive tuberculosis contact with drug-resistant tuberculosis (Mycobacterium tuberculosis (-) |
| 1.2.398.7.1.4.2.3.3.6 | Inactive tuberculosis contact with drug-sensitive tuberculosis (Mycobacterium tuberculosis (+) |
| 1.2.398.7.1.4.2.3.3.7 | Inactive contact tuberculosis with drug-sensitive tuberculosis (Mycobacterium tuberculosis (-) |
| 1.2.398.7.1.4.2.3.3.8 | First-time infected |
| 1.2.398.7.1.4.2.3.3.9 | Hyperergic reaction |
| 1.2.398.7.1.4.2.3.3.10 | Adverse reaction to tuberculosis vaccine (hereinafter referred to as BCG) - 2 |
| 4. | 1.2.398.7.1.4.2.3.4 | Type of a tuberculous patient | 1.2.398.7.1.4.2.3.4.1 | New case |
| 1.2.398.7.1.4.2.3.4.2 | Relapse |
| 1.2.398.7.1.4.2.3.4.3 | Ineffective treatment |
| 1.2.398.7.1.4.2.3.4.4 | Treatment after a break |
| 1.2.398.7.1.4.2.3.4.5 | Transferred |
| 1.2.398.7.1.4.2.3.4.6 | Others |
| 5. | 1.2.398.7.1.4.2.3.5 | Reasons for removing a tuberculous patient from the dispensary register | 1.2.398.7.1.4.2.3.5.1 | Transfer to group I |
| 1.2.398.7.1.4.2.3.5.2 | Transfer to group II |
| 1.2.398.7.1.4.2.3.5.3 | Transfer to group III |
| 1.2.398.7.1.4.2.3.5.4 | Died from tuberculosis |
| 1.2.398.7.1.4.2.3.5.5 | Died from other causes |
| 1.2.398.7.1.4.2.3.5.6 | Tuberculosis was not confirmed |
| 1.2.398.7.1.4.2.3.5.7 | Transfer to another institution |
| 1.2.398.7.1.4.2.3.5.8 | Time off from medical examination for “inactive tuberculosis” - 12 months |
| 1.2.398.7.1.4.2.3.5.9 | Time off from medical examination for “active tuberculosis” - 6 months |
| 1.2.398.7.1.4.2.3.5.10 | Removed from medical records |
| 6. | 1.2.398.7.1.4.2.3.6 | Reasons for removing a tuberculous patient with active bacterial excretion from the register | 1.2.398.7.1.4.2.3.6.1 | Transfer to Group II |
| 1.2.398.7.1.4.2.3.6.2 | Transfer to another institution |
| 1.2.398.7.1.4.2.3.6.3 | Died from tuberculosis or other causes |
| 1.2.398.7.1.4.2.3.6.4 | Removed from epidemiological control |
| 7. | 1.2.398.7.1.4.2.3.7 | Outcomes of treatment of a tuberculous patient | 1.2.398.7.1.4.2.3.7.1 | Cure |
| 1.2.398.7.1.4.2.3.7.2 | Cured |
| 1.2.398.7.1.4.2.3.7.3 | Treatment failure |
| 1.2.398.7.1.4.2.3.7.4 | Treatment completed |
| 1.2.398.7.1.4.2.3.7.5 | Treatment failure |
| 1.2.398.7.1.4.2.3.7.6 | Loss to follow-up |
| 1.2.398.7.1.4.2.3.7.7 | Outcome not assessed |
| 1.2.398.7.1.4.2.3.7.8 | Transferred to second-line anti-TB drugs (for drug-susceptible TB) |
| 1.2.398.7.1.4.2.3.7.9 | Death from TB |
| 1.2.398.7.1.4.2.3.7.10 | Death from other causes |
| 1.2.398.7.1.4.2.3.7.11 | Violation of regimen |
| 1.2.398.7.1.4.2.3.7.12 | Successful treatment |
| 8. | 1.2.398.7.1.4.2.3.8 | Recovery of a tuberculous patient | 1.2.398.7.1.4.2.3.8.1 | Sanatorium group |
| 1.2.398.7.1.4.2.3.8.2 | Sanatorium kindergarten |
| 1.2.398.7.1.4.2.3.8.3 | Sanatorium boarding school |
| 1.2.398.7.1.4.2.3.8.4 | Tuberculosis sanatorium |
| 9. | 1.2.398.7.1.4.2.3.9 | Tuberculosis risk factors | 1.2.398.7.1.4.2.3.9.1 | Contact with a patient with drug-susceptible tuberculosis |
| 1.2.398.7.1.4.2.3.9.2 | Pregnancy |
| 1.2.398.7.1.4.2.3.9.3 | Contact with a patient with multidrug-resistant tuberculosis |
| 1.2.398.7.1.4.2.3.9.4 | Not vaccinated with BCG |
| 1.2.398.7.1.4.2.3.9.5 | Contact with a patient with extensively drug-resistant tuberculosis |
| 1.2.398.7.1.4.2.3.9.6 | Diabetes mellitus |
| 1.2.398.7.1.4.2.3.9.7 | Chronic obstructive pulmonary disease |
| 1.2.398.7.1.4.2.3.9.8 | Immunosuppressive therapy |
| 1.2.398.7.1.4.2.3.9.9 | Residual effects in the lungs of any etiology |
| 1.2.398.7.1.4.2.3.9.10 | Drug addiction |
| 1.2.398.7.1.4.2.3.9.11 | Alcohol abuse |
| 1.2.398.7.1.4.2.3.9.12 | Being in prison in the last 2 years |
| 1.2.398.7.1.4.2.3.9.13 | Human immunodeficiency virus/Acquired immunodeficiency syndrome |
| 1.2.398.7.1.4.2.3.9.14 | Unknown |
| 1.2.398.7.1.4.2.3.9.15 | Women in the postpartum period up to 1 year |
| 10. | 1.2.398.7.1.4.2.3.10 | Localization of tuberculosis | 1.2.398.7.1.4.2.3.10.1 | Pulmonary |
| 1.2.398.7.1.4.2.3.10.2 | Extrapulmonary |
| 1.2.398.7.1.4.2.3.10.3 | Combined |
| 11. | 1.2.398.7.1.4.2.3.11 | Presence of drug resistance to anti-tuberculosis drugs | 1.2.398.7.1.4.2.3.11.1 | Confirmed drug resistance of tuberculosis |
| 1.2.398.7.1.4.2.3.11.2 | Suspected drug resistance of tuberculosis |
| 1.2.398.7.1.4.2.3.11.3 | Extensive drug resistance of tuberculosis confirmed |
| 12. | 1.2.398.7.1.4.2.3.12 | Method of diagnostics of drug resistance | 1.2.398.7.1.4.2.3.12.1 | Laboratory |
| 1.2.398.7.1.4.2.3.12.2 | Molecular |
| 1.2.398.7.1.4.2.3.12.3 | On analyzer |
| 13. | 1.2.398.7.1.4.2.3.13 | Result of drug susceptibility test | 1.2.398.7.1.4.2.3.13.1 | Resistant |
| 1.2.398.7.1.4.2.3.13.2 | Sensitive |
| 1.2.398.7.1.4.2.3.13.3 | Progress (result/date) |
| 14. | 1.2.398.7.1.4.2.3.14 | Anti-TB drugs | 1.2.398.7.1.4.2.3.14.1 | H |
| 1.2.398.7.1.4.2.3.14.2 | R |
| 1.2.398.7.1.4.2.3.14.3 | E |
| 1.2.398.7.1.4.2.3.14.4 | S |
| 1.2.398.7.1.4.2.3.14.5 | Z |
| 1.2.398.7.1.4.2.3.14.6 | Cm |
| 1.2.398.7.1.4.2.3.14.7 | Km |
| 1.2.398.7.1.4.2.3.14.8 | Am |
| 1.2.398.7.1.4.2.3.14.9 | Cs |
| 1.2.398.7.1.4.2.3.14.10 | Pto/ Eto |
| 1.2.398.7.1.4.2.3.14.11 | PAS |
| 1.2.398.7.1.4.2.3.14.12 | Ofx |
| 1.2.398.7.1.4.2.3.14.13 | Lfx |
| 1.2.398.7.1.4.2.3.14.14 | Mfx |
| 1.2.398.7.1.4.2.3.14.15 | Bdq |
| 1.2.398.7.1.4.2.3.14.16 | Lzd |
| 1.2.398.7.1.4.2.3.14.17 | Dlm. |
| 1.2.398.7.1.4.2.3.14.18 | Cfz |
| 1.2.398.7.1.4.2.3.14.19 | Mpm |
| 1.2.398.7.1.4.2.3.14.20 | Imp/Cln. |
| 1.2.398.7.1.4.2.3.14.21 | Amx/Clav. |
| 1.2.398.7.1.4.2.3.14.22 | Pa |
| 1.2.398.7.1.4.2.3.14.23 | Р |
| 15. | 1.2.398.7.1.4.2.3.15 | Category of a tuberculous patient | 1.2.398.7.1.4.2.3.15.1 | Sensitive tuberculosis |
| 1.2.398.7.1.4.2.3.15.2 | Drug-resistant tuberculosis |
| 16. | 1.2.398.7.1.4.2.3.16 | Purpose of the study of tuberculous patient | 1.2.398.7.1.4.2.3.16.1 | Diagnostics |
| 1.2.398.7.1.4.2.3.16.2 | Chemotherapy monitoring |
| 17. | 1.2.398.7.1.4.2.3.17 | Course of treatment | 1.2.398.7.1.4.2.3.17.1 | 60 days |
| 1.2.398.7.1.4.2.3.17.2 | 90 days |
| 1.2.398.7.1.4.2.3.17.3 | 180 days |
| 18. | 1.2.398.7.1.4.2.3.18 | Group of focus | 1.2.398.7.1.4.2.3.18.1 | 1 |
| 1.2.398.7.1.4.2.3.18.2 | 2 |
| 1.2.398.7.1.4.2.3.18.3 | 3 |
| 19.3 | 1.2.398.7.1.4.2.3.19 | Reason for removal from the group of focus | 1.2.398.7.1.4.2.3.19.1 | Transfer to Group II |
| 1.2.398.7.1.4.2.3.19.2 | Transfer to another institution |
| 1.2.398.7.1.4.2.3.19.3 | Died from tuberculosis or other causes |
| 1.2.398.7.1.4.2.3.19.4 | Removed from epidemiological control |

**Transfusion care reference books**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| № s/n | Object identifier code of the reference book | Name of the reference book | Object identifier code of the refernce book value | Contents |
| 1. | 1.2.398.7.1.4.2.4.1 | Purpose of blood product issuance | 1.2.398.7.1.4.2.4.1.1 | For transfusion |
| 1.2.398.7.1.4.2.4.1.2 | For replenishment of reserve |
| 2. | 1.2.398.7.1.4.2.4.2 | Reason for writing off blood product    Method of blood product disposal    Transfusion outcome | 1.2.398.7.1.4.2.4.2.1 | Expired |
| 1.2.398.7.1.4.2.4.2.2 | Bag seal failure |
| 1.2.398.7.1.4.2.4.2.3 | Signs of hemolysis |
| 1.2.398.7.1.4.2.4.2.4 | Signs of bacterial contamination |
| 1.2.398.7.1.4.2.4.2.5 | Individual incompatibility |
| 3. | 1.2.398.7.1.4.2.4.3 | Blood group | 1.2.398.7.1.4.2.4.3.1 | Destroyed as medical waste |
| 1.2.398.7.1.4.2.4.3.2 | Not used for transfusion |
| 4. | 1.2.398.7.1.4.2.4.4 | Purpose of blood product issuance | 1.2.398.7.1.4.2.4.4.1 | No signs of adverse transfusion effect |
| 1.2.398.7.1.4.2.4.4.2 | There are signs of adverse transfusion effect |
| 5. | 1.2.398.7.1.4.2.4.5 | Reason for writing off blood product | 1.2.398.7.1.4.2.4.5.1 | 0 (first) |
| 1.2.398.7.1.4.2.4.5.2 | A (second) |
| 1.2.398.7.1.4.2.4.5.3 | B (third) |
| 1.2.398.7.1.4.2.4.5.4 | AB (fourth) |
| 6. | 1.2.398.7.1.4.2.4.6 | Rhesus factor | 1.2.398.7.1.4.2.4.6.1 | Rh- (Rh-negative) |
| 1.2.398.7.1.4.2.4.6.2 | Rh+ (Rh-positive) |
| 7. | 1.2.398.7.1.4.2.4.7 | Transfusion tactics | 1.2.398.7.1.4.2.4.7.1 | Emergency for vital indications (15 minutes, universal blood components) |
| 1.2.398.7.1.4.2.4.7.2 | Emergency (within 2 hours) |
| 1.2.398.7.1.4.2.4.7.3 | Scheduled transfusion |
| 1.2.398.7.1.4.2.4.7.4 | Transfusion readiness |
| 1.2.398.7.1.4.2.4.7.5 | Individual selection |
| 8. | 1.2.398.7.1.4.2.4.8 | Indications for individual selection of blood cells | 1.2.398.7.1.4.2.4.8.1 | Burdened transfusion or obstetric history |
| 1.2.398.7.1.4.2.4.8.2 | Presence of anti-erythrocyte alloantibodies in the blood serum of a potential recipient |
| 1.2.398.7.1.4.2.4.8.3 | Positive or indeterminate result of a laboratory test for individual compatibility |
| 1.2.398.7.1.4.2.4.8.4 | Treatment of newborns with hemolytic disease of the newborn |
| 9. | 1.2.398.7.1.4.2.4.9 | Blood transfusion rate | 1.2.398.7.1.4.2.4.9.1 | Drip |
| 1.2.398.7.1.4.2.4.9.2 | Jet |
| 1.2.398.7.1.4.2.4.9.3 | Drip-jet |
| 10. | 1.2.398.7.1.4.2.4.10 | Transfusion history | 1.2.398.7.1.4.2.4.10.1 | No transfusions were performed |
| 1.2.398.7.1.4.2.4.10.2 | Transfusions were performed, without any special features |
| 1.2.398.7.1.4.2.4.10.3 | Transfusions were performed, according to the words there was an adverse effect of the transfusion |
| 1.2.398.7.1.4.2.4.10.4 | Transfusion history is unknown |
| 11. | 1.2.398.7.1.4.2.4.11 | Obstetric history before transfusion | 1.2.398.7.1.4.2.4.11.1 | Not complicated |
| 1.2.398.7.1.4.2.4.11.2 | Complicated, multiple (5 times or more) pregnancies/abortions |
| 1.2.398.7.1.4.2.4.11.3 | Complicated, stillbirth/miscarriage in early pregnancy |
| 1.2.398.7.1.4.2.4.11.4 | Complicated, hemolytic disease of the fetus/newborn |
| 12. | 1.2.398.7.1.4.2.4.12 | Presence of irregular immune anti-erythrocyte antibodies | 1.2.398.7.1.4.2.4.12.1 | Not detected |
| 1.2.398.7.1.4.2.4.12.2 | Detected, allo-antibodies |
| 1.2.398.7.1.4.2.4.12.3 | Detected, autoantibodies |
| 1.2.398.7.1.4.2.4.12.4 | Panaglutination |
| 1.2.398.7.1.4.2.4.12.5 | Not studied |
| 13. | 1.2.398.7.1.4.2.4.13 | Indications for the use of blood and its components | 1.2.398.7.1.4.2.4.13.1 | Signs of acute massive blood loss in combined, multiple or extensive injuries |
| 1.2.398.7.1.4.2.4.13.2 | Massive blood loss and traumatic shock of II-III degree |
| 1.2.398.7.1.4.2.4.13.3 | Acute uncompensated anemia |
| 1.2.398.7.1.4.2.4.13.4 | Chronic uncompensated anemia |
| 1.2.398.7.1.4.2.4.13.5 | Chronic compensated anemia with risk of decompensation |
| 1.2.398.7.1.4.2.4.13.6 | Deficient factors of coagulation hemostasis |
| 1.2.398.7.1.4.2.4.13.7 | Deficient plasma anticoagulants |
| 1.2.398.7.1.4.2.4.13.8 | Plasma exchange |
| 1.2.398.7.1.4.2.4.13.9 | Filling extracorporeal circuits of devices (artificial blood circulation apparatus, extracorporeal membrane oxygenation and others) |
| 14.3 | 1.2.398.7.1.4.2.4.14 | Clinical features of coagulation cell/factor deficiency | 1.2.398.7.1.4.2.4.14.1 | Hemic hypoxemia |
| 1.2.398.7.1.4.2.4.14.2 | Orthostatic collapse |
| 1.2.398.7.1.4.2.4.14.3 | Shortness of breath at rest or during physical exertion |
| 1.2.398.7.1.4.2.4.14.4 | Lethargy, drowsiness |
| 1.2.398.7.1.4.2.4.14.5 | General weakness, malaise |
| 1.2.398.7.1.4.2.4.14.6 | Arterial hypotension |
| 1.2.398.7.1.4.2.4.14.7 | Pale skin and visible mucous membranes |
| 1.2.398.7.1.4.2.4.14.8 | Dizziness |
| 1.2.398.7.1.4.2.4.14.9 | Tachycardia |
| 1.2.398.7.1.4.2.4.14.10 | Headaches |
| 1.2.398.7.1.4.2.4.14.11 | Angina pains |
| 1.2.398.7.1.4.2.4.14.12 | Decreased saturation |
| 1.2.398.7.1.4.2.4.14.13 | Impaired consciousness |
| 1.2.398.7.1.4.2.4.14.14 | Hemorrhagic syndrome |
| 1.2.398.7.1.4.2.4.14.15 | Skin hemorrhages (petechiae, ecchymosis, bruising) |
| 1.2.398.7.1.4.2.4.14.16 | Bleeding of mucous membranes |
| 1.2.398.7.1.4.2.4.14.17 | Tendency to bleeding after tooth extraction |
| 1.2.398.7.1.4.2.4.14.18 | Painful hematomas in soft tissues and joints and altered coagulogram/clotting time/thromboelastogram parameters |
| 1.2.398.7.1.4.2.4.14.19 | Bleeding of varying intensity: nasal, uterine, pulmonary, intestinal |
| 1.2.398.7.1.4.2.4.14.20 | Ongoing bleeding |
| 1.2.398.7.1.4.2.4.14.21 | Hemorrhagic discharge from drains, postoperative sutures |
| 1.2.398.7.1.4.2.4.14.22 | Acute posthemorrhagic syndrome |
| 1.2.398.7.1.4.2.4.14.23 | Signs of thrombocytopenic syndrome |
| 1.2.398.7.1.4.2.4.14.24 | Thrombocytopenia less than 10\*109/l without hemorrhagic syndrome |
| 1.2.398.7.1.4.2.4.14.25 | Thrombocytopenia less than 50\*109/l before surgery |
| 1.2.398.7.1.4.2.4.14.26 | Thrombocytopenia less than 100\*109/l, before neurosurgical intervention |
| 1.2.398.7.1.4.2.4.14.27 | Thrombocytopathy with hemorrhagic syndrome |
| 15. | 1.2.398.7.1.4.2.4.15 | Transfusion therapy status | 1.2.398.7.1.4.2.4.15.1 | Transfusion completed |
| 1.2.398.7.1.4.2.4.15.2 | Transfusion interrupted |
| 1.2.398.7.1.4.2.4.15.3 | Transfusion continues |
| 16. | 1.2.398.7.1.4.2.4.16 | Adverse effects of blood and blood component transfusion | 1.2.398.7.1.4.2.4.16.1 | Mild acute transfusion reactions |
| 1.2.398.7.1.4.2.4.16.2 | Moderate acute transfusion reactions (complications) |
| 1.2.398.7.1.4.2.4.16.3 | Acute life-threatening transfusion complications |
| 17. | 1.2.398.7.1.4.2.4.17 | Laboratory test method for individual compatibility | 1.2.398.7.1.4.2.4.17.1 | Indirect antiglobulin test |
| 1.2.398.7.1.4.2.4.17.2 | Compatibility test on a plane at room temperature |
| 1.2.398.7.1.4.2.4.17.3 | Compatibility test using 10% gelatin solution |
| 1.2.398.7.1.4.2.4.17.4 | Compatibility test using 33% polyglucin solution |
| 18. | 1.2.398.7.1.4.2.4.18 | Result and interpretation of laboratory test for individual compatibility | 1.2.398.7.1.4.2.4.18.1 | Test result is positive, recipient and donor blood are incompatible |
| 1.2.398.7.1.4.2.4.18.2 | Test result is negative, recipient and donor blood are compatible |
| 19. | 1.2.398.7.1.4.2.4.19 | Measures for the treatment of adverse effects of transfusion | 1.2.398.7.1.4.2.4.19.1 | Does not require treatment |
| 1.2.398.7.1.4.2.4.19.2 | High doses of corticosteroids |
| 1.2.398.7.1.4.2.4.19.3 | Immunoglobulins |
| 1.2.398.7.1.4.2.4.19.4 | Plasma exchange |
| 1.2.398.7.1.4.2.4.19.5 | There is no effective treatment |
| 1.2.398.7.1.4.2.4.19.6 | Correction of transfusion therapy |
| 1.2.398.7.1.4.2.4.19.7 | Symptomatic treatment |
| 20. | 1.2.398.7.1.4.2.4.20 | Transfusion media | 1.2.398.7.1.4.2.4.20.1 | Whole blood |
| 1.2.398.7.1.4.2.4.20.2 | Red blood containing |
| 1.2.398.7.1.4.2.4.20.3 | Thrombocytes |
| 1.2.398.7.1.4.2.4.20.4 | Leukocytes |
| 1.2.398.7.1.4.2.4.20.5 | Granulocytes |
| 1.2.398.7.1.4.2.4.20.6 | Lymphocytes |
| 1.2.398.7.1.4.2.4.20.7 | All types of plasma and cryoprecipitate |
| 21. | 1.2.398.7.1.4.2.4.21 | Blood and its components for transfusion | 1.2.398.7.1.4.2.4.21.1 | Whole blood, leukofiltered |
| 1.2.398.7.1.4.2.4.21.2 | Whole blood, for exchange transfusion, leukofiltered |
| 1.2.398.7.1.4.2.4.21.3 | Whole blood, for exchange transfusion, leukofiltered, irradiated |
| 1.2.398.7.1.4.2.4.21.4 | Whole blood, for exchange transfusion, with reduced plasma volume, leukofiltered |
| 1.2.398.7.1.4.2.4.21.5 | Whole blood, for exchange transfusion, with reduced plasma volume, leukofiltered, irradiated |
| 1.2.398.7.1.4.2.4.21.6 | Red blood cell mass |
| 1.2.398.7.1.4.2.4.21.7 | Red blood cell mass, leukofiltered |
| 1.2.398.7.1.4.2.4.21.8 | Irradiated erythrocyte mass |
| 1.2.398.7.1.4.2.4.21.9 | Erythrocyte mass, leukofiltered, irradiated |
| 1.2.398.7.1.4.2.4.21.10 | Erythrocyte mass with removed leukothrombocyte layer |
| 1.2.398.7.1.4.2.4.21.11 | Erythrocyte mass with removed leukothrombocyte layer, irradiated |
| 1.2.398.7.1.4.2.4.21.12 | Erythrocyte mass for intrauterine transfusion, leukofiltered, irradiated |
| 1.2.398.7.1.4.2.4.21.13 | Erythrocyte mass for transfusion to newborns and infants (small volumes), leukofiltered |
| 1.2.398.7.1.4.2.4.21.14 | Erythrocyte mass for transfusion to newborns and infants (small volumes), in an additional solution, leukofiltered |
| 1.2.398.7.1.4.2.4.21.15 | Erythrocyte mass for transfusion to newborns and infants (small volumes), leukofiltered, irradiated |
| 1.2.398.7.1.4.2.4.21.16 | Erythrocyte mass for transfusion to newborns and infants (small volumes), in an additional solution, leukofiltered, irradiated |
| 1.2.398.7.1.4.2.4.21.17 | Erythrocyte mass for transfusion to newborns and infants (small volumes), with the leukothrombocyte layer removed |
| 1.2.398.7.1.4.2.4.21.18 | Erythrocyte mass for transfusion to newborns and infants (small volumes), with the leukothrombocyte layer removed, in an additional solution |
| 1.2.398.7.1.4.2.4.21.19 | Erythrocyte mass for transfusion to newborns and infants (small volumes), with the leukothrombocyte layer removed, irradiated |
| 1.2.398.7.1.4.2.4.21.20 | Erythrocyte mass for transfusion to newborns and infants (small volumes) with a removed leukothrombocyte layer, in an additional solution, irradiated |
| 1.2.398.7.1.4.2.4.21.21 | Erythrocyte suspension |
| 1.2.398.7.1.4.2.4.21.22 | Erythrocyte suspension, leukofiltered |
| 1.2.398.7.1.4.2.4.21.23 | Erythrocyte suspension, leukofiltered with reduced volume |
| 1.2.398.7.1.4.2.4.21.24 | Irradiated erythrocyte suspension |
| 1.2.398.7.1.4.2.4.21.25 | Erythrocyte suspension, leukofiltered, irradiated |
| 1.2.398.7.1.4.2.4.21.26 | Erythrocyte suspension, leukofiltered, irradiated with a reduced volume |
| 1.2.398.7.1.4.2.4.21.27 | Virusinactivated erythrocytes, washed, resuspended in an additional solution |
| 1.2.398.7.1.4.2.4.21.28 | Erythrocyte suspension with removed leukothrombocyte layer |
| 1.2.398.7.1.4.2.4.21.29 | Erythrocyte suspension with removed leukothrombocyte layer, irradiated |
| 1.2.398.7.1.4.2.4.21.30 | Apheresis erythrocytes |
| 1.2.398.7.1.4.2.4.21.31 | Apheresis leukofiltered erythrocytes |
| 1.2.398.7.1.4.2.4.21.32 | Apheresis erythrocytes, leukofiltered, irradiated |
| 1.2.398.7.1.4.2.4.21.33 | Apheresis erythrocytes in an additional solution |
| 1.2.398.7.1.4.2.4.21.34 | Apheresis erythrocytes in an additional solution, leucofiltered |
| 1.2.398.7.1.4.2.4.21.35 | Apheresis erythrocytes in an additional solution, leukofiltered, irradiated |
| 1.2.398.7.1.4.2.4.21.36 | Washed erythrocytes |
| 1.2.398.7.1.4.2.4.21.37 | Erythrocytes washed and leucofiltered |
| 1.2.398.7.1.4.2.4.21.38 | Erythrocytes washed and irradiated |
| 1.2.398.7.1.4.2.4.21.39 | Erythrocytes, washed, leucofiltered, irradiated |
| 1.2.398.7.1.4.2.4.21.40 | The erythrocytes are washed, in an additional solution |
| 1.2.398.7.1.4.2.4.21.41 | Erythrocytes washed, in an additional solution, leucofiltered |
| 1.2.398.7.1.4.2.4.21.42 | Erythrocytes washed, leucofiltered, irradiated in an additional solution |
| 1.2.398.7.1.4.2.4.21.43 | Cryopreserved erythrocytes |
| 1.2.398.7.1.4.2.4.21.44 | Cryopreserved, restored erythrocytes |
| 1.2.398.7.1.4.2.4.21.45 | Platelets recovered from a dose of whole blood |
| 1.2.398.7.1.4.2.4.21.46 | Platelets recovered from a dose of whole blood, leukofiltered |
| 1.2.398.7.1.4.2.4.21.47 | Platelets recovered from a dose of whole blood, virusinactivated |
| 1.2.398.7.1.4.2.4.21.48 | Platelets recovered from a dose of whole blood, leukofiltered, virusinactivated |
| 1.2.398.7.1.4.2.4.21.49 | Platelets recovered from a dose of whole blood, irradiated |
| 1.2.398.7.1.4.2.4.21.50 | Platelets recovered from a dose of whole blood, leukofiltered, irradiated |
| 1.2.398.7.1.4.2.4.21.51 | Platelets recovered from a dose of whole blood, leukofiltered, irradiated, for intrauterine transfusion |
| 1.2.398.7.1.4.2.4.21.52 | Platelets, restored, polished |
| 1.2.398.7.1.4.2.4.21.53 | Platelets, restored, polished, leukofiltered |
| 1.2.398.7.1.4.2.4.21.54 | Platelets, restored, polished, virusinactivated |
| 1.2.398.7.1.4.2.4.21.55 | Platelets, recovered, pooled, leukofiltered, virusinactivated |
| 1.2.398.7.1.4.2.4.21.56 | Platelets, restored, polished, irradiated |
| 1.2.398.7.1.4.2.4.21.57 | Platelets, recovered, pulsed, leukofiltered, irradiated |
| 1.2.398.7.1.4.2.4.21.58 | Platelets, apheresis |
| 1.2.398.7.1.4.2.4.21.59 | Platelets, apheresis, leukofiltered |
| 1.2.398.7.1.4.2.4.21.60 | Platelets, apheresis, virusinactivated |
| 1.2.398.7.1.4.2.4.21.61 | Platelets, apheresis, leukofiltered, virusinactivated |
| 1.2.398.7.1.4.2.4.21.62 | Platelets, apheresis, irradiated |
| 1.2.398.7.1.4.2.4.21.63 | Platelets, apheresis, leukofiltered, irradiated |
| 1.2.398.7.1.4.2.4.21.64 | Platelets, apheresis, leukofiltered, irradiated, for intrauterine transfusion |
| 1.2.398.7.1.4.2.4.21.65 | Cryopreserved platelets |
| 1.2.398.7.1.4.2.4.21.66 | Platelets, cryopreserved, restored |
| 1.2.398.7.1.4.2.4.21.67 | Platelets, cryopreserved, restored |
| 1.2.398.7.1.4.2.4.21.68 | Leukocyte mass |
| 1.2.398.7.1.4.2.4.21.69 | Leukocyte mass, irradiated |
| 1.2.398.7.1.4.2.4.21.70 | Granulocytes, apheresis, irradiated |
| 1.2.398.7.1.4.2.4.21.71 | Apheresis granulocytes |
| 1.2.398.7.1.4.2.4.21.72 | Apheresis lymphocytes |
| 1.2.398.7.1.4.2.4.21.73 | Apheresis lymphocytes with photochemical treatment |
| 1.2.398.7.1.4.2.4.21.74 | Fresh frozen plasma |
| 1.2.398.7.1.4.2.4.21.75 | Plasma, freshly frozen, quarantined |
| 1.2.398.7.1.4.2.4.21.76 | Plasma, freshly frozen, leucofiltered |
| 1.2.398.7.1.4.2.4.21.77 | Plasma, freshly frozen, leucofiltered, quarantined |
| 1.2.398.7.1.4.2.4.21.78 | Plasma, freshly frozen, virusinactivated |
| 1.2.398.7.1.4.2.4.21.79 | Plasma, freshly frozen, leucofiltered, virusinactivated |
| 1.2.398.7.1.4.2.4.21.80 | Plasma is freshly frozen, apheresis |
| 1.2.398.7.1.4.2.4.21.81 | Plasma is freshly frozen, apheresis, quarantined |
| 1.2.398.7.1.4.2.4.21.82 | Freshly frozen apheresis quarantined plasma, small dose |
| 1.2.398.7.1.4.2.4.21.83 | Plasma is freshly frozen, apheresis, leucofiltered |
| 1.2.398.7.1.4.2.4.21.84 | Plasma, freshly frozen, apheresis, leukofiltered, quarantined |
| 1.2.398.7.1.4.2.4.21.85 | Plasma, freshly frozen, apheresis, virusinactivated |
| 1.2.398.7.1.4.2.4.21.86 | Freshly frozen apheresis virusinactivated plasma, low dose |
| 1.2.398.7.1.4.2.4.21.87 | Plasma, freshly frozen, apheresis, leukofiltered, virusinactivated |
| 1.2.398.7.1.4.2.4.21.88 | Plasma is freshly frozen, immune |
| 1.2.398.7.1.4.2.4.21.89 | Plasma is freshly frozen, apheresis, immune |
| 1.2.398.7.1.4.2.4.21.90 | Plasma is freshly frozen, apheresis, immune, quarantined |
| 1.2.398.7.1.4.2.4.21.91 | Plasma is freshly frozen, apheresis, immune, leukofiltered |
| 1.2.398.7.1.4.2.4.21.92 | Plasma, freshly frozen, apheresis, immune, leukofiltered, quarantined |
| 1.2.398.7.1.4.2.4.21.93 | Plasma, freshly frozen, apheresis, immune, virusinactivated |
| 1.2.398.7.1.4.2.4.21.94 | Plasma, freshly frozen, apheresis, immune, leukofiltered, virusinactivated |
| 1.2.398.7.1.4.2.4.21.95 | Plasma, freshly frozen, apheresis, immune, leukofiltered, quarantined |
| 1.2.398.7.1.4.2.4.21.96 | The plasma is supernatant |
| 1.2.398.7.1.4.2.4.21.97 | The plasma is supernatant, quarantined |
| 1.2.398.7.1.4.2.4.21.98 | The plasma is supernatant, leucofiltered |
| 1.2.398.7.1.4.2.4.21.99 | Plasma is supernatant, leukofiltered, quarantined |
| 1.2.398.7.1.4.2.4.21.100 | The plasma is supernatant, virusinactivated |
| 1.2.398.7.1.4.2.4.21.101 | Plasma is supernatant, leukofiltered, virusinactivated |
| 1.2.398.7.1.4.2.4.21.102 | Pulsed, freshly frozen monodontic leukofiltered, virusinactivated plasma |
| 1.2.398.7.1.4.2.4.21.103 | Pulsed, freshly frozen monodontic apheresis plasma, leukofiltered, virusinactivated |
| 1.2.398.7.1.4.2.4.21.104 | Plasma pulsed, freshly frozen, and donor leucofiltered, virusinactivated |
| 1.2.398.7.1.4.2.4.21.105 | Plasma pulsed, freshly frozen, sex and donor apheresis leukofiltered, virusinactivated |
| 1.2.398.7.1.4.2.4.21.106 | Cryoprecipitate |
| 1.2.398.7.1.4.2.4.21.107 | Fibrin glue |
| 1.2.398.7.1.4.2.4.21.108 | Plasma enriched with soluble platelet factors auto/allogeneic, for topical use |
| 1.2.398.7.1.4.2.4.21.109 | Plasma for contract fractionation |
| 22. | 1.2.398.7.1.4.2.4.22 | Laboratory indicators confirming the deficiency of cells/coagulation factors | 1.2.398.7.1.4.2.4.22.1 | Hemoglobin level (Hb) |
| 1.2.398.7.1.4.2.4.22.2 | Hematocrit level (Ht) |
|  | Blood gases: |
| 1.2.398.7.1.4.2.4.22.3 | PaO2 |
| 1.2.398.7.1.4.2.4.22.4 | PvO2 |
| 1.2.398.7.1.4.2.4.22.5 | SpO2 |
| 1.2.398.7.1.4.2.4.22.6 | Lactate |
|  | Coagulogram indicators: |
| 1.2.398.7.1.4.2.4.22.7 | PV - prothrombin time |
| 1.2.398.7.1.4.2.4.22.8 | MNO - International Normalized Attitude |
| 1.2.398.7.1.4.2.4.22.9 | ACTV - active partial thrombin time |
| 1.2.398.7.1.4.2.4.22.10 | Fibrinogen, g/l |
| 1.2.398.7.1.4.2.4.22.11 | AT-III - antithrombin III |
| 1.2.398.7.1.4.2.4.22.12 | Isolated clotting factors |
| 1.2.398.7.1.4.2.4.22.13 | Plasma tolerance to heparin |
|  | Bedside coagulation tests: |
| 1.2.398.7.1.4.2.4.22.14 | Blood clotting time |
| 1.2.398.7.1.4.2.4.22.15 | Duration of bleeding |
|  | Thromboelastogram indicators: |
| 1.2.398.7.1.4.2.4.22.16 | R - the indicator characterizes the latent reaction time and determines the period of blood clotting (initiation phase) |
| 1.2.398.7.1.4.2.4.22.17 | K - time of clot formation/coagulation |
| 1.2.398.7.1.4.2.4.22.18 | SP (split point time) - time of formation of the first fibrin threads |
| 1.2.398.7.1.4.2.4.22.19 | Delta - an indicator characterizes the release of thrombin |
| 1.2.398.7.1.4.2.4.22.20 | MA - maximum amplitude, the indicator characterizes the ultimate strength of the fibrin clot |
| 1.2.398.7.1.4.2.4.22.21 | Angle alpha - the indicator characterizes the function of fibrinogen |
| 1.2.398.7.1.4.2.4.22.22 | G - calculated value, characterizes the maximum strength of the clot |
| 1.2.398.7.1.4.2.4.22.23 | CI - coagulation index |
| 1.2.398.7.1.4.2.4.22.24 | Lysis 30 - the indicator characterizes the activity of fibrinolysis |
| 1.2.398.7.1.4.2.4.22.25 | FF - functional fibrinogen |
| 1.2.398.7.1.4.2.4.22.26 | Number of platelets |
| 1.2.398.7.1.4.2.4.22.27 | Number of granulocytes |

**Guides to pregnancy and childbirth**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| № s/n | Object identifier code of the reference book | Name of the reference book | Object identifier code of the reference book value | Contents |
| 1. | 1.2.398.7.1.4.2.5.1 | Level of delivery | 1.2.398.7.1.4.2.5.1.1 | First level of delivery (low risk) |
| 1.2.398.7.1.4.2.5.1.2 | Second level of delivery |
| 1.2.398.7.1.4.2.5.1.3 | Third level A of delivery (high risk) |
| 1.2.398.7.1.4.2.5.1.4 | Third level B of delivery (very high risk, requiring high-tech medical care) |
| 2. | 1.2.398.7.1.4.2.5.2 | Place of delivery | 1.2.398.7.1.4.2.5.2.1 | In hospital |
| 1.2.398.7.1.4.2.5.2.2 | At home |
| 1.2.398.7.1.4.2.5.2.3 | In a private clinic |
| 1.2.398.7.1.4.2.5.2.4 | In another place |
| 3. | 1.2.398.7.1.4.2.5.3 | Position of fetus | 1.2.398.7.1.4.2.5.3.1 | Longitudinal |
| 1.2.398.7.1.4.2.5.3.2 | Transverse |
| 1.2.398.7.1.4.2.5.3.3 | Oblique |
| 4. | 1.2.398.7.1.4.2.5.4 | Position and view of the fetus | 1.2.398.7.1.4.2.5.4.1 | First position, anterior view |
| 1.2.398.7.1.4.2.5.4.2 | First position, posterior view |
| 1.2.398.7.1.4.2.5.4.3 | Second position, anterior view |
| 1.2.398.7.1.4.2.5.4.4 | Second position, posterior view |
| 5. | 1.2.398.7.1.4.2.5.5 | Presenting part of the fetus | 1.2.398.7.1.4.2.5.5.1 | Head |
| 1.2.398.7.1.4.2.5.5.2 | Buttocks |
| 1.2.398.7.1.4.2.5.5.3 | Not determined |
| 6. | 1.2.398.7.1.4.2.5.6 | Родовая деятельность | 1.2.398.7.1.4.2.5.6.1 | Pathological preliminary period |
| 1.2.398.7.1.4.2.5.6.2 | Discoordinated labor activity |
| 1.2.398.7.1.4.2.5.6.2.1 | Spastic |
| 1.2.398.7.1.4.2.5.6.2.2 | Tonic |
| 1.2.398.7.1.4.2.5.6.2.3 | Total dystonia |
| 1.2.398.7.1.4.2.5.6.3 | Weak labor activity |
| 1.2.398.7.1.4.2.5.6.3.1 | Primary |
| 1.2.398.7.1.4.2.5.6.3.2 | Secondary |
| 1.2.398.7.1.4.2.5.6.3.3 | Weakness of attempts |
| 1.2.398.7.1.4.2.5.6.4 | Excessively strong labor activity |
| 7. | 1.2.398.7.1.4.2.5.7 | Period of labor activity | 1.2.398.7.1.4.2.5.7.1 | The first period (disclosure) |
| 1.2.398.7.1.4.2.5.7.2 | The second (exile) |
| 1.2.398.7.1.4.2.5.7.3 | The third (postpartum) |
| 8. | 1.2.398.7.1.4.2.5.8 | Criteria of live birth | 1.2.398.7.1.4.2.5.8.1 | Breath |
| 1.2.398.7.1.4.2.5.8.2 | Heartbeat |
| 1.2.398.7.1.4.2.5.8.3 | Umbilical cord pulsation |
| 1.2.398.7.1.4.2.5.8.4 | Arbitrary muscle contraction |
| 9. | 1.2.398.7.1.4.2.5.9 | Assessment according to the Apgar scale | 1.2.398.7.1.4.2.5.9.1 | 1 |
| 1.2.398.7.1.4.2.5.9.2 | 2 |
| 1.2.398.7.1.4.2.5.9.3 | 3 |
| 1.2.398.7.1.4.2.5.9.4 | 4 |
| 1.2.398.7.1.4.2.5.9.5 | 5 |
| 1.2.398.7.1.4.2.5.9.6 | 6 |
| 1.2.398.7.1.4.2.5.9.7 | 7 |
| 1.2.398.7.1.4.2.5.9.8 | 8 |
| 1.2.398.7.1.4.2.5.9.9 | 9 |
| 1.2.398.7.1.4.2.5.9.10 | 10 |
| 10. | 1.2.398.7.1.4.2.5.10 | The baby was born | 1.2.398.7.1.4.2.5.10.1 | In case of single births |
| 1.2.398.7.1.4.2.5.10.2 | The first of the twins |
| 1.2.398.7.1.4.2.5.10.3 | The second of the twins |
| 1.2.398.7.1.4.2.5.10.4 | In other multiple births |
| 11. | 1.2.398.7.1.4.2.5.11 | Information about the timing of childbirth | 1.2.398.7.1.4.2.5.11.1 | On time |
| 1.2.398.7.1.4.2.5.11.2 | Premature |
| 1.2.398.7.1.4.2.5.11.3 | Delayed (over 42 weeks of pregnancy) |
| 12. | 1.2.398.7.1.4.2.5.12 | Pregnancy outcome | 1.2.398.7.1.4.2.5.12.1 | The birth of a living child |
| 1.2.398.7.1.4.2.5.12.2 | Stillbirth |
| 1.2.398.7.1.4.2.5.12.3 | Spontaneous miscarriage |
| 1.2.398.7.1.4.2.5.12.4 | Artificial abortion |
| 13. | 1.2.398.7.1.4.2.5.13 | The birth was delivered | 1.2.398.7.1.4.2.5.13.1 | Doctor |
| 1.2.398.7.1.4.2.5.13.2 | The midwife |
| 1.2.398.7.1.4.2.5.13.3 | The paramedic |
| 1.2.398.7.1.4.2.5.13.4 | Another person |
| 14. | 1.2.398.7.1.4.2.5.14 | The period of pregnancy at the first visit to the obstetrician (midwife) | 1.2.398.7.1.4.2.5.14.1 | 12 weeks and earlier |
| 1.2.398.7.1.4.2.5.14.2 | 13-21 weeks |
| 1.2.398.7.1.4.2.5.14.3 | 22-27 weeks |
| 1.2.398.7.1.4.2.5.14.4 | 28 weeks and later |
| 1.2.398.7.1.4.2.5.14.5 | Not applied at all |
| 15. | 1.2.398.7.1.4.2.5.15 | Nature of amniotic fluid | 1.2.398.7.1.4.2.5.15.1 | Meconium |
| 1.2.398.7.1.4.2.5.15.2 | Cloudy |
| 1.2.398.7.1.4.2.5.15.3 | Foul-smelling |
| 1.2.398.7.1.4.2.5.15.4 | With blood |
| 1.2.398.7.1.4.2.5.15.5 | Light |
| 16. | 1.2.398.7.1.4.2.5.16 | Stillbirth | 1.2.398.7.1.4.2.5.16.1 | Antenatal |
| 1.2.398.7.1.4.2.5.16.2 | Intranatal |
| 17. | 1.2.398.7.1.4.2.5.17 | Type of contraception | 1.2.398.7.1.4.2.5.17.1 | Intrauterine devices |
| 1.2.398.7.1.4.2.5.17.2 | Hormonal devices |
| 1.2.398.7.1.4.2.5.17.3 | Oral |
| 1.2.398.7.1.4.2.5.17.4 | Injectable |
| 1.2.398.7.1.4.2.5.17.5 | Spermicides |
| 1.2.398.7.1.4.2.5.17.6 | Barrier |
| 1.2.398.7.1.4.2.5.17.7 | Condoms |

**Laboratory service reference books**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| № s/n | Object identifier code of the reference book | Name of the reference book | Object identifier code of the reference book | Contents |
| 1. | 1.2.398.7.1.4.2.6.1 | Type of biomaterial | 1.2.398.7.1.4.2.6.1.1 | Cytological material obtained from amniotic fluid |
| 1.2.398.7.1.4.2.6.1.2 | A sample of amniotic fluid |
| 1.2.398.7.1.4.2.6.1.3 | Cytological material from the amnion |
| 1.2.398.7.1.4.2.6.1.4 | A sample of amniotic membrane tissue |
| 1.2.398.7.1.4.2.6.1.5 | Surgical/biopsy material from the appendix and right colon |
| 1.2.398.7.1.4.2.6.1.6 | Surgical/biopsy material of appendix tissue |
| 1.2.398.7.1.4.2.6.1.7 | A sample of the secretion of the bartholin gland |
| 1.2.398.7.1.4.2.6.1.8 | A sample of fluid from a cyst of the bartholin gland |
| 1.2.398.7.1.4.2.6.1.9 | Surgical/biopsy material of vaginal tissue |
| 1.2.398.7.1.4.2.6.1.10 | A sample of vaginal discharge |
| 1.2.398.7.1.4.2.6.1.11 | A sample of vaginal secretions |
| 1.2.398.7.1.4.2.6.1.12 | A sample of vaginal flushing |
| 1.2.398.7.1.4.2.6.1.13 | Cytological material (combined) from endocervix, exocervix and vaginal arch |
| 1.2.398.7.1.4.2.6.1.14 | A sample of genital suckers |
| 1.2.398.7.1.4.2.6.1.15 | Cytological material from the vagina |
| 1.2.398.7.1.4.2.6.1.16 | Cytological material from the vagina and cervix |
| 1.2.398.7.1.4.2.6.1.17 | Surgical/biopsy material of cervical tissue |
| 1.2.398.7.1.4.2.6.1.18 | Cytological material from the vulva |
| 1.2.398.7.1.4.2.6.1.19 | Surgical/biopsy material of vulva tissue |
| 1.2.398.7.1.4.2.6.1.20 | A sample of subretinal fluid |
| 1.2.398.7.1.4.2.6.1.21 | Surgical/biopsy material from the vascular membrane of the eye |
| 1.2.398.7.1.4.2.6.1.22 | Surgical/biopsy material of eye tissue |
| 1.2.398.7.1.4.2.6.1.23 | Surgical/biopsy material from the retina |
| 1.2.398.7.1.4.2.6.1.24 | Cytological material from the eye area |
| 1.2.398.7.1.4.2.6.1.25 | A sample of vitreous moisture |
| 1.2.398.7.1.4.2.6.1.26 | A sample of discharge from the eyes |
| 1.2.398.7.1.4.2.6.1.27 | Sample of intraocular fluid |
| 1.2.398.7.1.4.2.6.1.28 | Cytological material from the pharynx |
| 1.2.398.7.1.4.2.6.1.29 | Flushing from the throat |
| 1.2.398.7.1.4.2.6.1.30 | A sample of pus |
| 1.2.398.7.1.4.2.6.1.31 | A smear of pus |
| 1.2.398.7.1.4.2.6.1.32 | Surgical/biopsy material from the larynx |
| 1.2.398.7.1.4.2.6.1.33 | Cytological material from the larynx |
| 1.2.398.7.1.4.2.6.1.34 | Cytological material from the epiglottis |
| 1.2.398.7.1.4.2.6.1.35 | Cytological material from the vocal cords |
| 1.2.398.7.1.4.2.6.1.36 | Breast milk sample |
| 1.2.398.7.1.4.2.6.1.37 | Colostrum sample |
| 1.2.398.7.1.4.2.6.1.38 | Surgical/biopsy material of duodenal tissue |
| 1.2.398.7.1.4.2.6.1.39 | Cytological material from the duodenum |
| 1.2.398.7.1.4.2.6.1.40 | Surgical/biopsy material of bronchial tissue |
| 1.2.398.7.1.4.2.6.1.41 | Cytological material from the upper respiratory tract |
| 1.2.398.7.1.4.2.6.1.42 | Cytological material from the lower respiratory tract |
| 1.2.398.7.1.4.2.6.1.43 | Cytological material from the left main bronchus |
| 1.2.398.7.1.4.2.6.1.44 | Cytological material from the left upper lobar bronchus |
| 1.2.398.7.1.4.2.6.1.45 | Cytological material from the left inferior lobar bronchus |
| 1.2.398.7.1.4.2.6.1.46 | A sample of bronchial fluid |
| 1.2.398.7.1.4.2.6.1.47 | Cytological material from the right main bronchus |
| 1.2.398.7.1.4.2.6.1.48 | Cytological material from the right inferior lobar bronchus |
| 1.2.398.7.1.4.2.6.1.49 | Cytological material from the right medial lobar bronchus |
| 1.2.398.7.1.4.2.6.1.50 | Surgical/biopsy material from the lower respiratory tract |
| 1.2.398.7.1.4.2.6.1.51 | Surgical/biopsy material from the upper respiratory tract |
| 1.2.398.7.1.4.2.6.1.52 | Cytological material from the trachea |
| 1.2.398.7.1.4.2.6.1.53 | Cytological material from the bronchi |
| 1.2.398.7.1.4.2.6.1.54 | Cytological material from the right upper lobar bronchus |
| 1.2.398.7.1.4.2.6.1.55 | A sample of fluid from the upper respiratory tract |
| 1.2.398.7.1.4.2.6.1.56 | A sample of fluid from the lower respiratory tract |
| 1.2.398.7.1.4.2.6.1.57 | Surgical/biopsy material of tracheal tissue |
| 1.2.398.7.1.4.2.6.1.58 | Surgical/biopsy material of the stomach body tissue |
| 1.2.398.7.1.4.2.6.1.59 | Surgical/biopsy material of the fundal gastric tissue |
| 1.2.398.7.1.4.2.6.1.60 | Surgical/biopsy material of tissue from the stomach |
| 1.2.398.7.1.4.2.6.1.61 | A sample of gastric juice |
| 1.2.398.7.1.4.2.6.1.62 | Surgical/biopsy material of the tissue of the cardiac part of the stomach |
| 1.2.398.7.1.4.2.6.1.63 | Surgical/biopsy material of the pyloric stomach tissue |
| 1.2.398.7.1.4.2.6.1.64 | A sample of stomach contents |
| 1.2.398.7.1.4.2.6.1.65 | Cytological material from the stomach |
| 1.2.398.7.1.4.2.6.1.66 | Surgical/biopsy material of a gastric polyp |
| 1.2.398.7.1.4.2.6.1.67 | A sample of gastric lavage waters |
| 1.2.398.7.1.4.2.6.1.68 | A sample of gastrointestinal juice |
| 1.2.398.7.1.4.2.6.1.69 | A sample of bile |
| 1.2.398.7.1.4.2.6.1.70 | Cytological material from the Fater's papilla |
| 1.2.398.7.1.4.2.6.1.71 | Surgical/biopsy tissue material from the Fater's papilla |
| 1.2.398.7.1.4.2.6.1.72 | Cytological material from the extrahepatic bile duct |
| 1.2.398.7.1.4.2.6.1.73 | Cytological material from the bile ducts |
| 1.2.398.7.1.4.2.6.1.74 | Surgical/biopsy material of biliary tract tissue |
| 1.2.398.7.1.4.2.6.1.75 | Surgical/biopsy material of extrahepatic bile duct tissue |
| 1.2.398.7.1.4.2.6.1.76 | A sample of a gallbladder stone |
| 1.2.398.7.1.4.2.6.1.77 | Surgical/biopsy material of gallbladder tissue |
| 1.2.398.7.1.4.2.6.1.78 | Cytological material from the gallbladder |
| 1.2.398.7.1.4.2.6.1.79 | A sample of the stone of the biliary system |
| 1.2.398.7.1.4.2.6.1.80 | A sample of body fluid obtained through a cholecystostomy tube |
| 1.2.398.7.1.4.2.6.1.81 | Surgical/biopsy material from the labia |
| 1.2.398.7.1.4.2.6.1.82 | Surgical/biopsy tissue material from the gastrointestinal tract |
| 1.2.398.7.1.4.2.6.1.83 | Retroperitoneal tissue sample |
| 1.2.398.7.1.4.2.6.1.84 | A sample of dental tissue |
| 1.2.398.7.1.4.2.6.1.85 | Surgical/biopsy material of skin tissue |
| 1.2.398.7.1.4.2.6.1.86 | Cytological material from the skin |
| 1.2.398.7.1.4.2.6.1.87 | A sample of sebum |
| 1.2.398.7.1.4.2.6.1.88 | Cytological material of subcutaneous tissue |
| 1.2.398.7.1.4.2.6.1.89 | Epidermis sample |
| 1.2.398.7.1.4.2.6.1.90 | A sample of the discharge from the colostomy |
| 1.2.398.7.1.4.2.6.1.91 | Surgical/biopsy material of conjunctival tissue |
| 1.2.398.7.1.4.2.6.1.92 | Cytological material from bone marrow |
| 1.2.398.7.1.4.2.6.1.93 | Sample of trepan bone marrow biopsy |
| 1.2.398.7.1.4.2.6.1.94 | Surgical/biopsy material of bone tissue |
| 1.2.398.7.1.4.2.6.1.95 | Cytological material from bone |
| 1.2.398.7.1.4.2.6.1.96 | Umbilical cord blood sample |
| 1.2.398.7.1.4.2.6.1.97 | A serum sample from the control group |
| 1.2.398.7.1.4.2.6.1.98 | Venous blood sample |
| 1.2.398.7.1.4.2.6.1.99 | Arterial blood sample |
| 1.2.398.7.1.4.2.6.1.100 | Menstrual blood sample |
| 1.2.398.7.1.4.2.6.1.101 | Capillary blood sample |
| 1.2.398.7.1.4.2.6.1.102 | Peripheral blood sample |
| 1.2.398.7.1.4.2.6.1.103 | A sample of the patient's serum |
| 1.2.398.7.1.4.2.6.1.104 | Fetal umbilical cord blood sample |
| 1.2.398.7.1.4.2.6.1.105 | A serum sample from donated blood |
| 1.2.398.7.1.4.2.6.1.106 | A sample of the patient's serum |
| 1.2.398.7.1.4.2.6.1.107 | A sample of serum from a blood preparation |
| 1.2.398.7.1.4.2.6.1.108 | Mixed venous blood sample |
| 1.2.398.7.1.4.2.6.1.109 | A sample of red blood cells from donated blood |
| 1.2.398.7.1.4.2.6.1.110 | A blood smear sample |
| 1.2.398.7.1.4.2.6.1.111 | A sample of venous cord blood |
| 1.2.398.7.1.4.2.6.1.112 | Arterial cord blood sample |
| 1.2.398.7.1.4.2.6.1.113 | Surgical/biopsy material of lung tissue |
| 1.2.398.7.1.4.2.6.1.114 | A sample of a donor lung |
| 1.2.398.7.1.4.2.6.1.115 | Cytological material from the lung |
| 1.2.398.7.1.4.2.6.1.116 | A sample of lymph |
| 1.2.398.7.1.4.2.6.1.117 | A sample of a frozen section of a lymph node |
| 1.2.398.7.1.4.2.6.1.118 | Surgical/biopsy material of lymph node tissue |
| 1.2.398.7.1.4.2.6.1.119 | Cytological material from the lymph node |
| 1.2.398.7.1.4.2.6.1.120 | Cytological material from the cervix |
| 1.2.398.7.1.4.2.6.1.121 | Surgical/biopsy material of tissue from the uterus |
| 1.2.398.7.1.4.2.6.1.122 | Aspirate from the uterine space |
| 1.2.398.7.1.4.2.6.1.123 | Surgical/biopsy tissue material from ectopic pregnancy |
| 1.2.398.7.1.4.2.6.1.124 | A tissue sample from the uterus obtained during curettage |
| 1.2.398.7.1.4.2.6.1.125 | Cytological material from the fallopian tube |
| 1.2.398.7.1.4.2.6.1.126 | Surgical/biopsy tissue material from the left fallopian tube |
| 1.2.398.7.1.4.2.6.1.127 | Surgical/biopsy tissue material from the right fallopian tube |
| 1.2.398.7.1.4.2.6.1.128 | Surgical/biopsy material of uterine and fallopian tube tissues |
| 1.2.398.7.1.4.2.6.1.129 | Sputum smear sample |
| 1.2.398.7.1.4.2.6.1.130 | Sputum sample |
| 1.2.398.7.1.4.2.6.1.131 | Cytological material obtained from sputum |
| 1.2.398.7.1.4.2.6.1.132 | Cytological material from the breast |
| 1.2.398.7.1.4.2.6.1.133 | Cytological material from the breast nipple |
| 1.2.398.7.1.4.2.6.1.134 | Surgical/biopsy material of breast tissue |
| 1.2.398.7.1.4.2.6.1.135 | A sample of fluid from a breast cyst |
| 1.2.398.7.1.4.2.6.1.136 | Surgical/biopsy material from a breast with a lymph node |
| 1.2.398.7.1.4.2.6.1.137 | A sample of breast fluid |
| 1.2.398.7.1.4.2.6.1.138 | Nipple discharge sample |
| 1.2.398.7.1.4.2.6.1.139 | Frozen breast section sample |
| 1.2.398.7.1.4.2.6.1.140 | Cytological material obtained from nipple secretions |
| 1.2.398.7.1.4.2.6.1.141 | A urine sample obtained by the Nechiporenko method |
| 1.2.398.7.1.4.2.6.1.142 | A sample of a single urine sample |
| 1.2.398.7.1.4.2.6.1.143 | 24-hour urine sample |
| 1.2.398.7.1.4.2.6.1.144 | Sample of an average portion of urine |
| 1.2.398.7.1.4.2.6.1.145 | Morning urine sample |
| 1.2.398.7.1.4.2.6.1.146 | A sample of a 2-hour urine sample |
| 1.2.398.7.1.4.2.6.1.147 | A sample of postcoital urine |
| 1.2.398.7.1.4.2.6.1.148 | Sample of an 8-hour urine sample |
| 1.2.398.7.1.4.2.6.1.149 | Sample of a 12-hour urine sample |
| 1.2.398.7.1.4.2.6.1.150 | Urine sample after ejaculation |
| 1.2.398.7.1.4.2.6.1.151 | A sample of a 48-hour urine sample |
| 1.2.398.7.1.4.2.6.1.152 | A sample of a 72-hour urine sample |
| 1.2.398.7.1.4.2.6.1.153 | A urine sample obtained through a catheter |
| 1.2.398.7.1.4.2.6.1.154 | A sample of the morning average portion of urine obtained during urine donation according to Nechiporenko |
| 1.2.398.7.1.4.2.6.1.155 | Urine sediment sample |
| 1.2.398.7.1.4.2.6.1.156 | A urine sample collected over a certain period of time |
| 1.2.398.7.1.4.2.6.1.157 | A sample of the first portion of urine |
| 1.2.398.7.1.4.2.6.1.158 | A urine sample obtained during the second emptying |
| 1.2.398.7.1.4.2.6.1.159 | A sample of urine from the bladder |
| 1.2.398.7.1.4.2.6.1.160 | Urine sample from the urethra |
| 1.2.398.7.1.4.2.6.1.161 | Cytological material obtained from urine |
| 1.2.398.7.1.4.2.6.1.162 | A urine sample obtained from the kidneys |
| 1.2.398.7.1.4.2.6.1.163 | Urine sample from the ureter |
| 1.2.398.7.1.4.2.6.1.164 | Cytological material from the bladder |
| 1.2.398.7.1.4.2.6.1.165 | Cytological material from the prostate |
| 1.2.398.7.1.4.2.6.1.166 | A sample of bladder scraping |
| 1.2.398.7.1.4.2.6.1.167 | A sample of a bladder stone |
| 1.2.398.7.1.4.2.6.1.168 | Surgical/biopsy material of bladder tissue |
| 1.2.398.7.1.4.2.6.1.169 | A sample of a frozen section of the bladder |
| 1.2.398.7.1.4.2.6.1.170 | Surgical/biopsy material of urethral tissue |
| 1.2.398.7.1.4.2.6.1.171 | Cytological material from the ureter |
| 1.2.398.7.1.4.2.6.1.172 | Cytological material from the urethra |
| 1.2.398.7.1.4.2.6.1.173 | Ureteral stone sample |
| 1.2.398.7.1.4.2.6.1.174 | Surgical/biopsy material of ureteral tissue |
| 1.2.398.7.1.4.2.6.1.175 | Cytological material from skeletal muscle |
| 1.2.398.7.1.4.2.6.1.176 | A sample of fascial-sheath cervical dissection |
| 1.2.398.7.1.4.2.6.1.177 | Fascia sample |
| 1.2.398.7.1.4.2.6.1.178 | Cytological material from the neck obtained during fine needle aspiration |
| 1.2.398.7.1.4.2.6.1.179 | Cytological material from the neck formation obtained during fine needle aspiration |
| 1.2.398.7.1.4.2.6.1.180 | Surgical/biopsy material of tissue from the axillary fossa |
| 1.2.398.7.1.4.2.6.1.181 | A sample of liquid from the subdiaphragmatic space |
| 1.2.398.7.1.4.2.6.1.182 | Surgical/biopsy material of the adrenal gland tissue |
| 1.2.398.7.1.4.2.6.1.183 | Nasal fluid sample |
| 1.2.398.7.1.4.2.6.1.184 | Surgical/biopsy material of tissue from the inner nose |
| 1.2.398.7.1.4.2.6.1.185 | Nasal polyp sample |
| 1.2.398.7.1.4.2.6.1.186 | Flushing from the nasopharynx |
| 1.2.398.7.1.4.2.6.1.187 | Cytological material from the nose |
| 1.2.398.7.1.4.2.6.1.188 | Cytological material from the nasopharynx |
| 1.2.398.7.1.4.2.6.1.189 | Cytological material from the paranasal sinus |
| 1.2.398.7.1.4.2.6.1.190 | Flushing from the paranasal sinuses |
| 1.2.398.7.1.4.2.6.1.191 | A sample of the contents of the paranasal sinus |
| 1.2.398.7.1.4.2.6.1.192 | A sample of the discharge from the sinus |
| 1.2.398.7.1.4.2.6.1.193 | Surgical/biopsy material of parathyroid tissue |
| 1.2.398.7.1.4.2.6.1.194 | Peritoneal fluid sample |
| 1.2.398.7.1.4.2.6.1.195 | Sample of ascitic fluid |
| 1.2.398.7.1.4.2.6.1.196 | Cytological material from the peritoneum |
| 1.2.398.7.1.4.2.6.1.197 | Surgical/biopsy material of liver tissue |
| 1.2.398.7.1.4.2.6.1.198 | Cytological material of the liver |
| 1.2.398.7.1.4.2.6.1.199 | A sample from an explanted liver |
| 1.2.398.7.1.4.2.6.1.200 | Surgical/biopsy material of esophageal tissue |
| 1.2.398.7.1.4.2.6.1.201 | Sample of brush scraping of the esophagus |
| 1.2.398.7.1.4.2.6.1.202 | Cytological material from the esophagus |
| 1.2.398.7.1.4.2.6.1.203 | Plasma sample |
| 1.2.398.7.1.4.2.6.1.204 | A sample of platelet-rich plasma |
| 1.2.398.7.1.4.2.6.1.205 | Venous plasma sample |
| 1.2.398.7.1.4.2.6.1.206 | Plasma sample with ethylenediaminetetraacetic acid |
| 1.2.398.7.1.4.2.6.1.207 | A sample of platelet-depleted plasma |
| 1.2.398.7.1.4.2.6.1.208 | A sample of the patient's platelet-poor plasma |
| 1.2.398.7.1.4.2.6.1.209 | A sample of platelet-depleted plasma from the control group |
| 1.2.398.7.1.4.2.6.1.210 | A sample of cell-free blood (serum or plasma) |
| 1.2.398.7.1.4.2.6.1.211 | Plasma sample with citrate |
| 1.2.398.7.1.4.2.6.1.212 | A sample of polished platelet-poor plasma |
| 1.2.398.7.1.4.2.6.1.213 | A tissue sample from the placenta |
| 1.2.398.7.1.4.2.6.1.214 | Cytological material from chorion |
| 1.2.398.7.1.4.2.6.1.215 | Cytological material from the placenta |
| 1.2.398.7.1.4.2.6.1.216 | Sample of umbilical cord tissue |
| 1.2.398.7.1.4.2.6.1.217 | A sample of placental sheath tissue |
| 1.2.398.7.1.4.2.6.1.218 | A sample of trophoblast tissue |
| 1.2.398.7.1.4.2.6.1.219 | Cytological material from the pleura |
| 1.2.398.7.1.4.2.6.1.220 | Surgical/biopsy material of pleural tissue |
| 1.2.398.7.1.4.2.6.1.221 | A sample of chyletic fluid |
| 1.2.398.7.1.4.2.6.1.222 | A sample of pleural fluid |
| 1.2.398.7.1.4.2.6.1.223 | A tissue sample from the chest mesothelium |
| 1.2.398.7.1.4.2.6.1.224 | Cytological material obtained from pleural fluid |
| 1.2.398.7.1.4.2.6.1.225 | Cytological material of the fetus (fetal) |
| 1.2.398.7.1.4.2.6.1.226 | Surgical/biopsy material of pancreatic glans tissue |
| 1.2.398.7.1.4.2.6.1.227 | Surgical/biopsy material of pancreatic tissue |
| 1.2.398.7.1.4.2.6.1.228 | Surgical/biopsy material of pancreatic tail tissue |
| 1.2.398.7.1.4.2.6.1.229 | Surgical/biopsy material of pancreatic body tissue |
| 1.2.398.7.1.4.2.6.1.230 | A sample of fluid from a pancreatic cyst |
| 1.2.398.7.1.4.2.6.1.231 | A sample of pancreatic stone |
| 1.2.398.7.1.4.2.6.1.232 | A sample of pancreatic juice |
| 1.2.398.7.1.4.2.6.1.233 | Cytological material from the pancreas |
| 1.2.398.7.1.4.2.6.1.234 | Surgical/biopsy material of tissue from the ileum |
| 1.2.398.7.1.4.2.6.1.235 | Cytological material from the ileum |
| 1.2.398.7.1.4.2.6.1.236 | A sample of tissue from the penis |
| 1.2.398.7.1.4.2.6.1.237 | Cytological material from the penis |
| 1.2.398.7.1.4.2.6.1.238 | A sample of discharge from the penis |
| 1.2.398.7.1.4.2.6.1.239 | Sweat sample |
| 1.2.398.7.1.4.2.6.1.240 | Cytological material from the renal pelvis |
| 1.2.398.7.1.4.2.6.1.241 | A sample of fluid from the renal pelvis |
| 1.2.398.7.1.4.2.6.1.242 | Surgical/biopsy tissue material from the renal pelvis |
| 1.2.398.7.1.4.2.6.1.243 | Flushing from the kidney |
| 1.2.398.7.1.4.2.6.1.244 | Surgical/biopsy material of kidney tissue |
| 1.2.398.7.1.4.2.6.1.245 | A sample of a brush biopsy of the kidney |
| 1.2.398.7.1.4.2.6.1.246 | Surgical/biopsy tissue material from the left kidney |
| 1.2.398.7.1.4.2.6.1.247 | Kidney stone sample |
| 1.2.398.7.1.4.2.6.1.248 | Surgical/biopsy tissue material from the right kidney |
| 1.2.398.7.1.4.2.6.1.249 | Surgical/biopsy material of the tissue of the upper pole of the left kidney |
| 1.2.398.7.1.4.2.6.1.250 | Surgical/biopsy material of the tissue of the lower pole of the left kidney |
| 1.2.398.7.1.4.2.6.1.251 | Surgical/biopsy material of the tissue of the lower pole of the right kidney |
| 1.2.398.7.1.4.2.6.1.252 | Surgical/biopsy material of the tissue of the upper pole of the right kidney |
| 1.2.398.7.1.4.2.6.1.253 | Surgical/biopsy material of prostate tissue |
| 1.2.398.7.1.4.2.6.1.254 | A sample of prostatic secretions |
| 1.2.398.7.1.4.2.6.1.255 | Biopsy of the rectal mucosa |
| 1.2.398.7.1.4.2.6.1.256 | An anal polyp sample |
| 1.2.398.7.1.4.2.6.1.257 | A sample of hemorrhoidal tissue |
| 1.2.398.7.1.4.2.6.1.258 | Cytological material from the anus |
| 1.2.398.7.1.4.2.6.1.259 | Cytological material from the rectum |
| 1.2.398.7.1.4.2.6.1.260 | Surgical/biopsy tissue material from the anus |
| 1.2.398.7.1.4.2.6.1.261 | Rectal pollip sample |
| 1.2.398.7.1.4.2.6.1.262 | Surgical/biopsy material of rectal tissue |
| 1.2.398.7.1.4.2.6.1.263 | A sample of vomit |
| 1.2.398.7.1.4.2.6.1.264 | Surgical/biopsy material of corneal tissue |
| 1.2.398.7.1.4.2.6.1.265 | A tissue sample from a donor cornea |
| 1.2.398.7.1.4.2.6.1.266 | Surgical/biopsy material of oral tissue |
| 1.2.398.7.1.4.2.6.1.267 | Sample of oral secretions |
| 1.2.398.7.1.4.2.6.1.268 | Cytological material from the lips |
| 1.2.398.7.1.4.2.6.1.269 | Cytological material from the oral cavity |
| 1.2.398.7.1.4.2.6.1.270 | Surgical/biopsy material of the uvula tissue |
| 1.2.398.7.1.4.2.6.1.271 | A sample of dentoalveolar fluid |
| 1.2.398.7.1.4.2.6.1.272 | Oropharyngeal aspirate |
| 1.2.398.7.1.4.2.6.1.273 | Biopsy of ligaments |
| 1.2.398.7.1.4.2.6.1.274 | Tendon biopsy |
| 1.2.398.7.1.4.2.6.1.275 | Surgical/biopsy material of tissue from the heart |
| 1.2.398.7.1.4.2.6.1.276 | Heart Valve Tissue |
| 1.2.398.7.1.4.2.6.1.277 | Cytological material obtained from pericardial fluid |
| 1.2.398.7.1.4.2.6.1.278 | Cytological material of the heart |
| 1.2.398.7.1.4.2.6.1.279 | Cytological material from the pericardium |
| 1.2.398.7.1.4.2.6.1.280 | Surgical/biopsy material of pericardial tissue |
| 1.2.398.7.1.4.2.6.1.281 | Synovial fluid sample |
| 1.2.398.7.1.4.2.6.1.282 | Cytological material obtained from articular fluid |
| 1.2.398.7.1.4.2.6.1.283 | Surgical/biopsy material of the synovial bag |
| 1.2.398.7.1.4.2.6.1.284 | Cytological material obtained from synovial fluid |
| 1.2.398.7.1.4.2.6.1.285 | A sample containing crystals from the synovial joint |
| 1.2.398.7.1.4.2.6.1.286 | A sample of tears |
| 1.2.398.7.1.4.2.6.1.287 | A sample of fluid from the mucous membrane of the lacrimal sac |
| 1.2.398.7.1.4.2.6.1.288 | Cytological material from the parotid gland |
| 1.2.398.7.1.4.2.6.1.289 | Cytological material from the salivary gland |
| 1.2.398.7.1.4.2.6.1.290 | Cytological material from the submandibular gland |
| 1.2.398.7.1.4.2.6.1.291 | Saliva sample |
| 1.2.398.7.1.4.2.6.1.292 | Surgical/biopsy material of sublingual salivary gland tissue |
| 1.2.398.7.1.4.2.6.1.293 | Surgical/biopsy material of submandibular salivary gland tissue |
| 1.2.398.7.1.4.2.6.1.294 | Surgical/biopsy material of parotid salivary gland tissue |
| 1.2.398.7.1.4.2.6.1.295 | Salivary stone sample |
| 1.2.398.7.1.4.2.6.1.296 | Surgical/biopsy material of salivary gland tissue |
| 1.2.398.7.1.4.2.6.1.297 | Surgical/biopsy material of tissue from the large salivary gland |
| 1.2.398.7.1.4.2.6.1.298 | A tissue sample from an aneurysm obtained during surgical excision |
| 1.2.398.7.1.4.2.6.1.299 | A tissue sample from the aorta |
| 1.2.398.7.1.4.2.6.1.300 | Seminal fluid sample |
| 1.2.398.7.1.4.2.6.1.301 | Seminal plasma sample |
| 1.2.398.7.1.4.2.6.1.302 | A sample of liquid from seroma |
| 1.2.398.7.1.4.2.6.1.303 | Cytological material from spermatozoa |
| 1.2.398.7.1.4.2.6.1.304 | A sample of fluid from a spermatocele |
| 1.2.398.7.1.4.2.6.1.305 | Cytological material from cerebrospinal fluid |
| 1.2.398.7.1.4.2.6.1.306 | A sample of cerebrospinal fluid |
| 1.2.398.7.1.4.2.6.1.307 | A sample of a cerebrospinal fluid smear |
| 1.2.398.7.1.4.2.6.1.308 | Centrifuged cerebrospinal fluid |
| 1.2.398.7.1.4.2.6.1.309 | A sample of cerebrospinal fluid from the ventricle of the brain |
| 1.2.398.7.1.4.2.6.1.310 | A sample of cerebrospinal fluid obtained from the Rackham reservoir |
| 1.2.398.7.1.4.2.6.1.311 | A sample of cerebrospinal fluid obtained through a ventriculoperitoneal shunt |
| 1.2.398.7.1.4.2.6.1.312 | A sample of liquid from the subdural space |
| 1.2.398.7.1.4.2.6.1.313 | A sample of fluid from the epidural space |
| 1.2.398.7.1.4.2.6.1.314 | A sample of fecal fluid |
| 1.2.398.7.1.4.2.6.1.315 | Fecal smear |
| 1.2.398.7.1.4.2.6.1.316 | A sample of fecal calculus |
| 1.2.398.7.1.4.2.6.1.317 | Chair sample |
| 1.2.398.7.1.4.2.6.1.318 | The meconium sample |
| 1.2.398.7.1.4.2.6.1.319 | A sample of articular tissue |
| 1.2.398.7.1.4.2.6.1.320 | Surgical/biopsy material of thymus tissue |
| 1.2.398.7.1.4.2.6.1.321 | Surgical/biopsy material of the distal ileum |
| 1.2.398.7.1.4.2.6.1.322 | A sample of a colon polyp |
| 1.2.398.7.1.4.2.6.1.323 | A sample of a brush smear of the sigmoid colon |
| 1.2.398.7.1.4.2.6.1.324 | Cytological material from the colon |
| 1.2.398.7.1.4.2.6.1.325 | Surgical/biopsy material of colon tissue |
| 1.2.398.7.1.4.2.6.1.326 | Surgical/biopsy material of colon tissue |
| 1.2.398.7.1.4.2.6.1.327 | Ileostomy fluid sample |
| 1.2.398.7.1.4.2.6.1.328 | A sample of a sigmoid colon polyp |
| 1.2.398.7.1.4.2.6.1.329 | Surgical/biopsy material from the appendix and colon |
| 1.2.398.7.1.4.2.6.1.330 | Cytological material from the small intestine |
| 1.2.398.7.1.4.2.6.1.331 | Surgical/biopsy material of tissue from the small intestine |
| 1.2.398.7.1.4.2.6.1.332 | A sample of jejunum juice |
| 1.2.398.7.1.4.2.6.1.333 | Cytological material from the jejunum |
| 1.2.398.7.1.4.2.6.1.334 | A sample of fluid from the middle ear |
| 1.2.398.7.1.4.2.6.1.335 | Cytological material from the ear |
| 1.2.398.7.1.4.2.6.1.336 | A sample of fluid from the ear |
| 1.2.398.7.1.4.2.6.1.337 | A sample of fluid from the external auditory canal |
| 1.2.398.7.1.4.2.6.1.338 | Sample of sulfur plug |
| 1.2.398.7.1.4.2.6.1.339 | Ear tissue sample |
| 1.2.398.7.1.4.2.6.1.340 | Surgical material of cartilage tissue |
| 1.2.398.7.1.4.2.6.1.341 | A sample of fluid from a cyst of the central nervous system |
| 1.2.398.7.1.4.2.6.1.342 | Cytological material from cerebroventricular fluid |
| 1.2.398.7.1.4.2.6.1.343 | Surgical/biopsy material of brain tissue |
| 1.2.398.7.1.4.2.6.1.344 | Surgical/biopsy material of nervous system tissue |
| 1.2.398.7.1.4.2.6.1.345 | Surgical/biopsy material of central nervous system tissue |
| 1.2.398.7.1.4.2.6.1.346 | A sample of cervical secretions |
| 1.2.398.7.1.4.2.6.1.347 | A sample of an endocervical polyp |
| 1.2.398.7.1.4.2.6.1.348 | A sample of cervical mucus |
| 1.2.398.7.1.4.2.6.1.349 | Cytological material from the cervix |
| 1.2.398.7.1.4.2.6.1.350 | Surgical/biopsy material from a cervical polyp |
| 1.2.398.7.1.4.2.6.1.351 | Surgical/biopsy material from the thyroid gland |
| 1.2.398.7.1.4.2.6.1.352 | A sample of fluid from a thyroid cyst |
| 1.2.398.7.1.4.2.6.1.353 | Cytological material from the thyroid gland |
| 1.2.398.7.1.4.2.6.1.354 | Surgical/biopsy material of the left lobe of the thyroid gland |
| 1.2.398.7.1.4.2.6.1.355 | Surgical/biopsy material of the right lobe of the thyroid gland |
| 1.2.398.7.1.4.2.6.1.356 | A sample of thyroid fluid |
| 1.2.398.7.1.4.2.6.1.357 | Surgical/biopsy material of endometrial tissue |
| 1.2.398.7.1.4.2.6.1.358 | Endometrial polyp sample |
| 1.2.398.7.1.4.2.6.1.359 | Cytological material from the endometrium |
| 1.2.398.7.1.4.2.6.1.360 | Surgical/biopsy material of testicular tissue |
| 1.2.398.7.1.4.2.6.1.361 | A sample of liquid from a hydrocele |
| 1.2.398.7.1.4.2.6.1.362 | Cytological material from the testis |
| 1.2.398.7.1.4.2.6.1.363 | Cytological material from the epididymis |
| 1.2.398.7.1.4.2.6.1.364 | Cytological material from the vas deferens |
| 1.2.398.7.1.4.2.6.1.365 | Cytological material from seminal vesicles |
| 1.2.398.7.1.4.2.6.1.366 | A sample of fluid from the epididymis |
| 1.2.398.7.1.4.2.6.1.367 | Surgical/biopsy material of ovarian tissue |
| 1.2.398.7.1.4.2.6.1.368 | Surgical/biopsy material of the tissue of the left ovary |
| 1.2.398.7.1.4.2.6.1.369 | Surgical/biopsy material of right ovarian tissue |
| 1.2.398.7.1.4.2.6.1.370 | Cytological material from the ovary |
| 1.2.398.7.1.4.2.6.1.371 | Ovarian fluid sample |
| 1.2.398.7.1.4.2.6.1.372 | A sample of fluid from an ovarian cyst |
| 1.2.398.7.1.4.2.6.1.373 | A sample of adipose tissue |
| 1.2.398.7.1.4.2.6.1.374 | A sample of scar tissue |
| 1.2.398.7.1.4.2.6.1.375 | A sample of fluid from a sebaceous gland cyst |
| 1.2.398.7.1.4.2.6.1.376 | A sample of the discharge from the wound |
| 1.2.398.7.1.4.2.6.1.377 | Burn tissue |
| 1.2.398.7.1.4.2.6.1.378 | A sample of the stuffing box fabric |
| 1.2.398.7.1.4.2.6.1.379 | A sample of necrotic tissue |
| 1.2.398.7.1.4.2.6.1.380 | A sample from granulation tissue |
| 2. | 1.2.398.7.1.4.2.6.2 | Urine color | 1.2.398.7.1.4.2.6.2.1 | Yellow |
| 1.2.398.7.1.4.2.6.2.2 | Pale yellow |
| 1.2.398.7.1.4.2.6.2.3 | Saturated yellow |
| 1.2.398.7.1.4.2.6.2.4 | Straw yellow |
| 1.2.398.7.1.4.2.6.2.5 | Pale straw yellow |
| 1.2.398.7.1.4.2.6.2.6 | Anuria |
| 1.2.398.7.1.4.2.6.2.7 | Red |
| 1.2.398.7.1.4.2.6.2.8 | Brown |
| 1.2.398.7.1.4.2.6.2.9 | Reddish yellow |
| 1.2.398.7.1.4.2.6.2.10 | Pink-red |
| 1.2.398.7.1.4.2.6.2.11 | Grey-pink |
| 1.2.398.7.1.4.2.6.2.12 | Greenish |
| 1.2.398.7.1.4.2.6.2.13 | Greenish yellow |
| 1.2.398.7.1.4.2.6.2.14 | Yellow-brown |
| 1.2.398.7.1.4.2.6.2.15 | Brown |
| 1.2.398.7.1.4.2.6.2.16 | Milky white |
| 1.2.398.7.1.4.2.6.2.17 | Dark brown |
| 1.2.398.7.1.4.2.6.2.18 | Black |
| 1.2.398.7.1.4.2.6.2.19 | Bluish |
| 1.2.398.7.1.4.2.6.2.20 | Colorless |
| 1.2.398.7.1.4.2.6.2.21 | Pus in the urine |
| 1.2.398.7.1.4.2.6.2.22 | Fat in the urine |
| 1.2.398.7.1.4.2.6.2.23 | Macrohematuria |
| 3. | 1.2.398.7.1.4.2.6.3 | Contingent of the examined for human immunodeficiency virus | 1.2.398.7.1.4.2.6.3.1 | Citizens of the Republic of Kazakhstan (total), including |
| 1.2.398.7.1.4.2.6.3.2 | Persons who have been in contact with people infected with the human immunodeficiency virus or patients with acquired immunodeficiency syndrome, including |
| 1.2.398.7.1.4.2.6.3.2.1 | sexual contact |
| 1.2.398.7.1.4.2.6.3.2.2 | and drug administration |
| 1.2.398.7.1.4.2.6.3.3 | People who inject drugs, including |
| 1.2.398.7.1.4.2.6.3.3.1 | People who inject drugs, examined when registering with a narcologist |
| 1.2.398.7.1.4.2.6.3.3.2 | People who inject drugs who are registered with a narcologist |
| 1.2.398.7.1.4.2.6.3.3.3 | People who inject drugs, who have applied to preventive programs (points of trust, friendly offices, non-governmental organizations) |
| 1.2.398.7.1.4.2.6.3.3.4 | Men having sex with men |
| 1.2.398.7.1.4.2.6.3.3.5 | Patients, persons with symptoms of sexually transmitted |
| 1.2.398.7.1.4.2.6.3.3.6 | infections Sex workers |
| 1.2.398.7.1.4.2.6.3.4 | Persons examined during the epidermis (total), including |
| 1.2.398.7.1.4.2.6.3.4.1 | adults examined during the epidermis, |
| 1.2.398.7.1.4.2.6.3.4.2 | children examined during the epidermis |
| 1.2.398.7.1.4.2.6.3.5 | Persons examined in emergency situations (total), including |
| 1.2.398.7.1.4.2.6.3.5.1 | number of medical workers examined in case of an emergency |
| 1.2.398.7.1.4.2.6.3.5.2 | number of other persons examined in case of an emergency |
| 1.2.398.7.1.4.2.6.3.6 | Donors (of blood and other biological fluids, organs, parts of organs and tissues) total, including |
| 1.2.398.7.1.4.2.6.3.6.1 | donors of blood and its components |
| 1.2.398.7.1.4.2.6.3.6.2 | donors of germ cells (gametes) and embryos |
| 1.2.398.7.1.4.2.6.3.6.3 | donors of tissues and organs |
| 1.2.398.7.1.4.2.6.3.7 | Pregnant women (total) |
| 1.2.398.7.1.4.2.6.3.7.1 | first test (at registration) |
| 1.2.398.7.1.4.2.6.3.7.2 | second test |
| 1.2.398.7.1.4.2.6.3.7.3 | testing at the maternity hospital |
| 1.2.398.7.1.4.2.6.3.7.4 | termination of pregnancy |
| 1.2.398.7.1.4.2.6.3.8 | Recipients of blood components and other biological materials (total), including |
| 1.2.398.7.1.4.2.6.3.8.1 | persons examined before hemotransfusion and organ transplantation, parts of organs of tissues, genital, fetal cells |
| 1.2.398.7.1.4.2.6.3.8.2 | recipients examined after hemotransfusion and transplantation of organs, tissues, genital, fetal cells after 1 month |
| 1.2.398.7.1.4.2.6.3.8.3 | recipients examined after hemotransfusion and transplantation of organs, tissues, genital, fetal cells after 3 months |
| 1.2.398.7.1.4.2.6.3.9 | Military personnel |
| 1.2.398.7.1.4.2.6.3.9.1 | persons called up for military service, entering service under contract, applicants to military educational institutions |
| 1.2.398.7.1.4.2.6.3.10 | Persons held in pre-trial detention centres and correctional institutions, total |
| 1.2.398.7.1.4.2.6.3.10.1 | persons arrested under investigation, examined upon admission to a pre-trial detention centre |
| 1.2.398.7.1.4.2.6.3.10.2 | arrested under investigation, examined after six months in a pre-trial detention centre |
| 1.2.398.7.1.4.2.6.3.10.3 | convicted persons examined upon admission to a correctional institution |
| 1.2.398.7.1.4.2.6.3.10.4 | convicted persons examined after six or more months in a correctional institution |
| 1.2.398.7.1.4.2.6.3.10.5 | convicted persons examined before release from penitentiary institutions |
| 1.2.398.7.1.4.2.6.3.11 | Examined for clinical indications (adults) in total, including |
| 1.2.398.7.1.4.2.6.3.11.1 | pulmonary tuberculosis and extrapulmonary |
| 1.2.398.7.1.4.2.6.3.11.2 | viral hepatitis B |
| 1.2.398.7.1.4.2.6.3.11.3 | viral hepatitis C |
| 1.2.398.7.1.4.2.6.3.11.4 | other clinical conditions possible with human immunodeficiency virus infection |
| 1.2.398.7.1.4.2.6.3.12 | Examined anonymously |
| 1.2.398.7.1.4.2.6.3.13 | Persons traveling abroad |
| 1.2.398.7.1.4.2.6.3.14 | Persons applying for quotas for treatment in specialized clinics |
| 1.2.398.7.1.4.2.6.3.15 | Children examined for clinical indications, total |
| 1.2.398.7.1.4.2.6.3.16 | Persons held in temporary detention facilities, juvenile adaptation centers, distribution centers |
| 1.2.398.7.1.4.2.6.3.17 | Medical workers |
| 1.2.398.7.1.4.2.6.3.18 | Persons who applied to participate in donation, from whom blood components were not harvested. |
| 1.2.398.7.1.4.2.6.3.19 | Children born to mothers infected with the human immunodeficiency virus |
| 1.2.398.7.1.4.2.6.3.20 | Persons applying to children's homes, boarding schools, social protection organizations |
| 1.2.398.7.1.4.2.6.3.21 | Other persons who do not belong to any of the above codes (adults) |
| 1.2.398.7.1.4.2.6.3.22 | Foreign citizens (total), including |
| 1.2.398.7.1.4.2.6.3.22.1 | vulnerable groups (people who inject drugs, sex workers, men who have sex with men) |
| 1.2.398.7.1.4.2.6.3.22.2 | persons held in pre-trial detention centers and correctional institutions |
| 1.2.398.7.1.4.2.6.3.22.3 | pregnant women |
| 4. | 1.2.398.7.1.4.2.6.4 | Active ingredient (allergens) | 1.2.398.7.1.4.2.6.4.1 | Cocaine |
| 1.2.398.7.1.4.2.6.4.2 | Dokuzat |
| 1.2.398.7.1.4.2.6.4.3 | Alverin |
| 1.2.398.7.1.4.2.6.4.4 | Ketamine |
| 1.2.398.7.1.4.2.6.4.5 | Propofol |
| 1.2.398.7.1.4.2.6.4.6 | Procaine |
| 1.2.398.7.1.4.2.6.4.7 | Busulfan |
| 1.2.398.7.1.4.2.6.4.8 | Tiotepa |
| 1.2.398.7.1.4.2.6.4.9 | Razoxan |
| 1.2.398.7.1.4.2.6.4.10 | Mazindol |
| 1.2.398.7.1.4.2.6.4.11 | Lactulose |
| 1.2.398.7.1.4.2.6.4.12 | Etomidate |
| 1.2.398.7.1.4.2.6.4.13 | Lidocaine |
| 1.2.398.7.1.4.2.6.4.14 | Lomustin |
| 1.2.398.7.1.4.2.6.4.15 | Mitomycin |
| 1.2.398.7.1.4.2.6.4.16 | Etoposide |
| 1.2.398.7.1.4.2.6.4.17 | Melphalan |
| 1.2.398.7.1.4.2.6.4.18 | Bleomycin |
| 1.2.398.7.1.4.2.6.4.19 | Amsacrine |
| 1.2.398.7.1.4.2.6.4.20 | Nefopam |
| 1.2.398.7.1.4.2.6.4.21 | Dantron |
| 1.2.398.7.1.4.2.6.4.22 | Mebeverine |
| 1.2.398.7.1.4.2.6.4.23 | Thiopental |
| 1.2.398.7.1.4.2.6.4.24 | Prilocaine |
| 1.2.398.7.1.4.2.6.4.25 | Aspirin |
| 1.2.398.7.1.4.2.6.4.26 | Benzocaine |
| 1.2.398.7.1.4.2.6.4.27 | Codeine |
| 1.2.398.7.1.4.2.6.4.28 | Tetracaine |
| 1.2.398.7.1.4.2.6.4.29 | Morphine |
| 1.2.398.7.1.4.2.6.4.30 | Amifostin |
| 1.2.398.7.1.4.2.6.4.31 | Fentanyl |
| 1.2.398.7.1.4.2.6.4.32 | Filgrastim |
| 1.2.398.7.1.4.2.6.4.33 | Etodolac |
| 1.2.398.7.1.4.2.6.4.34 | Levamisole |
| 1.2.398.7.1.4.2.6.4.35 | Felbinac |
| 1.2.398.7.1.4.2.6.4.36 | Treosulfan |
| 1.2.398.7.1.4.2.6.4.37 | Fenbufen |
| 1.2.398.7.1.4.2.6.4.38 | Etoglucid |
| 1.2.398.7.1.4.2.6.4.39 | Sulindac |
| 1.2.398.7.1.4.2.6.4.40 | Ifosfamide |
| 1.2.398.7.1.4.2.6.4.41 | Tolmetin |
| 1.2.398.7.1.4.2.6.4.42 | Carmustine |
| 1.2.398.7.1.4.2.6.4.43 | Nabilone |
| 1.2.398.7.1.4.2.6.4.44 | Pethidine |
| 1.2.398.7.1.4.2.6.4.45 | Plicamycin |
| 1.2.398.7.1.4.2.6.4.46 | Ketorolac |
| 1.2.398.7.1.4.2.6.4.47 | Epirubicin |
| 1.2.398.7.1.4.2.6.4.48 | Piroxicam |
| 1.2.398.7.1.4.2.6.4.49 | Thioguanine |
| 1.2.398.7.1.4.2.6.4.50 | Tenoxicam |
| 1.2.398.7.1.4.2.6.4.51 | Cytarabine |
| 1.2.398.7.1.4.2.6.4.52 | Cisapride |
| 1.2.398.7.1.4.2.6.4.53 | Paclitaxel |
| 1.2.398.7.1.4.2.6.4.54 | Bisacodyl |
| 1.2.398.7.1.4.2.6.4.55 | Trilostane |
| 1.2.398.7.1.4.2.6.4.56 | Diclofenac |
| 1.2.398.7.1.4.2.6.4.57 | Mepenzolate |
| 1.2.398.7.1.4.2.6.4.58 | Nabumethon |
| 1.2.398.7.1.4.2.6.4.59 | Bupivacaine |
| 1.2.398.7.1.4.2.6.4.60 | Clobazam |
| 1.2.398.7.1.4.2.6.4.61 | Sucralfate |
| 1.2.398.7.1.4.2.6.4.62 | Prazepam |
| 1.2.398.7.1.4.2.6.4.63 | Cimetidine |
| 1.2.398.7.1.4.2.6.4.64 | Lenograstim |
| 1.2.398.7.1.4.2.6.4.65 | Famotidine |
| 1.2.398.7.1.4.2.6.4.66 | Dacarbazine |
| 1.2.398.7.1.4.2.6.4.67 | Ranitidine |
| 1.2.398.7.1.4.2.6.4.68 | Aclarubicin |
| 1.2.398.7.1.4.2.6.4.69 | Omeprazole |
| 1.2.398.7.1.4.2.6.4.70 | Oxazepam |
| 1.2.398.7.1.4.2.6.4.71 | Doxorubicin |
| 1.2.398.7.1.4.2.6.4.72 | Pergolide |
| 1.2.398.7.1.4.2.6.4.73 | Pancreatin |
| 1.2.398.7.1.4.2.6.4.74 | Iprindol |
| 1.2.398.7.1.4.2.6.4.75 | Fludarabine |
| 1.2.398.7.1.4.2.6.4.76 | Olsalazine |
| 1.2.398.7.1.4.2.6.4.77 | Nadolol |
| 1.2.398.7.1.4.2.6.4.78 | Pipenzolate |
| 1.2.398.7.1.4.2.6.4.79 | Sotalol |
| 1.2.398.7.1.4.2.6.4.80 | Amoxapine |
| 1.2.398.7.1.4.2.6.4.81 | Doxazosin |
| 1.2.398.7.1.4.2.6.4.82 | Beclamid |
| 1.2.398.7.1.4.2.6.4.83 | Phenytoin |
| 1.2.398.7.1.4.2.6.4.84 | Indoramin |
| 1.2.398.7.1.4.2.6.4.85 | Imipramine |
| 1.2.398.7.1.4.2.6.4.86 | Terazosin |
| 1.2.398.7.1.4.2.6.4.87 | Iproniazid |
| 1.2.398.7.1.4.2.6.4.88 | Verapamil |
| 1.2.398.7.1.4.2.6.4.89 | Sertraline |
| 1.2.398.7.1.4.2.6.4.90 | Carbachol |
| 1.2.398.7.1.4.2.6.4.91 | Paroxetine |
| 1.2.398.7.1.4.2.6.4.92 | Fenoterol |
| 1.2.398.7.1.4.2.6.4.93 | Felodipine |
| 1.2.398.7.1.4.2.6.4.94 | Amantadine |
| 1.2.398.7.1.4.2.6.4.95 | Naloxone |
| 1.2.398.7.1.4.2.6.4.96 | Dopamine |
| 1.2.398.7.1.4.2.6.4.97 | Domifen |
| 1.2.398.7.1.4.2.6.4.98 | Coal tar |
| 1.2.398.7.1.4.2.6.4.99 | Pyrantel |
| 1.2.398.7.1.4.2.6.4.100 | Noscapine |
| 1.2.398.7.1.4.2.6.4.101 | Flavoxate |
| 1.2.398.7.1.4.2.6.4.102 | Vecuronium |
| 1.2.398.7.1.4.2.6.4.103 | Vidarabine |
| 1.2.398.7.1.4.2.6.4.104 | Naltrexone |
| 1.2.398.7.1.4.2.6.4.105 | Mefloquine |
| 1.2.398.7.1.4.2.6.4.106 | Oxytropium |
| 1.2.398.7.1.4.2.6.4.107 | Hexetidine |
| 1.2.398.7.1.4.2.6.4.108 | Reproterol |
| 1.2.398.7.1.4.2.6.4.109 | Dipivefrin |
| 1.2.398.7.1.4.2.6.4.110 | Noxythioline |
| 1.2.398.7.1.4.2.6.4.111 | Boric acid |
| 1.2.398.7.1.4.2.6.4.112 | Oxybutynin |
| 1.2.398.7.1.4.2.6.4.113 | Carmellose |
| 1.2.398.7.1.4.2.6.4.114 | Netilmicin |
| 1.2.398.7.1.4.2.6.4.115 | Probenecid |
| 1.2.398.7.1.4.2.6.4.116 | Atracurium |
| 1.2.398.7.1.4.2.6.4.117 | Rocuronium |
| 1.2.398.7.1.4.2.6.4.118 | Dantrolene |
| 1.2.398.7.1.4.2.6.4.119 | Papaverine |
| 1.2.398.7.1.4.2.6.4.120 | Carboprost |
| 1.2.398.7.1.4.2.6.4.121 | Castor oil |
| 1.2.398.7.1.4.2.6.4.122 | Flumazenil |
| 1.2.398.7.1.4.2.6.4.123 | Alimemazine |
| 1.2.398.7.1.4.2.6.4.124 | Dapsone |
| 1.2.398.7.1.4.2.6.4.125 | Enoxacin |
| 1.2.398.7.1.4.2.6.4.126 | Colistin |
| 1.2.398.7.1.4.2.6.4.127 | Cefixime |
| 1.2.398.7.1.4.2.6.4.128 | Mafenide |
| 1.2.398.7.1.4.2.6.4.129 | Sulfiram |
| 1.2.398.7.1.4.2.6.4.130 | Estriol |
| 1.2.398.7.1.4.2.6.4.131 | Aztreonam |
| 1.2.398.7.1.4.2.6.4.132 | Cortisol |
| 1.2.398.7.1.4.2.6.4.133 | Sulfalene |
| 1.2.398.7.1.4.2.6.4.134 | Megestrol |
| 1.2.398.7.1.4.2.6.4.135 | Rifabutin |
| 1.2.398.7.1.4.2.6.4.136 | Flutamide |
| 1.2.398.7.1.4.2.6.4.137 | Isoniazid |
| 1.2.398.7.1.4.2.6.4.138 | Mestranol |
| 1.2.398.7.1.4.2.6.4.139 | Tinidazole |
| 1.2.398.7.1.4.2.6.4.140 | Gestrinone |
| 1.2.398.7.1.4.2.6.4.141 | Mersalil |
| 1.2.398.7.1.4.2.6.4.142 | Inositol |
| 1.2.398.7.1.4.2.6.4.143 | Xipamide |
| 1.2.398.7.1.4.2.6.4.144 | Fluoride |
| 1.2.398.7.1.4.2.6.4.145 | Tramadol |
| 1.2.398.7.1.4.2.6.4.146 | Meropenem |
| 1.2.398.7.1.4.2.6.4.147 | Iodophor |
| 1.2.398.7.1.4.2.6.4.148 | Protirelin |
| 1.2.398.7.1.4.2.6.4.149 | Diazoxide |
| 1.2.398.7.1.4.2.6.4.150 | Calcitonin |
| 1.2.398.7.1.4.2.6.4.151 | Denosumab |
| 1.2.398.7.1.4.2.6.4.152 | Enoxaparin |
| 1.2.398.7.1.4.2.6.4.153 | Dalteparin |
| 1.2.398.7.1.4.2.6.4.154 | Piretanide |
| 1.2.398.7.1.4.2.6.4.155 | Torasemide |
| 1.2.398.7.1.4.2.6.4.156 | Metirozine |
| 1.2.398.7.1.4.2.6.4.157 | Clofibrate |
| 1.2.398.7.1.4.2.6.4.158 | Nicorandil |
| 1.2.398.7.1.4.2.6.4.159 | Flecainide |
| 1.2.398.7.1.4.2.6.4.160 | Mexiletine |
| 1.2.398.7.1.4.2.6.4.161 | Furosemide |
| 1.2.398.7.1.4.2.6.4.162 | Lovastatin |
| 1.2.398.7.1.4.2.6.4.163 | Tinzaparin |
| 1.2.398.7.1.4.2.6.4.164 | Doxacurium |
| 1.2.398.7.1.4.2.6.4.165 | Leuprorelin |
| 1.2.398.7.1.4.2.6.4.166 | Bumetanide |
| 1.2.398.7.1.4.2.6.4.167 | Phenindione |
| 1.2.398.7.1.4.2.6.4.168 | Sufentanil |
| 1.2.398.7.1.4.2.6.4.169 | Ergometrine |
| 1.2.398.7.1.4.2.6.4.170 | Bametan |
| 1.2.398.7.1.4.2.6.4.171 | Thiourea |
| 1.2.398.7.1.4.2.6.4.172 | Thiamine |
| 1.2.398.7.1.4.2.6.4.173 | Ethinodiol |
| 1.2.398.7.1.4.2.6.4.174 | Nebivolol |
| 1.2.398.7.1.4.2.6.4.175 | Thiouracil |
| 1.2.398.7.1.4.2.6.4.176 | Danaparoid |
| 1.2.398.7.1.4.2.6.4.177 | Senna |
| 1.2.398.7.1.4.2.6.4.178 | Cascara |
| 1.2.398.7.1.4.2.6.4.179 | Poldin |
| 1.2.398.7.1.4.2.6.4.180 | Vindesine |
| 1.2.398.7.1.4.2.6.4.181 | Doxepin |
| 1.2.398.7.1.4.2.6.4.182 | Formestan |
| 1.2.398.7.1.4.2.6.4.183 | Alfentanil |
| 1.2.398.7.1.4.2.6.4.184 | Diazepam |
| 1.2.398.7.1.4.2.6.4.185 | Meptazinol |
| 1.2.398.7.1.4.2.6.4.186 | Nitrosourea |
| 1.2.398.7.1.4.2.6.4.187 | Lisuride |
| 1.2.398.7.1.4.2.6.4.188 | Acemethacin |
| 1.2.398.7.1.4.2.6.4.189 | Zolpidem |
| 1.2.398.7.1.4.2.6.4.190 | Idarubicin |
| 1.2.398.7.1.4.2.6.4.191 | Cinchocaine |
| 1.2.398.7.1.4.2.6.4.192 | Levodopa |
| 1.2.398.7.1.4.2.6.4.193 | Mesalazine |
| 1.2.398.7.1.4.2.6.4.194 | Vinblastine |
| 1.2.398.7.1.4.2.6.4.195 | Timolol |
| 1.2.398.7.1.4.2.6.4.196 | Vincristine |
| 1.2.398.7.1.4.2.6.4.197 | Dosulepin |
| 1.2.398.7.1.4.2.6.4.198 | Nizatidine |
| 1.2.398.7.1.4.2.6.4.199 | Esmolol |
| 1.2.398.7.1.4.2.6.4.200 | Phentermine |
| 1.2.398.7.1.4.2.6.4.201 | Mianserin |
| 1.2.398.7.1.4.2.6.4.202 | Pimozide |
| 1.2.398.7.1.4.2.6.4.203 | Trazodone |
| 1.2.398.7.1.4.2.6.4.204 | Amfepramone |
| 1.2.398.7.1.4.2.6.4.205 | Dipipanone |
| 1.2.398.7.1.4.2.6.4.206 | Piracetam |
| 1.2.398.7.1.4.2.6.4.207 | Pemoline |
| 1.2.398.7.1.4.2.6.4.208 | Indomethacin |
| 1.2.398.7.1.4.2.6.4.209 | Zopiclone |
| 1.2.398.7.1.4.2.6.4.210 | Atenolol |
| 1.2.398.7.1.4.2.6.4.211 | Misoprostol |
| 1.2.398.7.1.4.2.6.4.212 | Triazolam |
| 1.2.398.7.1.4.2.6.4.213 | Nicotine |
| 1.2.398.7.1.4.2.6.4.214 | Pirenzepine |
| 1.2.398.7.1.4.2.6.4.215 | Ketazolam |
| 1.2.398.7.1.4.2.6.4.216 | Pindolol |
| 1.2.398.7.1.4.2.6.4.217 | Medazepam |
| 1.2.398.7.1.4.2.6.4.218 | Domperidone |
| 1.2.398.7.1.4.2.6.4.219 | Prazosin |
| 1.2.398.7.1.4.2.6.4.220 | Midazolam |
| 1.2.398.7.1.4.2.6.4.221 | Promazine |
| 1.2.398.7.1.4.2.6.4.222 | Lorazepam |
| 1.2.398.7.1.4.2.6.4.223 | Betaxolol |
| 1.2.398.7.1.4.2.6.4.224 | Temazepam |
| 1.2.398.7.1.4.2.6.4.225 | Carteolol |
| 1.2.398.7.1.4.2.6.4.226 | Buspirone |
| 1.2.398.7.1.4.2.6.4.227 | Labetalol |
| 1.2.398.7.1.4.2.6.4.228 | Sulpiride |
| 1.2.398.7.1.4.2.6.4.229 | Practolol |
| 1.2.398.7.1.4.2.6.4.230 | Primidon |
| 1.2.398.7.1.4.2.6.4.231 | Alfuzosin |
| 1.2.398.7.1.4.2.6.4.232 | Nefazodone |
| 1.2.398.7.1.4.2.6.4.233 | Diltiazem |
| 1.2.398.7.1.4.2.6.4.234 | Citalopram |
| 1.2.398.7.1.4.2.6.4.235 | Selegilin |
| 1.2.398.7.1.4.2.6.4.236 | Prolintan |
| 1.2.398.7.1.4.2.6.4.237 | Fluoxetine |
| 1.2.398.7.1.4.2.6.4.238 | Viloxazine |
| 1.2.398.7.1.4.2.6.4.239 | Disulfiram |
| 1.2.398.7.1.4.2.6.4.240 | Gabapentin |
| 1.2.398.7.1.4.2.6.4.241 | Celiprolol |
| 1.2.398.7.1.4.2.6.4.242 | Vigabatrin |
| 1.2.398.7.1.4.2.6.4.243 | Carvedilol |
| 1.2.398.7.1.4.2.6.4.244 | Clonazepam |
| 1.2.398.7.1.4.2.6.4.245 | Oxprenolol |
| 1.2.398.7.1.4.2.6.4.246 | Loprazolam |
| 1.2.398.7.1.4.2.6.4.247 | Penbutolol |
| 1.2.398.7.1.4.2.6.4.248 | Nitrazepam |
| 1.2.398.7.1.4.2.6.4.249 | Nifedipine |
| 1.2.398.7.1.4.2.6.4.250 | Alprazolam |
| 1.2.398.7.1.4.2.6.4.251 | Bromazepam |
| 1.2.398.7.1.4.2.6.4.252 | Benperidol |
| 1.2.398.7.1.4.2.6.4.253 | Lacidipine |
| 1.2.398.7.1.4.2.6.4.254 | Nimodipine |
| 1.2.398.7.1.4.2.6.4.255 | Phenelzine |
| 1.2.398.7.1.4.2.6.4.256 | Amlodipine |
| 1.2.398.7.1.4.2.6.4.257 | Demecarius |
| 1.2.398.7.1.4.2.6.4.258 | Droperidol |
| 1.2.398.7.1.4.2.6.4.259 | Pirbuterol |
| 1.2.398.7.1.4.2.6.4.260 | Flurazepam |
| 1.2.398.7.1.4.2.6.4.261 | Salmeterol |
| 1.2.398.7.1.4.2.6.4.262 | Apomorphine |
| 1.2.398.7.1.4.2.6.4.263 | Salbutamol |
| 1.2.398.7.1.4.2.6.4.264 | Desipramine |
| 1.2.398.7.1.4.2.6.4.265 | Bambuterol |
| 1.2.398.7.1.4.2.6.4.266 | Moclobemide |
| 1.2.398.7.1.4.2.6.4.267 | Oxypertine |
| 1.2.398.7.1.4.2.6.4.268 | Acebutolol |
| 1.2.398.7.1.4.2.6.4.269 | Bisoprolol |
| 1.2.398.7.1.4.2.6.4.270 | Metoprolol |
| 1.2.398.7.1.4.2.6.4.271 | Isradipin |
| 1.2.398.7.1.4.2.6.4.272 | Distigmine bromide |
| 1.2.398.7.1.4.2.6.4.273 | Neostigmine |
| 1.2.398.7.1.4.2.6.4.274 | Mesna |
| 1.2.398.7.1.4.2.6.4.275 | Quinine |
| 1.2.398.7.1.4.2.6.4.276 | Glycine |
| 1.2.398.7.1.4.2.6.4.277 | Nystatin |
| 1.2.398.7.1.4.2.6.4.278 | Glycerol |
| 1.2.398.7.1.4.2.6.4.279 | Amikacin |
| 1.2.398.7.1.4.2.6.4.280 | Baclofen |
| 1.2.398.7.1.4.2.6.4.281 | Neomycin |
| 1.2.398.7.1.4.2.6.4.282 | Antidote |
| 1.2.398.7.1.4.2.6.4.283 | Kanamycin |
| 1.2.398.7.1.4.2.6.4.284 | Natamycin |
| 1.2.398.7.1.4.2.6.4.285 | Biperiden |
| 1.2.398.7.1.4.2.6.4.286 | Econazole |
| 1.2.398.7.1.4.2.6.4.287 | Rimiterol |
| 1.2.398.7.1.4.2.6.4.288 | Ribavirin |
| 1.2.398.7.1.4.2.6.4.289 | Ephedrine |
| 1.2.398.7.1.4.2.6.4.290 | Acyclovir |
| 1.2.398.7.1.4.2.6.4.291 | Xamoterol |
| 1.2.398.7.1.4.2.6.4.292 | Cetrimide |
| 1.2.398.7.1.4.2.6.4.293 | Tyloxapol |
| 1.2.398.7.1.4.2.6.4.294 | Befenium |
| 1.2.398.7.1.4.2.6.4.295 | Pumaktant |
| 1.2.398.7.1.4.2.6.4.296 | Foscarnet |
| 1.2.398.7.1.4.2.6.4.297 | Emollient |
| 1.2.398.7.1.4.2.6.4.298 | Didanosine |
| 1.2.398.7.1.4.2.6.4.299 | Gallamine |
| 1.2.398.7.1.4.2.6.4.300 | Gemeprost |
| 1.2.398.7.1.4.2.6.4.301 | Framycetin |
| 1.2.398.7.1.4.2.6.4.302 | Dinoprost |
| 1.2.398.7.1.4.2.6.4.303 | Primaquin |
| 1.2.398.7.1.4.2.6.4.304 | Protamine |
| 1.2.398.7.1.4.2.6.4.305 | Piperazine |
| 1.2.398.7.1.4.2.6.4.306 | Bentonite |
| 1.2.398.7.1.4.2.6.4.307 | Tolnaftat |
| 1.2.398.7.1.4.2.6.4.308 | Methixene |
| 1.2.398.7.1.4.2.6.4.309 | Amorolfine |
| 1.2.398.7.1.4.2.6.4.310 | Beractant |
| 1.2.398.7.1.4.2.6.4.311 | Miconazole |
| 1.2.398.7.1.4.2.6.4.312 | Mivacurium (bromide) |
| 1.2.398.7.1.4.2.6.4.313 | Mucolytics |
| 1.2.398.7.1.4.2.6.4.314 | Azelastine |
| 1.2.398.7.1.4.2.6.4.315 | Gentamicin |
| 1.2.398.7.1.4.2.6.4.316 | Nedocromil |
| 1.2.398.7.1.4.2.6.4.317 | Lodoxamide |
| 1.2.398.7.1.4.2.6.4.318 | Tobramycin |
| 1.2.398.7.1.4.2.6.4.319 | Vancomycin |
| 1.2.398.7.1.4.2.6.4.320 | Isoaminyl |
| 1.2.398.7.1.4.2.6.4.321 | Folcodin |
| 1.2.398.7.1.4.2.6.4.322 | Cefaclor |
| 1.2.398.7.1.4.2.6.4.323 | Polymyxin |
| 1.2.398.7.1.4.2.6.4.324 | Mupirocin |
| 1.2.398.7.1.4.2.6.4.325 | Rosoxacin |
| 1.2.398.7.1.4.2.6.4.326 | Cinoxacin |
| 1.2.398.7.1.4.2.6.4.327 | Ofloxacin |
| 1.2.398.7.1.4.2.6.4.328 | Cephalexin |
| 1.2.398.7.1.4.2.6.4.329 | Insulin |
| 1.2.398.7.1.4.2.6.4.330 | Cefalothin |
| 1.2.398.7.1.4.2.6.4.331 | Danazol |
| 1.2.398.7.1.4.2.6.4.332 | Cefazolin |
| 1.2.398.7.1.4.2.6.4.333 | Cefradine |
| 1.2.398.7.1.4.2.6.4.334 | Glucagon |
| 1.2.398.7.1.4.2.6.4.335 | Latamoxef |
| 1.2.398.7.1.4.2.6.4.336 | Tibolone |
| 1.2.398.7.1.4.2.6.4.337 | Androgen |
| 1.2.398.7.1.4.2.6.4.338 | Cefpirome |
| 1.2.398.7.1.4.2.6.4.339 | Estrogen |
| 1.2.398.7.1.4.2.6.4.340 | Cefoxitine |
| 1.2.398.7.1.4.2.6.4.341 | Acarbose |
| 1.2.398.7.1.4.2.6.4.342 | Nitrofural |
| 1.2.398.7.1.4.2.6.4.343 | Nafarelin |
| 1.2.398.7.1.4.2.6.4.344 | Clioquinol |
| 1.2.398.7.1.4.2.6.4.345 | Buserelin |
| 1.2.398.7.1.4.2.6.4.346 | Cefadroxil |
| 1.2.398.7.1.4.2.6.4.347 | Goserelin |
| 1.2.398.7.1.4.2.6.4.348 | Cefuroxime |
| 1.2.398.7.1.4.2.6.4.349 | Estradiol |
| 1.2.398.7.1.4.2.6.4.350 | Cefotaxime |
| 1.2.398.7.1.4.2.6.4.351 | Thyroxine |
| 1.2.398.7.1.4.2.6.4.352 | Cefodizim |
| 1.2.398.7.1.4.2.6.4.353 | Budesonide |
| 1.2.398.7.1.4.2.6.4.354 | Ceftibuten |
| 1.2.398.7.1.4.2.6.4.355 | Mometasone |
| 1.2.398.7.1.4.2.6.4.356 | Cefsulodin |
| 1.2.398.7.1.4.2.6.4.357 | Nandrolone |
| 1.2.398.7.1.4.2.6.4.358 | Cefamycin |
| 1.2.398.7.1.4.2.6.4.359 | Stanozolol |
| 1.2.398.7.1.4.2.6.4.360 | Fosfomycin |
| 1.2.398.7.1.4.2.6.4.361 | Cyclophenyl |
| 1.2.398.7.1.4.2.6.4.362 | Nimorazole |
| 1.2.398.7.1.4.2.6.4.363 | Hinestrol |
| 1.2.398.7.1.4.2.6.4.364 | Atovaquone |
| 1.2.398.7.1.4.2.6.4.365 | Dienestrol |
| 1.2.398.7.1.4.2.6.4.366 | Diloxanide |
| 1.2.398.7.1.4.2.6.4.367 | Phosfestrol |
| 1.2.398.7.1.4.2.6.4.368 | Rifampicin |
| 1.2.398.7.1.4.2.6.4.369 | Carbimazole |
| 1.2.398.7.1.4.2.6.4.370 | Ethambutol |
| 1.2.398.7.1.4.2.6.4.371 | Fluticasone |
| 1.2.398.7.1.4.2.6.4.372 | Cyproterone |
| 1.2.398.7.1.4.2.6.4.373 | Mesterolone |
| 1.2.398.7.1.4.2.6.4.374 | Cabergoline |
| 1.2.398.7.1.4.2.6.4.375 | Quinagolide |
| 1.2.398.7.1.4.2.6.4.376 | Vasopressin |
| 1.2.398.7.1.4.2.6.4.377 | Gonadorelin |
| 1.2.398.7.1.4.2.6.4.378 | Triptorelin |
| 1.2.398.7.1.4.2.6.4.379 | Finasteride |
| 1.2.398.7.1.4.2.6.4.380 | Ancrod |
| 1.2.398.7.1.4.2.6.4.381 | Nickel |
| 1.2.398.7.1.4.2.6.4.382 | Heparin |
| 1.2.398.7.1.4.2.6.4.383 | Retinol |
| 1.2.398.7.1.4.2.6.4.384 | Digoxin |
| 1.2.398.7.1.4.2.6.4.385 | Ouabain |
| 1.2.398.7.1.4.2.6.4.386 | Oxytocin |
| 1.2.398.7.1.4.2.6.4.387 | Mannitol |
| 1.2.398.7.1.4.2.6.4.388 | Warfarin |
| 1.2.398.7.1.4.2.6.4.389 | Collagen |
| 1.2.398.7.1.4.2.6.4.390 | Imipenem |
| 1.2.398.7.1.4.2.6.4.391 | Probucol |
| 1.2.398.7.1.4.2.6.4.392 | Acipimox |
| 1.2.398.7.1.4.2.6.4.393 | Ertapenem |
| 1.2.398.7.1.4.2.6.4.394 | Vitamin D |
| 1.2.398.7.1.4.2.6.4.395 | Mephruzid |
| 1.2.398.7.1.4.2.6.4.396 | Vitamin K |
| 1.2.398.7.1.4.2.6.4.397 | Digitoxin |
| 1.2.398.7.1.4.2.6.4.398 | Quinidine |
| 1.2.398.7.1.4.2.6.4.399 | Enoxymon |
| 1.2.398.7.1.4.2.6.4.400 | Tokainid |
| 1.2.398.7.1.4.2.6.4.401 | Bretylium |
| 1.2.398.7.1.4.2.6.4.402 | Milrinone |
| 1.2.398.7.1.4.2.6.4.403 | Aprotinin |
| 1.2.398.7.1.4.2.6.4.404 | Minoxidil |
| 1.2.398.7.1.4.2.6.4.405 | Adenosine |
| 1.2.398.7.1.4.2.6.4.406 | Alteplase |
| 1.2.398.7.1.4.2.6.4.407 | Amiloride |
| 1.2.398.7.1.4.2.6.4.408 | Octreotide |
| 1.2.398.7.1.4.2.6.4.409 | Urokinase |
| 1.2.398.7.1.4.2.6.4.410 | Heparinoid |
| 1.2.398.7.1.4.2.6.4.411 | Indapamide |
| 1.2.398.7.1.4.2.6.4.412 | Etamsylate |
| 1.2.398.7.1.4.2.6.4.413 | Metolazone |
| 1.2.398.7.1.4.2.6.4.414 | Folic acid |
| 1.2.398.7.1.4.2.6.4.415 | Bethanidine |
| 1.2.398.7.1.4.2.6.4.416 | Colestipol |
| 1.2.398.7.1.4.2.6.4.417 | Moxisylite |
| 1.2.398.7.1.4.2.6.4.418 | Bromelain |
| 1.2.398.7.1.4.2.6.4.419 | Moracizine |
| 1.2.398.7.1.4.2.6.4.420 | Amiodarone |
| 1.2.398.7.1.4.2.6.4.421 | Raloxifene |
| 1.2.398.7.1.4.2.6.4.422 | Triclofos |
| 1.2.398.7.1.4.2.6.4.423 | Isosorbide |
| 1.2.398.7.1.4.2.6.4.424 | Emepronium |
| 1.2.398.7.1.4.2.6.4.425 | Pyridoxine |
| 1.2.398.7.1.4.2.6.4.426 | Lansoprazole |
| 1.2.398.7.1.4.2.6.4.427 | Fluorouracil |
| 1.2.398.7.1.4.2.6.4.428 | Pantoprazole |
| 1.2.398.7.1.4.2.6.4.429 | Procarbazine |
| 1.2.398.7.1.4.2.6.4.430 | Atorvastatin |
| 1.2.398.7.1.4.2.6.4.431 | Azathioprine |
| 1.2.398.7.1.4.2.6.4.432 | Levofloxacin |
| 1.2.398.7.1.4.2.6.4.433 | Methohexital |
| 1.2.398.7.1.4.2.6.4.434 | Phenoperidine |
| 1.2.398.7.1.4.2.6.4.435 | Dicyclomine |
| 1.2.398.7.1.4.2.6.4.436 | Carbenoxolone |
| 1.2.398.7.1.4.2.6.4.437 | Propantheline |
| 1.2.398.7.1.4.2.6.4.438 | Sulfasalazine |
| 1.2.398.7.1.4.2.6.4.439 | Buprenorphine |
| 1.2.398.7.1.4.2.6.4.440 | Oxybuprocaine |
| 1.2.398.7.1.4.2.6.4.441 | Hydroxycarbamide |
| 1.2.398.7.1.4.2.6.4.442 | Magnesium sulfate |
| 1.2.398.7.1.4.2.6.4.443 | Prenylamine |
| 1.2.398.7.1.4.2.6.4.444 | Ethosuximide |
| 1.2.398.7.1.4.2.6.4.445 | Nicardipine |
| 1.2.398.7.1.4.2.6.4.446 | Butobarbital |
| 1.2.398.7.1.4.2.6.4.447 | Secobarbital |
| 1.2.398.7.1.4.2.6.4.448 | Methoxamine |
| 1.2.398.7.1.4.2.6.4.449 | Amitriptyline |
| 1.2.398.7.1.4.2.6.4.450 | Naphazoline |
| 1.2.398.7.1.4.2.6.4.451 | Isocarboxazid |
| 1.2.398.7.1.4.2.6.4.452 | Dexamphetamine |
| 1.2.398.7.1.4.2.6.4.453 | Chlordiazepoxide |
| 1.2.398.7.1.4.2.6.4.454 | Physostigmine |
| 1.2.398.7.1.4.2.6.4.455 | Sodium valproate |
| 1.2.398.7.1.4.2.6.4.456 | Phenylephrine |
| 1.2.398.7.1.4.2.6.4.457 | Lithium carbonate |
| 1.2.398.7.1.4.2.6.4.458 | Pyridostigmine |
| 1.2.398.7.1.4.2.6.4.459 | Carbamate sedative |
| 1.2.398.7.1.4.2.6.4.460 | Norepinephrine |
| 1.2.398.7.1.4.2.6.4.461 | Dichloralphenazone |
| 1.2.398.7.1.4.2.6.4.462 | Xylometazoline |
| 1.2.398.7.1.4.2.6.4.463 | Methylphenobarbital |
| 1.2.398.7.1.4.2.6.4.464 | Chloroquine |
| 1.2.398.7.1.4.2.6.4.465 | Phenoxybenzamine |
| 1.2.398.7.1.4.2.6.4.466 | Acetic acid |
| 1.2.398.7.1.4.2.6.4.467 | Triethylperazine |
| 1.2.398.7.1.4.2.6.4.468 | Teicoplanin |
| 1.2.398.7.1.4.2.6.4.469 | Monoamine oxidase inhibitor |
| 1.2.398.7.1.4.2.6.4.470 | Prochlorperazine |
| 1.2.398.7.1.4.2.6.4.471 | Flucytosine |
| 1.2.398.7.1.4.2.6.4.472 | Terbinafine |
| 1.2.398.7.1.4.2.6.4.473 | Nitrophenol |
| 1.2.398.7.1.4.2.6.4.474 | Oxedrine tartrate |
| 1.2.398.7.1.4.2.6.4.475 | Tioconazole |
| 1.2.398.7.1.4.2.6.4.476 | Pralidoxime |
| 1.2.398.7.1.4.2.6.4.477 | Isoconazole |
| 1.2.398.7.1.4.2.6.4.478 | Isoethrine hydrochloride |
| 1.2.398.7.1.4.2.6.4.479 | Sulconazole |
| 1.2.398.7.1.4.2.6.4.480 | Terbutaline |
| 1.2.398.7.1.4.2.6.4.481 | Homatropine |
| 1.2.398.7.1.4.2.6.4.482 | Beta-2 adrenergic receptor agonist |
| 1.2.398.7.1.4.2.6.4.483 | Ganciclovir |
| 1.2.398.7.1.4.2.6.4.484 | Famciclovir |
| 1.2.398.7.1.4.2.6.4.485 | Beta-adrenergic receptor antagonist |
| 1.2.398.7.1.4.2.6.4.486 | Ipratropium |
| 1.2.398.7.1.4.2.6.4.487 | Amphetamine and amphetamine derivative |
| 1.2.398.7.1.4.2.6.4.488 | Amodiquine |
| 1.2.398.7.1.4.2.6.4.489 | Colfosceril (palmitate) |
| 1.2.398.7.1.4.2.6.4.490 | Niclosamide |
| 1.2.398.7.1.4.2.6.4.491 | Chenodeoxycholic acid |
| 1.2.398.7.1.4.2.6.4.492 | H+-K+- (exchange) adenosine triphosphatase inhibitors |
| 1.2.398.7.1.4.2.6.4.493 | Anthraquinone laxative |
| 1.2.398.7.1.4.2.6.4.494 | Fluvoxamine |
| 1.2.398.7.1.4.2.6.4.495 | Antineoplastic triazene |
| 1.2.398.7.1.4.2.6.4.496 | 5-hydroxytryptamine-3 receptor antagonist |
| 1.2.398.7.1.4.2.6.4.497 | Maprotiline |
| 1.2.398.7.1.4.2.6.4.498 | Lamotrigine |
| 1.2.398.7.1.4.2.6.4.499 | Metiprylon |
| 1.2.398.7.1.4.2.6.4.500 | Nitrogen mustard analogues |
| 1.2.398.7.1.4.2.6.4.501 | Paraldehyde |
| 1.2.398.7.1.4.2.6.4.502 | Chenodeoxycholic acid and ursodeoxycholic acid |
| 1.2.398.7.1.4.2.6.4.503 | Amobarbital |
| 1.2.398.7.1.4.2.6.4.504 | Haloperidol |
| 1.2.398.7.1.4.2.6.4.505 | Periziazine |
| 1.2.398.7.1.4.2.6.4.506 | Lofepramine |
| 1.2.398.7.1.4.2.6.4.507 | Flupenthixol |
| 1.2.398.7.1.4.2.6.4.508 | Remoxypride |
| 1.2.398.7.1.4.2.6.4.509 | Venlafaxine |
| 1.2.398.7.1.4.2.6.4.510 | Levobunolol |
| 1.2.398.7.1.4.2.6.4.511 | Meprobamate |
| 1.2.398.7.1.4.2.6.4.512 | Propranolol |
| 1.2.398.7.1.4.2.6.4.513 | Fenfluramine |
| 1.2.398.7.1.4.2.6.4.514 | Lidoflazin |
| 1.2.398.7.1.4.2.6.4.515 | Butriptyline |
| 1.2.398.7.1.4.2.6.4.516 | Trimipramine |
| 1.2.398.7.1.4.2.6.4.517 | Clomipramine |
| 1.2.398.7.1.4.2.6.4.518 | Edrophonium |
| 1.2.398.7.1.4.2.6.4.519 | Bethanechol |
| 1.2.398.7.1.4.2.6.4.520 | Lormetazepam |
| 1.2.398.7.1.4.2.6.4.521 | Metaraminol |
| 1.2.398.7.1.4.2.6.4.522 | Bromocriptine |
| 1.2.398.7.1.4.2.6.4.523 | Phenobarbital |
| 1.2.398.7.1.4.2.6.4.524 | Pilocarpine |
| 1.2.398.7.1.4.2.6.4.525 | Carbamazepine |
| 1.2.398.7.1.4.2.6.4.526 | Ecotiopat |
| 1.2.398.7.1.4.2.6.4.527 | Chlormezanone |
| 1.2.398.7.1.4.2.6.4.528 | Pipothiazine |
| 1.2.398.7.1.4.2.6.4.529 | Cyclobarbital |
| 1.2.398.7.1.4.2.6.4.530 | Fluphenazine |
| 1.2.398.7.1.4.2.6.4.531 | Flunitrazepam |
| 1.2.398.7.1.4.2.6.4.532 | Thioridazine |
| 1.2.398.7.1.4.2.6.4.533 | Clomethiazole |
| 1.2.398.7.1.4.2.6.4.534 | Thioxanthene |
| 1.2.398.7.1.4.2.6.4.535 | Tetrabenazine |
| 1.2.398.7.1.4.2.6.4.536 | Metypranolol |
| 1.2.398.7.1.4.2.6.4.537 | Trifluperidol |
| 1.2.398.7.1.4.2.6.4.538 | Phentolamine |
| 1.2.398.7.1.4.2.6.4.539 | Nortriptyline |
| 1.2.398.7.1.4.2.6.4.540 | Fluspirilene |
| 1.2.398.7.1.4.2.6.4.541 | Protriptyline |
| 1.2.398.7.1.4.2.6.4.542 | Perphenazine |
| 1.2.398.7.1.4.2.6.4.543 | Methacholine |
| 1.2.398.7.1.4.2.6.4.544 | Lithium citrate |
| 1.2.398.7.1.4.2.6.4.545 | Chloral hydrate |
| 1.2.398.7.1.4.2.6.4.546 | Phenothiazine |
| 1.2.398.7.1.4.2.6.4.547 | Tranylcypromine |
| 1.2.398.7.1.4.2.6.4.548 | Chlorpromazine |
| 1.2.398.7.1.4.2.6.4.549 | Zuclopenthixol |
| 1.2.398.7.1.4.2.6.4.550 | Haloperidol decanoate |
| 1.2.398.7.1.4.2.6.4.551 | Levomepromazine |
| 1.2.398.7.1.4.2.6.4.552 | Trifluoperazine |
| 1.2.398.7.1.4.2.6.4.553 | Carbidopa and levodopa |
| 1.2.398.7.1.4.2.6.4.554 | Chlorprothixene |
| 1.2.398.7.1.4.2.6.4.555 | Dequalinium |
| 1.2.398.7.1.4.2.6.4.556 | Diphenylbutylpiperidine |
| 1.2.398.7.1.4.2.6.4.557 | Pseudoephedrine |
| 1.2.398.7.1.4.2.6.4.558 | Fluconazole |
| 1.2.398.7.1.4.2.6.4.559 | Benserazide and levodopa |
| 1.2.398.7.1.4.2.6.4.560 | Methylphenidate |
| 1.2.398.7.1.4.2.6.4.561 | Polynoxylin |
| 1.2.398.7.1.4.2.6.4.562 | Pancuronium |
| 1.2.398.7.1.4.2.6.4.563 | Formaldehyde |
| 1.2.398.7.1.4.2.6.4.564 | Alprostadil |
| 1.2.398.7.1.4.2.6.4.565 | Amphotericin |
| 1.2.398.7.1.4.2.6.4.566 | Ipecacuanha |
| 1.2.398.7.1.4.2.6.4.567 | Hydrargafen |
| 1.2.398.7.1.4.2.6.4.568 | Dimercaprol |
| 1.2.398.7.1.4.2.6.4.569 | Griseofulvin |
| 1.2.398.7.1.4.2.6.4.570 | Clotrimazole |
| 1.2.398.7.1.4.2.6.4.571 | Scopolamine |
| 1.2.398.7.1.4.2.6.4.572 | Dinoprostone |
| 1.2.398.7.1.4.2.6.4.573 | Ketoconazole |
| 1.2.398.7.1.4.2.6.4.574 | Deferoxamine |
| 1.2.398.7.1.4.2.6.4.575 | Isoprenaline |
| 1.2.398.7.1.4.2.6.4.576 | Valaciclovir |
| 1.2.398.7.1.4.2.6.4.577 | Benzatropine |
| 1.2.398.7.1.4.2.6.4.578 | Benzalkonium |
| 1.2.398.7.1.4.2.6.4.579 | Thiabendazole |
| 1.2.398.7.1.4.2.6.4.580 | Streptomycin |
| 1.2.398.7.1.4.2.6.4.581 | Fenticonazole |
| 1.2.398.7.1.4.2.6.4.582 | Mifepristone |
| 1.2.398.7.1.4.2.6.4.583 | Epoprostenol |
| 1.2.398.7.1.4.2.6.4.584 | Glutaraldehyde |
| 1.2.398.7.1.4.2.6.4.585 | Orphenadrine |
| 1.2.398.7.1.4.2.6.4.586 | Clarithromycin |
| 1.2.398.7.1.4.2.6.4.587 | Aminophylline |
| 1.2.398.7.1.4.2.6.4.588 | Oxymetazoline |
| 1.2.398.7.1.4.2.6.4.589 | Cetylpyridine(-ium) |
| 1.2.398.7.1.4.2.6.4.590 | Carbocysteine |
| 1.2.398.7.1.4.2.6.4.591 | Aminoglycosides |
| 1.2.398.7.1.4.2.6.4.592 | Methocarbamol |
| 1.2.398.7.1.4.2.6.4.592 | Sodium perborate |
| 1.2.398.7.1.4.2.6.4.594 | Prostaglandin |
| 1.2.398.7.1.4.2.6.4.595 | Penicillamine |
| 1.2.398.7.1.4.2.6.4.596 | Hydrogen peroxide |
| 1.2.398.7.1.4.2.6.4.597 | Sodium nitrate |
| 1.2.398.7.1.4.2.6.4.598 | Interferon alpha-n1 |
| 1.2.398.7.1.4.2.6.4.599 | Methylcysteine |
| 1.2.398.7.1.4.2.6.4.600 | Acetylcysteine |
| 1.2.398.7.1.4.2.6.4.601 | Sulfinpyrazone |
| 1.2.398.7.1.4.2.6.4.602 | Norfloxacin |
| 1.2.398.7.1.4.2.6.4.603 | Interferon alpha-2a |
| 1.2.398.7.1.4.2.6.4.604 | Polymyxin b |
| 1.2.398.7.1.4.2.6.4.605 | Interferon alpha-2b |
| 1.2.398.7.1.4.2.6.4.606 | Glycopyrronium |
| 1.2.398.7.1.4.2.6.4.607 | Cefamandole |
| 1.2.398.7.1.4.2.6.4.608 | Hydroxychloroquine |
| 1.2.398.7.1.4.2.6.4.609 | Ceftazidime |
| 1.2.398.7.1.4.2.6.4.610 | Diethylcarbamazine |
| 1.2.398.7.1.4.2.6.4.611 | Cefizoxime |
| 1.2.398.7.1.4.2.6.4.612 | Diphenhydramine |
| 1.2.398.7.1.4.2.6.4.613 | Cefpodoxime |
| 1.2.398.7.1.4.2.6.4.614 | Interferon gamma-1b |
| 1.2.398.7.1.4.2.6.4.615 | Ceftriaxone |
| 1.2.398.7.1.4.2.6.4.616 | Succinylcholine |
| 1.2.398.7.1.4.2.6.4.617 | Cycloserine |
| 1.2.398.7.1.4.2.6.4.618 | Antimalarial quinine |
| 1.2.398.7.1.4.2.6.4.619 | Activated carbon |
| 1.2.398.7.1.4.2.6.4.620 | Doxycycline |
| 1.2.398.7.1.4.2.6.4.621 | Azole antifungal |
| 1.2.398.7.1.4.2.6.4.622 | Digitalis antitoxin |
| 1.2.398.7.1.4.2.6.4.623 | Lymecycline |
| 1.2.398.7.1.4.2.6.4.624 | Gestonoron |
| 1.2.398.7.1.4.2.6.4.625 | Antifungal triazole |
| 1.2.398.7.1.4.2.6.4.626 | Fuller's earth |
| 1.2.398.7.1.4.2.6.4.627 | Capreomycin |
| 1.2.398.7.1.4.2.6.4.628 | Anthelmintic benzimidazole |
| 1.2.398.7.1.4.2.6.4.629 | Oxymetholone |
| 1.2.398.7.1.4.2.6.4.630 | Clofazimine |
| 1.2.398.7.1.4.2.6.4.631 | Antifungal agent imidazole |
| 1.2.398.7.1.4.2.6.4.632 | Prostaglandin group A |
| 1.2.398.7.1.4.2.6.4.633 | Bicalutamide |
| 1.2.398.7.1.4.2.6.4.634 | Crystal violet |
| 1.2.398.7.1.4.2.6.4.635 | Trimetoprim |
| 1.2.398.7.1.4.2.6.4.636 | Prostaglandin group E |
| 1.2.398.7.1.4.2.6.4.637 | Testosterone |
| 1.2.398.7.1.4.2.6.4.638 | Fusidic acid |
| 1.2.398.7.1.4.2.6.4.639 | Quinestradol |
| 1.2.398.7.1.4.2.6.4.640 | Prostaglandin group F |
| 1.2.398.7.1.4.2.6.4.641 | Quinolones 4th generation |
| 1.2.398.7.1.4.2.6.4.642 | Liothyronine |
| 1.2.398.7.1.4.2.6.4.643 | Prostaglandin group I |
| 1.2.398.7.1.4.2.6.4.644 | Temafloxacin |
| 1.2.398.7.1.4.2.6.4.645 | Antimalarial aminoquinoline |
| 1.2.398.7.1.4.2.6.4.646 | Methyldopa and diuretic |
| 1.2.398.7.1.4.2.6.4.647 | Piperidolate hydrochloride |
| 1.2.398.7.1.4.2.6.4.648 | Rabies vaccine |
| 1.2.398.7.1.4.2.6.4.649 | Benzodiazepine receptor antagonist |
| 1.2.398.7.1.4.2.6.4.650 | Hydrocortisone |
| 1.2.398.7.1.4.2.6.4.651 | Sulfacetamide |
| 1.2.398.7.1.4.2.6.4.652 | Noretisterone |
| 1.2.398.7.1.4.2.6.4.653 | Mandelic acid |
| 1.2.398.7.1.4.2.6.4.654 | Tetracosactide |
| 1.2.398.7.1.4.2.6.4.655 | Metronidazole |
| 1.2.398.7.1.4.2.6.4.656 | Levonorgestrel |
| 1.2.398.7.1.4.2.6.4.657 | Sulfadimidine |
| 1.2.398.7.1.4.2.6.4.658 | Sulfafurazole |
| 1.2.398.7.1.4.2.6.4.659 | Dydrogesterone |
| 1.2.398.7.1.4.2.6.4.660 | Sulfacarbamide |
| 1.2.398.7.1.4.2.6.4.661 | Rubella vaccine |
| 1.2.398.7.1.4.2.6.4.662 | Nitrofurantoin |
| 1.2.398.7.1.4.2.6.4.663 | Tetanus vaccine |
| 1.2.398.7.1.4.2.6.4.664 | Nalidixic acid |
| 1.2.398.7.1.4.2.6.4.665 | Typhoid vaccine |
| 1.2.398.7.1.4.2.6.4.666 | Nitroimidazole |
| 1.2.398.7.1.4.2.6.4.667 | Anthrax vaccine |
| 1.2.398.7.1.4.2.6.4.668 | Sulfaguanidine |
| 1.2.398.7.1.4.2.6.4.669 | Smallpox vaccine |
| 1.2.398.7.1.4.2.6.4.670 | Demeclocycline |
| 1.2.398.7.1.4.2.6.4.671 | Insulin isophane |
| 1.2.398.7.1.4.2.6.4.672 | Oxytetracycline |
| 1.2.398.7.1.4.2.6.4.673 | Propylthiouracil |
| 1.2.398.7.1.4.2.6.4.674 | Chloramphenicol |
| 1.2.398.7.1.4.2.6.4.675 | Ethinylestradiol |
| 1.2.398.7.1.4.2.6.4.676 | Benzyl benzoate |
| 1.2.398.7.1.4.2.6.4.677 | Sulfadimethoxine |
| 1.2.398.7.1.4.2.6.4.678 | Calcium sulfaloxate |
| 1.2.398.7.1.4.2.6.4.679 | Methyltestosterone |
| 1.2.398.7.1.4.2.6.4.680 | Phthalylsulfathiazole |
| 1.2.398.7.1.4.2.6.4.681 | Edetate |
| 1.2.398.7.1.4.2.6.4.682 | Terpene |
| 1.2.398.7.1.4.2.6.4.683 | Loxapine |
| 1.2.398.7.1.4.2.6.4.684 | Ibuprofen |
| 1.2.398.7.1.4.2.6.4.685 | Bufexamak |
| 1.2.398.7.1.4.2.6.4.686 | Enflurane |
| 1.2.398.7.1.4.2.6.4.687 | Auranofin |
| 1.2.398.7.1.4.2.6.4.688 | Ftorotan |
| 1.2.398.7.1.4.2.6.4.689 | Octoxynol |
| 1.2.398.7.1.4.2.6.4.690 | Tamoxifen |
| 1.2.398.7.1.4.2.6.4.691 | Cyclizine |
| 1.2.398.7.1.4.2.6.4.692 | Azatadine |
| 1.2.398.7.1.4.2.6.4.693 | Triclosan |
| 1.2.398.7.1.4.2.6.4.694 | Hyaetellosis |
| 1.2.398.7.1.4.2.6.4.695 | Antazoline |
| 1.2.398.7.1.4.2.6.4.696 | Fenoprofen |
| 1.2.398.7.1.4.2.6.4.697 | Ichthammol |
| 1.2.398.7.1.4.2.6.4.698 | Ketoprofen |
| 1.2.398.7.1.4.2.6.4.699 | Crotamiton |
| 1.2.398.7.1.4.2.6.4.700 | Etretinate |
| 1.2.398.7.1.4.2.6.4.701 | Tuberculin |
| 1.2.398.7.1.4.2.6.4.702 | Colchicine |
| 1.2.398.7.1.4.2.6.4.703 | Loperamide |
| 1.2.398.7.1.4.2.6.4.704 | Alcuronia |
| 1.2.398.7.1.4.2.6.4.705 | Isoflurane |
| 1.2.398.7.1.4.2.6.4.706 | Dimethicone |
| 1.2.398.7.1.4.2.6.4.707 | Desflurane |
| 1.2.398.7.1.4.2.6.4.708 | Zidovudine |
| 1.2.398.7.1.4.2.6.4.709 | Tryptophan |
| 1.2.398.7.1.4.2.6.4.710 | Lincomycin |
| 1.2.398.7.1.4.2.6.4.711 | Dobutamine |
| 1.2.398.7.1.4.2.6.4.712 | Methicillin |
| 1.2.398.7.1.4.2.6.4.713 | Dopexamine |
| 1.2.398.7.1.4.2.6.4.714 | Methyldopa |
| 1.2.398.7.1.4.2.6.4.715 | Ampicillin |
| 1.2.398.7.1.4.2.6.4.716 | Temocillin |
| 1.2.398.7.1.4.2.6.4.717 | Lofexidine |
| 1.2.398.7.1.4.2.6.4.718 | Azlocillin |
| 1.2.398.7.1.4.2.6.4.719 | Astemizole |
| 1.2.398.7.1.4.2.6.4.720 | Mecillinam |
| 1.2.398.7.1.4.2.6.4.721 | Loratadine |
| 1.2.398.7.1.4.2.6.4.722 | Karbapenemov |
| 1.2.398.7.1.4.2.6.4.723 | Cetirizine |
| 1.2.398.7.1.4.2.6.4.724 | Clemastine |
| 1.2.398.7.1.4.2.6.4.725 | Monobactam |
| 1.2.398.7.1.4.2.6.4.726 | Mepyramin |
| 1.2.398.7.1.4.2.6.4.727 | Zalcitabine |
| 1.2.398.7.1.4.2.6.4.728 | Idoxuridine |
| 1.2.398.7.1.4.2.6.4.729 | Enbucrylate |
| 1.2.398.7.1.4.2.6.4.730 | Salicylate |
| 1.2.398.7.1.4.2.6.4.731 | Nalbuphine |
| 1.2.398.7.1.4.2.6.4.732 | Undecanoate |
| 1.2.398.7.1.4.2.6.4.733 | Amoxicillin |
| 1.2.398.7.1.4.2.6.4.734 | Levorphanol |
| 1.2.398.7.1.4.2.6.4.735 | Cloxacillin |
| 1.2.398.7.1.4.2.6.4.736 | Carboplatin |
| 1.2.398.7.1.4.2.6.4.737 | Cyclacillin |
| 1.2.398.7.1.4.2.6.4.738 | Risperidone |
| 1.2.398.7.1.4.2.6.4.739 | Mezlocillin |
| 1.2.398.7.1.4.2.6.4.740 | Ticarcillin |
| 1.2.398.7.1.4.2.6.4.741 | Tropicamide |
| 1.2.398.7.1.4.2.6.4.742 | Niketamide |
| 1.2.398.7.1.4.2.6.4.743 | Carfecillin |
| 1.2.398.7.1.4.2.6.4.744 | Clindamycin |
| 1.2.398.7.1.4.2.6.4.745 | Mebhydrolin |
| 1.2.398.7.1.4.2.6.4.746 | Trifluridine |
| 1.2.398.7.1.4.2.6.4.747 | Terfenadine |
| 1.2.398.7.1.4.2.6.4.748 | Isotretinoin |
| 1.2.398.7.1.4.2.6.4.749 | Acrivastine |
| 1.2.398.7.1.4.2.6.4.750 | Tubocurarine |
| 1.2.398.7.1.4.2.6.4.751 | Mequitazine |
| 1.2.398.7.1.4.2.6.4.752 | Opioid receptor antagonist |
| 1.2.398.7.1.4.2.6.4.753 | Cinnarizine |
| 1.2.398.7.1.4.2.6.4.754 | Dimethindine |
| 1.2.398.7.1.4.2.6.4.755 | Hypromellose |
| 1.2.398.7.1.4.2.6.4.756 | Halofantrine |
| 1.2.398.7.1.4.2.6.4.757 | Pheniramine |
| 1.2.398.7.1.4.2.6.4.758 | Piperacillin |
| 1.2.398.7.1.4.2.6.4.759 | Tulobuterol |
| 1.2.398.7.1.4.2.6.4.760 | Pyrimethamine |
| 1.2.398.7.1.4.2.6.4.761 | Flurbiprofen |
| 1.2.398.7.1.4.2.6.4.762 | Chloroxylenol |
| 1.2.398.7.1.4.2.6.4.763 | Promethazine |
| 1.2.398.7.1.4.2.6.4.764 | Pheneticillin |
| 1.2.398.7.1.4.2.6.4.765 | Pivampicillin |
| 1.2.398.7.1.4.2.6.4.766 | Triprolidine |
| 1.2.398.7.1.4.2.6.4.767 | Bacampicillin |
| 1.2.398.7.1.4.2.6.4.768 | Talampicillin |
| 1.2.398.7.1.4.2.6.4.769 | Pivmecillinam |
| 1.2.398.7.1.4.2.6.4.770 | Trihexyphenidyl |
| 1.2.398.7.1.4.2.6.4.771 | Opioid morphinan |
| 1.2.398.7.1.4.2.6.4.772 | Benetamine penicillin |
| 1.2.398.7.1.4.2.6.4.773 | Clomiphene |
| 1.2.398.7.1.4.2.6.4.774 | Penicillinase-sensitive penicillin |
| 1.2.398.7.1.4.2.6.4.775 | Penicillinase-resistant penicillin |
| 1.2.398.7.1.4.2.6.4.776 | Histamine H1-receptor antagonists |
| 1.2.398.7.1.4.2.6.4.777 | Phenothrin |
| 1.2.398.7.1.4.2.6.4.778 | Darunavir |
| 1.2.398.7.1.4.2.6.4.779 | Permethrin |
| 1.2.398.7.1.4.2.6.4.780 | Flunisolide |
| 1.2.398.7.1.4.2.6.4.781 | Halcinonide |
| 1.2.398.7.1.4.2.6.4.782 | Perithroid |
| 1.2.398.7.1.4.2.6.4.783 | Clobetasone |
| 1.2.398.7.1.4.2.6.4.784 | Tolbutamide |
| 1.2.398.7.1.4.2.6.4.785 | Trimetaphan |
| 1.2.398.7.1.4.2.6.4.786 | Nevirapine |
| 1.2.398.7.1.4.2.6.4.787 | Penicillin |
| 1.2.398.7.1.4.2.6.4.788 | Ethyl alcohol |
| 1.2.398.7.1.4.2.6.4.789 | Adrenocorticotropic hormone |
| 1.2.398.7.1.4.2.6.4.790 | Glycine ferrous sulfate |
| 1.2.398.7.1.4.2.6.4.791 | Iron polysaccharide complex |
| 1.2.398.7.1.4.2.6.4.792 | Phosphodiesterase inhibitor |
| 1.2.398.7.1.4.2.6.4.793 | Omega-3 fatty acids of fish origin |
| 1.2.398.7.1.4.2.6.4.794 | Corticosteroid and corticosteroid derivative |
| 1.2.398.7.1.4.2.6.4.795 | Naproxen |
| 1.2.398.7.1.4.2.6.4.796 | Atropine |
| 1.2.398.7.1.4.2.6.4.797 | Etamivan |
| 1.2.398.7.1.4.2.6.4.798 | Doxapram |
| 1.2.398.7.1.4.2.6.4.799 | Thymol |
| 1.2.398.7.1.4.2.6.4.800 | Xanthine |
| 1.2.398.7.1.4.2.6.4.801 | Phenol |
| 1.2.398.7.1.4.2.6.4.802 | Collodion |
| 1.2.398.7.1.4.2.6.4.803 | Clozapine |
| 1.2.398.7.1.4.2.6.4.804 | Tretinoin |
| 1.2.398.7.1.4.2.6.4.805 | Nonoxynol |
| 1.2.398.7.1.4.2.6.4.806 | Ritodrine |
| 1.2.398.7.1.4.2.6.4.807 | Dithranol |
| 1.2.398.7.1.4.2.6.4.808 | Clonidine |
| 1.2.398.7.1.4.2.6.4.809 | Trientin |
| 1.2.398.7.1.4.2.6.4.810 | Oxatomide |
| 1.2.398.7.1.4.2.6.4.811 | Acitretin |
| 1.2.398.7.1.4.2.6.4.812 | Cisplatin |
| 1.2.398.7.1.4.2.6.4.813 | Proguanil |
| 1.2.398.7.1.4.2.6.4.814 | Mepacrine |
| 1.2.398.7.1.4.2.6.4.815 | Ketotifen |
| 1.2.398.7.1.4.2.6.4.816 | Methadone |
| 1.2.398.7.1.4.2.6.4.817 | Phenindamin |
| 1.2.398.7.1.4.2.6.4.818 | Carbenicillin |
| 1.2.398.7.1.4.2.6.4.819 | Orciprenaline |
| 1.2.398.7.1.4.2.6.4.820 | Flucloxacillin |
| 1.2.398.7.1.4.2.6.4.821 | Opium alkaloid |
| 1.2.398.7.1.4.2.6.4.822 | Podophyllotoxin |
| 1.2.398.7.1.4.2.6.4.823 | Chlorphenamine |
| 1.2.398.7.1.4.2.6.4.824 | Dimenhydrinate |
| 1.2.398.7.1.4.2.6.4.825 | Lindan |
| 1.2.398.7.1.4.2.6.4.826 | Benzoyl peroxide |
| 1.2.398.7.1.4.2.6.4.827 | Cyproheptadine |
| 1.2.398.7.1.4.2.6.4.828 | Benzylpenicillin |
| 1.2.398.7.1.4.2.6.4.829 | Cyclopentolate |
| 1.2.398.7.1.4.2.6.4.830 | Brompheniramine |
| 1.2.398.7.1.4.2.6.4.831 | Diphenylpyralin |
| 1.2.398.7.1.4.2.6.4.832 | Dimethyl ether and propane |
| 1.2.398.7.1.4.2.6.4.833 | Metformin |
| 1.2.398.7.1.4.2.6.4.834 | Phenoxymethylpenicillin |
| 1.2.398.7.1.4.2.6.4.835 | Glimidine |
| 1.2.398.7.1.4.2.6.4.836 | Broad-spectrum penicillin |
| 1.2.398.7.1.4.2.6.4.837 | Xanthine oxidase inhibitor |
| 1.2.398.7.1.4.2.6.4.838 | Biguanide |
| 1.2.398.7.1.4.2.6.4.839 | Lachesin chloride |
| 1.2.398.7.1.4.2.6.4.840 | Antipsychomonal penicillin |
| 1.2.398.7.1.4.2.6.4.841 | Aldehyde |
| 1.2.398.7.1.4.2.6.4.842 | Radiopharmaceuticals |
| 1.2.398.7.1.4.2.6.4.843 | Shell clams |
| 1.2.398.7.1.4.2.6.4.844 | Ampicillin and cloxacillin |
| 1.2.398.7.1.4.2.6.4.845 | Abacavir |
| 1.2.398.7.1.4.2.6.4.846 | Belladonna alkaloids |
| 1.2.398.7.1.4.2.6.4.847 | Malathion |
| 1.2.398.7.1.4.2.6.4.848 | Antimalarial drug biguanide |
| 1.2.398.7.1.4.2.6.4.849 | Prednisone |
| 1.2.398.7.1.4.2.6.4.850 | Bromine and bromine compound |
| 1.2.398.7.1.4.2.6.4.851 | Clobetazole |
| 1.2.398.7.1.4.2.6.4.852 | Industrial Methylated alcohol |
| 1.2.398.7.1.4.2.6.4.853 | Gliclazide |
| 1.2.398.7.1.4.2.6.4.854 | Ursodeoxycholic acid |
| 1.2.398.7.1.4.2.6.4.855 | Ampicillin and flucloxacillin |
| 1.2.398.7.1.4.2.6.4.856 | Glychidone |
| 1.2.398.7.1.4.2.6.4.857 | Pivampicillin and pivmecillin |
| 1.2.398.7.1.4.2.6.4.858 | Bile acid |
| 1.2.398.7.1.4.2.6.4.859 | Magnesium Trisilicate |
| 1.2.398.7.1.4.2.6.4.860 | Tolazamide |
| 1.2.398.7.1.4.2.6.4.861 | Ticarcillin and clavulanic acid |
| 1.2.398.7.1.4.2.6.4.862 | Fluocinolone |
| 1.2.398.7.1.4.2.6.4.863 | Prednisolone |
| 1.2.398.7.1.4.2.6.4.864 | Sulfourea |
| 1.2.398.7.1.4.2.6.4.865 | Glybornuride |
| 1.2.398.7.1.4.2.6.4.866 | Usnic acid |
| 1.2.398.7.1.4.2.6.4.867 | Fluclorolone |
| 1.2.398.7.1.4.2.6.4.868 | Meglitinide |
| 1.2.398.7.1.4.2.6.4.869 | Thyroid stimulating hormone |
| 1.2.398.7.1.4.2.6.4.870 | Folinic acid |
| 1.2.398.7.1.4.2.6.4.871 | Ethanolamine |
| 1.2.398.7.1.4.2.6.4.872 | Sevoflurane |
| 1.2.398.7.1.4.2.6.4.873 | Propamidine |
| 1.2.398.7.1.4.2.6.4.874 | Fluocortolone |
| 1.2.398.7.1.4.2.6.4.875 | Sulfonamide |
| 1.2.398.7.1.4.2.6.4.876 | Alclomethasone |
| 1.2.398.7.1.4.2.6.4.877 | Dexamethesone |
| 1.2.398.7.1.4.2.6.4.878 | Triamcinolone |
| 1.2.398.7.1.4.2.6.4.879 | Acetohexamine |
| 1.2.398.7.1.4.2.6.4.880 | Glibenclamide |
| 1.2.398.7.1.4.2.6.4.881 | Betamethasone |
| 1.2.398.7.1.4.2.6.4.882 | Sorbitol iron |
| 1.2.398.7.1.4.2.6.4.883 | Phospholipid |
| 1.2.398.7.1.4.2.6.4.884 | Diclofenamide |
| 1.2.398.7.1.4.2.6.4.885 | Desoximetasone |
| 1.2.398.7.1.4.2.6.4.886 | Iron compounds |
| 1.2.398.7.1.4.2.6.4.887 | Diflucortolone |
| 1.2.398.7.1.4.2.6.4.888 | Diethyl ether |
| 1.2.398.7.1.4.2.6.4.889 | Chlorpropamide |
| 1.2.398.7.1.4.2.6.4.890 | Fludroxycortide |
| 1.2.398.7.1.4.2.6.4.891 | Fludrocortisone |
| 1.2.398.7.1.4.2.6.4.892 | Fluorometholone |
| 1.2.398.7.1.4.2.6.4.893 | Salicylic acid |
| 1.2.398.7.1.4.2.6.4.894 | Iron sulfate |
| 1.2.398.7.1.4.2.6.4.895 | Albumin solution |
| 1.2.398.7.1.4.2.6.4.896 | Thyroid hormone |
| 1.2.398.7.1.4.2.6.4.897 | Iron fumarate |
| 1.2.398.7.1.4.2.6.4.898 | Dextromethorphan |
| 1.2.398.7.1.4.2.6.4.899 | Perfluorochemicals |
| 1.2.398.7.1.4.2.6.4.900 | Dibromopropamidine |
| 1.2.398.7.1.4.2.6.4.901 | Sodium feredetate |
| 1.2.398.7.1.4.2.6.4.902 | Iron gluconate |
| 1.2.398.7.1.4.2.6.4.903 | Chlorinated phenol |
| 1.2.398.7.1.4.2.6.4.904 | Iron succinate |
| 1.2.398.7.1.4.2.6.4.905 | Ferric phosphate |
| 1.2.398.7.1.4.2.6.4.906 | Meclozine hydrochloride |
| 1.2.398.7.1.4.2.6.4.907 | Methylprednisolone |
| 1.2.398.7.1.4.2.6.4.908 | Phosphodiesterase type 5 inhibitor |
| 1.2.398.7.1.4.2.6.4.909 | Tiaprofenic acid |
| 1.2.398.7.1.4.2.6.4.910 | Sodium aurothiomalate |
| 1.2.398.7.1.4.2.6.4.911 | Glipizide |
| 1.2.398.7.1.4.2.6.4.912 | Desonide |
| 1.2.398.7.1.4.2.6.4.913 | Colchicum alkaloid |
| 1.2.398.7.1.4.2.6.4.914 | Belladonna alkaloids |
| 1.2.398.7.1.4.2.6.4.915 | Calamine |
| 1.2.398.7.1.4.2.6.4.916 | Intravenous immunoglobulin |
| 1.2.398.7.1.4.2.6.4.917 | Hamolenic acid |
| 5. | 1.2.398.7.1.4.2.6.5 | Allergens food, household | 1.2.398.7.1.4.2.6.5.1 | Food additive |
| 1.2.398.7.1.4.2.6.5.2 | An edible egg |
| 1.2.398.7.1.4.2.6.5.3 | Egg white |
| 1.2.398.7.1.4.2.6.5.4 | Fruit |
| 1.2.398.7.1.4.2.6.5.5 | Strawberry |
| 1.2.398.7.1.4.2.6.5.6 | Citrus fruit |
| 1.2.398.7.1.4.2.6.5.7 | Banana |
| 1.2.398.7.1.4.2.6.5.8 | Mango |
| 1.2.398.7.1.4.2.6.5.9 | Pineapple |
| 1.2.398.7.1.4.2.6.5.10 | Kiwi |
| 1.2.398.7.1.4.2.6.5.11 | Cherry |
| 1.2.398.7.1.4.2.6.5.12 | Apple juice |
| 1.2.398.7.1.4.2.6.5.13 | Rye |
| 1.2.398.7.1.4.2.6.5.14 | Barley |
| 1.2.398.7.1.4.2.6.5.15 | Wheat |
| 1.2.398.7.1.4.2.6.5.16 | Corn |
| 1.2.398.7.1.4.2.6.5.17 | Seeds |
| 1.2.398.7.1.4.2.6.5.18 | Poppy |
| 1.2.398.7.1.4.2.6.5.19 | Nut |
| 1.2.398.7.1.4.2.6.5.20 | Peanut butter |
| 1.2.398.7.1.4.2.6.5.21 | Peanut |
| 1.2.398.7.1.4.2.6.5.22 | Almond |
| 1.2.398.7.1.4.2.6.5.23 | Walnut |
| 1.2.398.7.1.4.2.6.5.24 | Hazelnut |
| 1.2.398.7.1.4.2.6.5.25 | Macadamia nut |
| 1.2.398.7.1.4.2.6.5.26 | Wood nut |
| 1.2.398.7.1.4.2.6.5.27 | Cashew |
| 1.2.398.7.1.4.2.6.5.28 | Meat |
| 1.2.398.7.1.4.2.6.5.29 | Red meat |
| 1.2.398.7.1.4.2.6.5.30 | Chicken |
| 1.2.398.7.1.4.2.6.5.31 | Pork |
| 1.2.398.7.1.4.2.6.5.32 | Casein |
| 1.2.398.7.1.4.2.6.5.33 | Beef |
| 1.2.398.7.1.4.2.6.5.34 | Animal protein |
| 1.2.398.7.1.4.2.6.5.35 | Legumes |
| 1.2.398.7.1.4.2.6.5.36 | Beans |
| 1.2.398.7.1.4.2.6.5.37 | Peas |
| 1.2.398.7.1.4.2.6.5.38 | Oat flakes |
| 1.2.398.7.1.4.2.6.5.39 | Tomato |
| 1.2.398.7.1.4.2.6.5.40 | Potato |
| 1.2.398.7.1.4.2.6.5.41 | Carrot |
| 1.2.398.7.1.4.2.6.5.42 | Mustard (seasoning) |
| 1.2.398.7.1.4.2.6.5.43 | Celery |
| 1.2.398.7.1.4.2.6.5.44 | Licorice |
| 1.2.398.7.1.4.2.6.5.45 | Mushrooms |
| 1.2.398.7.1.4.2.6.5.46 | Cinnamon |
| 1.2.398.7.1.4.2.6.5.47 | Caffeine |
| 1.2.398.7.1.4.2.6.5.48 | Cheese |
| 1.2.398.7.1.4.2.6.5.49 | Olive oil |
| 1.2.398.7.1.4.2.6.5.50 | Dairy |
| 1.2.398.7.1.4.2.6.5.51 | Cow's milk protein |
| 1.2.398.7.1.4.2.6.5.52 | Almond butter |
| 1.2.398.7.1.4.2.6.5.53 | Chocolate |
| 1.2.398.7.1.4.2.6.5.54 | Coconut oil |
| 1.2.398.7.1.4.2.6.5.55 | Fish |
| 1.2.398.7.1.4.2.6.5.56 | Seafood |
| 1.2.398.7.1.4.2.6.5.57 | Shellfish |
| 1.2.398.7.1.4.2.6.5.58 | Fish oil |
| 1.2.398.7.1.4.2.6.5.59 | Lobster |
| 1.2.398.7.1.4.2.6.5.60 | Shrimp |
| 1.2.398.7.1.4.2.6.5.61 | Oysters |
| 1.2.398.7.1.4.2.6.5.62 | Shellfish |
| 1.2.398.7.1.4.2.6.5.63 | Guar gum |
| 1.2.398.7.1.4.2.6.5.64 | Dietary mushroom |
| 1.2.398.7.1.4.2.6.5.65 | Dust |
| 1.2.398.7.1.4.2.6.5.66 | House dust |
| 1.2.398.7.1.4.2.6.5.67 | Wood dust |
| 1.2.398.7.1.4.2.6.5.68 | Lanolin |
| 1.2.398.7.1.4.2.6.5.69 | Wool |
| 1.2.398.7.1.4.2.6.5.70 | Animal hair |
| 1.2.398.7.1.4.2.6.5.71 | Animal dandruff |
| 1.2.398.7.1.4.2.6.5.72 | Cat dandruff |
| 1.2.398.7.1.4.2.6.5.73 | Guinea pig dandruff |
| 1.2.398.7.1.4.2.6.5.74 | Dog dandruff |
| 1.2.398.7.1.4.2.6.5.75 | Cow dandruff |
| 1.2.398.7.1.4.2.6.5.76 | Laboratory animal dandruff |
| 1.2.398.7.1.4.2.6.5.77 | Horse dandruff |
| 1.2.398.7.1.4.2.6.5.78 | Insect venom |
| 1.2.398.7.1.4.2.6.5.79 | Honeybee venom |
| 1.2.398.7.1.4.2.6.5.80 | Wasp venom |
| 1.2.398.7.1.4.2.6.5.81 | Clostridium botulinum venom |
| 1.2.398.7.1.4.2.6.5.82 | Hymenoptera venom |
| 1.2.398.7.1.4.2.6.5.83 | True wasp venom |
| 1.2.398.7.1.4.2.6.5.84 | Spider venom |
| 1.2.398.7.1.4.2.6.5.85 | Bee venom |
| 1.2.398.7.1.4.2.6.5.86 | Scorpion venom |
| 1.2.398.7.1.4.2.6.5.87 | Dust mite protein |
| 1.2.398.7.1.4.2.6.5.88 | Dermatophagoides pteronyssinus mite protein |
| 1.2.398.7.1.4.2.6.5.89 | Chelating agent |
| 1.2.398.7.1.4.2.6.5.90 | Insect protein |
| 1.2.398.7.1.4.2.6.5.91 | Wood resin |
| 1.2.398.7.1.4.2.6.5.92 | Orris root |
| 1.2.398.7.1.4.2.6.5.93 | Fenugreek (Greek/hay) |
| 1.2.398.7.1.4.2.6.5.94 | Grass pollen |
| 1.2.398.7.1.4.2.6.5.95 | Ragweed pollen |
| 1.2.398.7.1.4.2.6.5.96 | Pollen |
| 1.2.398.7.1.4.2.6.5.97 | Lupin seeds |
| 1.2.398.7.1.4.2.6.5.98 | Wallwort pollen |
| 1.2.398.7.1.4.2.6.5.99 | Weed pollen |
| 1.2.398.7.1.4.2.6.5.100 | Sooty mold pollen |
| 1.2.398.7.1.4.2.6.5.101 | Tree pollen |
| 1.2.398.7.1.4.2.6.5.102 | Wormwood pollen |
| 1.2.398.7.1.4.2.6.5.103 | Podophyllum resin |
| 1.2.398.7.1.4.2.6.5.104 | Metal |
| 1.2.398.7.1.4.2.6.5.105 | Rust protein |
| 1.2.398.7.1.4.2.6.5.106 | Zinc |
| 1.2.398.7.1.4.2.6.5.107 | Iron oxide salt |
| 1.2.398.7.1.4.2.6.5.108 | Gold |
| 1.2.398.7.1.4.2.6.5.109 | Silver nitrate |
| 1.2.398.7.1.4.2.6.5.110 | Aluminum |
| 1.2.398.7.1.4.2.6.5.111 | Cosmetic material |
| 1.2.398.7.1.4.2.6.5.112 | Retinoids |
| 1.2.398.7.1.4.2.6.5.113 | Azelaic acid |
| 1.2.398.7.1.4.2.6.5.114 | Perfume |
| 1.2.398.7.1.4.2.6.5.115 | Serum |
| 1.2.398.7.1.4.2.6.5.116 | Rubber |
| 1.2.398.7.1.4.2.6.5.117 | Latex |
| 1.2.398.7.1.4.2.6.5.118 | Polyvinyl alcohol |
| 1.2.398.7.1.4.2.6.5.119 | Paraffin |
| 1.2.398.7.1.4.2.6.5.120 | Silicone |
| 1.2.398.7.1.4.2.6.5.121 | Borate salt |
| 1.2.398.7.1.4.2.6.5.122 | Organophosphorus compounds |
| 1.2.398.7.1.4.2.6.5.123 | X-ray contrast agents |
| 1.2.398.7.1.4.2.6.5.124 | Carbomer 940 |
| 1.2.398.7.1.4.2.6.5.125 | Mold |
| 1.2.398.7.1.4.2.6.5.126 | Yeast antigen |
| 1.2.398.7.1.4.2.6.5.127 | White paraffin |
| 1.2.398.7.1.4.2.6.5.128 | Yellow paraffin |
| 1.2.398.7.1.4.2.6.5.129 | Alkali metal soap |
| 1.2.398.7.1.4.2.6.5.130 | Nonionic surfactant |
| 1.2.398.7.1.4.2.6.5.131 | Amidine disinfectant |
| 1.2.398.7.1.4.2.6.5.132 | Hexachlorophene |
| 1.2.398.7.1.4.2.6.5.133 | Carbamate pesticide |
| 1.2.398.7.1.4.2.6.5.134 | Organochloride pesticide |
| 1.2.398.7.1.4.2.6.5.135 | Biocide |
| 1.2.398.7.1.4.2.6.5.136 | Diagnostic agent |
| 1.2.398.7.1.4.2.6.5.137 | Contrast agent |
| 1.2.398.7.1.4.2.6.5.138 | Magnetic resonance imaging contrast agent |
| 1.2.398.7.1.4.2.6.5.139 | Fixed oil |
| 1.2.398.7.1.4.2.6.5.140 | Urea |
| 1.2.398.7.1.4.2.6.5.141 | Adhesive |
| 1.2.398.7.1.4.2.6.5.142 | Viscosity modifier derived from cellulose |
| 1.2.398.7.1.4.2.6.5.143 | Existing dental restorative material |
| 6. | 1.2.398.7.1.4.2.6.6 | Type of laboratory tests | 1.2.398.7.1.4.2.6.6.1 | Hematological |
| 1.2.398.7.1.4.2.6.6.2 | Cytological |
| 1.2.398.7.1.4.2.6.6.3 | Biochemical |
| 1.2.398.7.1.4.2.6.6.4 | Microbiological |
| 1.2.398.7.1.4.2.6.6.5 | Immunological |
| 1.2.398.7.1.4.2.6.6.6 | Medical genetic |
| 1.2.398.7.1.4.2.6.6.7 | General clinical |

**Medicinal reference books**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| № s/n | Object identifier code of the reference book | Name of the reference book | Object identifier code of the reference book value | Contents |
| 1.1. . | 1.2.398.7.1.4.2.7.1 | Route of administration | 1.2.398.7.1.4.2.7.1.1 | Nasal |
| 1.2.398.7.1.4.2.7.1.2 | Buccal (Transbuccal) |
| 1.2.398.7.1.4.2.7.1.3 | Local administration |
| 1.2.398.7.1.4.2.7.1.4 | Intraureteral administration |
| 1.2.398.7.1.4.2.7.1.5 | Ileal |
| 1.2.398.7.1.4.2.7.1.6 | Intratumoral |
| 1.2.398.7.1.4.2.7.1.7 | Submucosal |
| 1.2.398.7.1.4.2.7.1.8 | Intrasinusal |
| 1.2.398.7.1.4.2.7.1.9 | Intramural |
| 1.2.398.7.1.4.2.7.1.10 | Introduction into the cavity (bed) of the removed tumor |
| 1.2.398.7.1.4.2.7.1.11 | Introduction into the fistula |
| 1.2.398.7.1.4.2.7.1.12 | Gastric |
| 1.2.398.7.1.4.2.7.1.13 | Vaginal |
| 1.2.398.7.1.4.2.7.1.14 | Intralingual |
| 1.2.398.7.1.4.2.7.1.15 | Enteral |
| 1.2.398.7.1.4.2.7.1.16 | Intrahepatic |
| 1.2.398.7.1.4.2.7.1.17 | Epidural |
| 1.2.398.7.1.4.2.7.1.18 | Intrauterine |
| 1.2.398.7.1.4.2.7.1.19 | Gingival |
| 1.2.398.7.1.4.2.7.1.20 | Subcutaneous |
| 1.2.398.7.1.4.2.7.1.21 | Introduction through a colostomy |
| 1.2.398.7.1.4.2.7.1.22 | Intramammary |
| 1.2.398.7.1.4.2.7.1.23 | For oral administration |
| 1.2.398.7.1.4.2.7.1.24 | Colonic |
| 1.2.398.7.1.4.2.7.1.25 | Sublingual |
| 1.2.398.7.1.4.2.7.1.26 | Conjunctival |
| 1.2.398.7.1.4.2.7.1.27 | Oromucous (administration through the oral mucosa) |
| 1.2.398.7.1.4.2.7.1.28 | Intracranial |
| 1.2.398.7.1.4.2.7.1.29 | Heralny |
| 1.2.398.7.1.4.2.7.1.30 | Perineural |
| 1.2.398.7.1.4.2.7.1.31 | Nasoduodenal |
| 1.2.398.7.1.4.2.7.1.32 | Parabulbar (peribulbar, near-bulbar) |
| 1.2.398.7.1.4.2.7.1.33 | Subcutaneous |
| 1.2.398.7.1.4.2.7.1.34 | Interstitial |
| 1.2.398.7.1.4.2.7.1.35 | Infraorbital |
| 1.2.398.7.1.4.2.7.1.36 | Introduction into the tympanic cavity |
| 1.2.398.7.1.4.2.7.1.37 | Nasogastric |
| 1.2.398.7.1.4.2.7.1.38 | Intrabursal |
| 1.2.398.7.1.4.2.7.1.39 | Intravascular |
| 1.2.398.7.1.4.2.7.1.40 | Intradermal |
| 1.2.398.7.1.4.2.7.1.41 | Intraduodenal |
| 1.2.398.7.1.4.2.7.1.42 | Intradiscal |
| 1.2.398.7.1.4.2.7.1.43 | Transtracheal |
| 1.2.398.7.1.4.2.7.1.44 | Intraocular |
| 1.2.398.7.1.4.2.7.1.45 | Intramuscular |
| 1.2.398.7.1.4.2.7.1.46 | Nasojejunal |
| 1.2.398.7.1.4.2.7.1.47 | Introduction through an esophagostomy |
| 1.2.398.7.1.4.2.7.1.48 | Paravertebral |
| 1.2.398.7.1.4.2.7.1.49 | Transcervical |
| 1.2.398.7.1.4.2.7.1.50 | Insertion through jejunostomy |
| 1.2.398.7.1.4.2.7.1.51 | Intracerebral |
| 1.2.398.7.1.4.2.7.1.52 | Intraductal (intraductal) |
| 1.2.398.7.1.4.2.7.1.53 | Intrameningeal |
| 1.2.398.7.1.4.2.7.1.54 | Retrobulbar |
| 1.2.398.7.1.4.2.7.1.55 | Extracorporeal |
| 1.2.398.7.1.4.2.7.1.56 | Intravitreal |
| 1.2.398.7.1.4.2.7.1.57 | Intrabronchial |
| 1.2.398.7.1.4.2.7.1.58 | Transmucosal |
| 1.2.398.7.1.4.2.7.1.59 | Intrabiliary |
| 1.2.398.7.1.4.2.7.1.60 | Intraarterial |
| 1.2.398.7.1.4.2.7.1.61 | Endocervical |
| 1.2.398.7.1.4.2.7.1.62 | Intramedullary |
| 1.2.398.7.1.4.2.7.1.63 | Introduction into paranasal sinuses |
| 1.2.398.7.1.4.2.7.1.64 | Intrapulmonary (intrapulmonary) |
| 1.2.398.7.1.4.2.7.1.65 | Intrapleural |
| 1.2.398.7.1.4.2.7.1.66 | Intrasternal |
| 1.2.398.7.1.4.2.7.1.67 | Transplacental |
| 1.2.398.7.1.4.2.7.1.68 | Intraepidermal |
| 1.2.398.7.1.4.2.7.1.69 | Intracorneal |
| 1.2.398.7.1.4.2.7.1.70 | Intraprostatic |
| 1.2.398.7.1.4.2.7.1.71 | Intravesical |
| 1.2.398.7.1.4.2.7.1.72 | Intracardiac |
| 1.2.398.7.1.4.2.7.1.73 | Intraabdominal |
| 1.2.398.7.1.4.2.7.1.74 | Intracisternal |
| 1.2.398.7.1.4.2.7.1.75 | Paracervical |
| 1.2.398.7.1.4.2.7.1.76 | Introduction into the esophagus (intraesophageal) |
| 1.2.398.7.1.4.2.7.1.77 | Subcutaneous |
| 1.2.398.7.1.4.2.7.1.78 | Enteral (administration through the gastrointestinal tract) |
| 1.2.398.7.1.4.2.7.1.79 | Periurethral (Circumurethral) |
| 1.2.398.7.1.4.2.7.1.80 | Intracoronal |
| 1.2.398.7.1.4.2.7.1.81 | Introduction into the surgical cavity |
| 1.2.398.7.1.4.2.7.1.82 | Intraepicardial (Epicardial) |
| 1.2.398.7.1.4.2.7.1.83 | Intra-articular (Intra-synovial) |
| 1.2.398.7.1.4.2.7.1.84 | Intrathoracic |
| 1.2.398.7.1.4.2.7.1.85 | Intracavernous |
| 1.2.398.7.1.4.2.7.1.86 | Extra-amniotic |
| 1.2.398.7.1.4.2.7.1.87 | Introduction through a drainage tube |
| 1.2.398.7.1.4.2.7.1.88 | Intralymphatic |
| 1.2.398.7.1.4.2.7.1.89 | Intratendinous |
| 1.2.398.7.1.4.2.7.1.90 | Intracartilaginous |
| 1.2.398.7.1.4.2.7.1.91 | Introduction into central veins |
| 1.2.398.7.1.4.2.7.1.92 | Introduction into a urostomy |
| 1.2.398.7.1.4.2.7.1.93 | Ureteral |
| 1.2.398.7.1.4.2.7.1.94 | Cutaneous |
| 1.2.398.7.1.4.2.7.1.95 | Peridural |
| 1.2.398.7.1.4.2.7.1.96 | Laryngopharyngeal (Laryngeal) |
| 1.2.398.7.1.4.2.7.1.97 | Introduction through ileostomy |
| 1.2.398.7.1.4.2.7.1.98 | Intradural |
| 1.2.398.7.1.4.2.7.1.99 | Periosteal |
| 1.2.398.7.1.4.2.7.1.100 | Ocular |
| 1.2.398.7.1.4.2.7.1.101 | Intrathecal |
| 1.2.398.7.1.4.2.7.1.102 | Introduction to the lesion |
| 1.2.398.7.1.4.2.7.1.103 | Periodontal |
| 1.2.398.7.1.4.2.7.1.104 | Intravenous |
| 1.2.398.7.1.4.2.7.1.105 | Subgingival (subgingival) |
| 1.2.398.7.1.4.2.7.1.106 | Transdermal |
| 1.2.398.7.1.4.2.7.1.107 | Introduction into body cavities |
| 1.2.398.7.1.4.2.7.1.108 | Auricular |
| 1.2.398.7.1.4.2.7.1.109 | Intraneural |
| 1.2.398.7.1.4.2.7.1.110 | For oral administration (Oral) |
| 1.2.398.7.1.4.2.7.1.111 | Dental |
| 1.2.398.7.1.4.2.7.1.112 | Infiltration |
| 1.2.398.7.1.4.2.7.1.113 | Rectal |
| 1.2.398.7.1.4.2.7.1.114 | Intraovarian |
| 1.2.398.7.1.4.2.7.1.115 | Caudal |
| 1.2.398.7.1.4.2.7.1.116 | Intragingival (introduction into the gum) |
| 1.2.398.7.1.4.2.7.1.117 | Introduction through a gastrostomy |
| 1.2.398.7.1.4.2.7.1.118 | Peritendinous (Peritendinous) |
| 1.2.398.7.1.4.2.7.1.119 | Intracameral (Introduction into the eye chamber) |
| 1.2.398.7.1.4.2.7.1.120 | Intraosseous |
| 1.2.398.7.1.4.2.7.1.121 | Intratesticular |
| 1.2.398.7.1.4.2.7.1.122 | Intraluminal |
| 1.2.398.7.1.4.2.7.1.123 | Intrapericardial |
| 1.2.398.7.1.4.2.7.1.124 | Endotracheal |
| 1.2.398.7.1.4.2.7.1.125 | Transendocardial |
| 1.2.398.7.1.4.2.7.1.126 | Transurethral |
| 1.2.398.7.1.4.2.7.1.127 | Inhalation |
| 1.2.398.7.1.4.2.7.1.128 | Gastroenteric |
| 1.2.398.7.1.4.2.7.1.129 | Introduction into arteriovenous fistula |
| 1.2.398.7.1.4.2.7.1.130 | Intraamniotic |
| 1.2.398.7.1.4.2.7.1.131 | Intracavernous |
| 1.2.398.7.1.4.2.7.1.132 | Intracoronary (intracoronary) |
| 1.2.398.7.1.4.2.7.1.133 | Introduction into peripheral veins |
| 1.2.398.7.1.4.2.7.1.134 | Intracerebroventricular |
| 1.2.398.7.1.4.2.7.1.135 | Introduction into the lesion |
| 1.2.398.7.1.4.2.7.1.136 | Periarticular |
| 1.2.398.7.1.4.2.7.1.137 | Intraventricular |
| 1.2.398.7.1.4.2.7.1.138 | Oropharyngeal |
| 1.2.398.7.1.4.2.7.1.139 | Hemodialysis |
| 1.2.398.7.1.4.2.7.1.140 | Intratympanic |
| 1.2.398.7.1.4.2.7.1.141 | Subconjunctival |
| 1.2.398.7.1.4.2.7.1.142 | Intraperitoneal |
| 1.2.398.7.1.4.2.7.1.143 | Intra-articular |
| 1.2.398.7.1.4.2.7.1.144 | Introduction into the myometrium |
| 1.2.398.7.1.4.2.7.1.145 | Endotracheopulmonary |
| 1.2.398.7.1.4.2.7.1.146 | Introduction through a gastrointestinal stoma |
| 1.2.398.7.1.4.2.7.1.147 | Implantation |
| 1.2.398.7.1.4.2.7.1.148 | Intestinal |
| 1.2.398.7.1.4.2.7.1.149 | Into the anterior chamber of the eye |
| 1.2.398.7.1.4.2.7.1.150 | Iontophoresis |
| 1.2.398.7.1.4.2.7.1.151 | Posterior juxtascleral |
| 1.2.398.7.1.4.2.7.1.152 | Skin scarification |
| 1.2.398.7.1.4.2.7.1.153 | Intracholangiopancreatic |
| 1.2.398.7.1.4.2.7.1.154 | Peritumor |
| 1.2.398.7.1.4.2.7.1.155 | Intraportal |
| 1.2.398.7.1.4.2.7.1.156 | Intraglandular |
| 1.2.398.7.1.4.2.7.1.157 | Subretinal |
| 1.2.398.7.1.4.2.7.1.158 | Intracervical |
| 2. | 1.2.398.7.1.4.2.7.2 | Dosage frequency | 1.2.398.7.1.4.2.7.2.1 | Every hour |
| 1.2.398.7.1.4.2.7.2.2 | Every 2 hours |
| 1.2.398.7.1.4.2.7.2.3 | Every 3 hours |
| 1.2.398.7.1.4.2.7.2.4 | Every 4 hours |
| 1.2.398.7.1.4.2.7.2.5 | Every 5 hours |
| 1.2.398.7.1.4.2.7.2.6 | Every 6 hours |
| 1.2.398.7.1.4.2.7.2.7 | Every 8 hours |
| 1.2.398.7.1.4.2.7.2.8 | Every 12 hours |
| 1.2.398.7.1.4.2.7.2.9 | Every 24 hours |
| 1.2.398.7.1.4.2.7.2.10 | Every 48 hours |
| 1.2.398.7.1.4.2.7.2.11 | Every 72 hours |
| 1.2.398.7.1.4.2.7.2.12 | Weekly |
| 1.2.398.7.1.4.2.7.2.13 | As needed |
| 3. | 1.2.398.7.1.4.2.7.3 | List of diseases against which the vaccine is used | 1.2.398.7.1.4.2.7.3.1 | Against whooping cough, diphtheria, tetanus, Haemophilus influenzae type b, viral hepatitis B, poliomyelitis |
| 1.2.398.7.1.4.2.7.3.2 | Against whooping cough, diphtheria, tetanus, Haemophilus influenzae type b, poliomyelitis |
| 1.2.398.7.1.4.2.7.3.3 | Against whooping cough, diphtheria, tetanus |
| 1.2.398.7.1.4.2.7.3.4 | Against diphtheria, tetanus |
| 1.2.398.7.1.4.2.7.3.5 | Against tuberculosis |
| 1.2.398.7.1.4.2.7.3.6 | Against poliomyelitis |
| 1.2.398.7.1.4.2.7.3.7 | Against rubella |
| 1.2.398.7.1.4.2.7.3.8 | Against measles |
| 1.2.398.7.1.4.2.7.3.9 | Against measles, rubella and mumps |
| 1.2.398.7.1.4.2.7.3.10 | Against viral hepatitis B |
| 1.2.398.7.1.4.2.7.3.11 | Against Haemophilus influenzae type b |
| 1.2.398.7.1.4.2.7.3.12 | Against pneumococcal infection |
| 1.2.398.7.1.4.2.7.3.13 | Against viral hepatitis A |
| 1.2.398.7.1.4.2.7.3.14 | Against influenza |
| 1.2.398.7.1.4.2.7.3.15 | Against rabies |
| 1.2.398.7.1.4.2.7.3.16 | Against typhoid fever |
| 1.2.398.7.1.4.2.7.3.17 | Against plague |
| 1.2.398.7.1.4.2.7.3.18 | Against tick-borne encephalitis |
| 1.2.398.7.1.4.2.7.3.19 | Against anthrax |
| 1.2.398.7.1.4.2.7.3.20 | Against tularemia |
| 1.2.398.7.1.4.2.7.3.21 | Against tetanus |
| 1.2.398.7.1.4.2.7.3.22 | Against meningococcal infection |
| 1.2.398.7.1.4.2.7.3.23 | Against mumps |
| 1.2.398.7.1.4.2.7.3.24 | Against yellow fever |
| 1.2.398.7.1.4.2.7.3.25 | Against human papillomavirus |
| 1.2.398.7.1.4.2.7.3.26 | Against coronavirus infection |

**Dialysis service reference books**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| № s/n | Object identifier code of the reference book | Name of the reference book | Object identifier code of the reference book value | Contents |
| 1. | 1.2.398.7.1.4.2.8.1 | Dialyzer capacity | 1.2.398.7.1.4.2.8.1.1 | Low-flow |
| 1.2.398.7.1.4.2.8.1.2 | High-flow |
| 2. | 1.2.398.7.1.4.2.8.2 | Ultrafiltration profile (hemodialysis) | 1.2.398.7.1.4.2.8.2.1 | Isolated ultrafiltration |
| 1.2.398.7.1.4.2.8.2.2 | Ultrafiltration |
| 1.2.398.7.1.4.2.8.2.3 | Sodium |
| 3. | 1.2.398.7.1.4.2.8.3 | Vascular access (hemodialysis) | 1.2.398.7.1.4.2.8.3.1 | Arteriovenous fistula |
| 1.2.398.7.1.4.2.8.3.2 | Prosthesis |
| 1.2.398.7.1.4.2.8.3.3 | Temporary catheter |
| 1.2.398.7.1.4.2.8.3.4 | Permanent catheter |
| 4. | 1.2.398.7.1.4.2.8.4 | Renal replacement therapy method | 1.2.398.7.1.4.2.8.4.1 | Continuous venovenous hemodialysis |
| 1.2.398.7.1.4.2.8.4.2 | Continuous venovenous hemodiafiltration |
| 1.2.398.7.1.4.2.8.4.3 | Continuous venovenous hemofiltration |
| 5. | 1.2.398.7.1.4.2.8.5 | Plasma replacement solution | 1.2.398.7.1.4.2.8.5.1 | No |
| 1.2.398.7.1.4.2.8.5.2 | Fresh frozen plasma |
| 1.2.398.7.1.4.2.8.5.3 | Albumin |
| 1.2.398.7.1.4.2.8.5.4 | Sodium chloride |
| 1.2.398.7.1.4.2.8.5.5 | Mixed |
| 1.2.398.7.1.4.2.8.5.6 | Other |
| 6. | 1.2.398.7.1.4.2.8.6 | Peritoneal dialysis program | 1.2.398.7.1.4.2.8.6.1 | Automated peritoneal dialysis |
| 1.2.398.7.1.4.2.8.6.2 | Continuous ambulatory peritoneal dialysis |
| 7. | 1.2.398.7.1.4.2.8.7 | Anticoagulation during the procedure | 1.2.398.7.1.4.2.8.7.1 | No |
| 1.2.398.7.1.4.2.8.7.2 | Unfractionated heparin |
| 1.2.398.7.1.4.2.8.7.3 | Low molecular weight heparin: enoxaparin |
| 1.2.398.7.1.4.2.8.7.4 | Low molecular weight heparin: fraxiparin |
| 1.2.398.7.1.4.2.8.7.5 | Sodium citrate 4% |
| 1.2.398.7.1.4.2.8.7.6 | Mixed anticoagulation |
| 1.2.398.7.1.4.2.8.7.7 | Other |
| 8. | 1.2.398.7.1.4.2.8.8 | Transfusion frequency | 1.2.398.7.1.4.2.8.8.1 | Primary |
| 1.2.398.7.1.4.2.8.8.2 | Repeated |
| 9. | 1.2.398.7.1.4.2.8.9 | Procedures in renal replacement therapy | 1.2.398.7.1.4.2.8.9.1 | Hemodialysis |
| 1.2.398.7.1.4.2.8.9.2 | Hemodiafiltration |
| 1.2.398.7.1.4.2.8.9.3 | Hemodiafiltration predilution |
| 1.2.398.7.1.4.2.8.9.4 | Hemodiafiltration postdilution |
| 1.2.398.7.1.4.2.8.9.5 | Isolated ultrafiltration |
| 1.2.398.7.1.4.2.8.9.6 | Hemofiltration |
| 1.2.398.7.1.4.2.8.9.7 | Hemosorption |
| 1.2.398.7.1.4.2.8.9.8 | Plasmapheresis |
| 1.2.398.7.1.4.2.8.9.9 | Plasma exchange |
| 10. | 1.2.398.7.1.4.2.8.10 | Sorbent | 1.2.398.7.1.4.2.8.10.1 | Renal (uremia) |
| 1.2.398.7.1.4.2.8.10.2 | Liver |
| 1.2.398.7.1.4.2.8.10.3 | Septic |
| 1.2.398.7.1.4.2.8.10.4 | Septic with gram-negative bacteria |
| 1.2.398.7.1.4.2.8.10.5 | Autoimmune |
| 1.2.398.7.1.4.2.8.10.6 | Narcotic (toxic) |
| 1.2.398.7.1.4.2.8.10.7 | Lipid |
| 11. | 1.2.398.7.1.4.2.8.11 | Technical complications of dialysis | 1.2.398.7.1.4.2.8.11.1 | Line thrombosis |
| 1.2.398.7.1.4.2.8.11.2 | Filter thrombosis |
| 1.2.398.7.1.4.2.8.11.3 | Needle thrombosis |
| 1.2.398.7.1.4.2.8.11.4 | Vascular access puncture |
| 1.2.398.7.1.4.2.8.11.5 | Catheter thrombosis |
| 12. | 1.2.398.7.1.4.2.8.12 | Clinical complications of dialysis | 1.2.398.7.1.4.2.8.12.1 | Intradialytic arterial hypotension |
| 1.2.398.7.1.4.2.8.12.2 | Intradialytic arterial hypertension |
| 1.2.398.7.1.4.2.8.12.3 | Muscle cramps |
| 1.2.398.7.1.4.2.8.12.4 | Nausea and vomiting |
| 1.2.398.7.1.4.2.8.12.5 | Headache |
| 1.2.398.7.1.4.2.8.12.6 | Pain behind the sternum |
| 1.2.398.7.1.4.2.8.12.7 | Heart rhythm disturbances |
| 13. | 1.2.398.7.1.4.2.8.13 | Hemodialysis method | 1.2.398.7.1.4.2.8.13.1 | General |
| 1.2.398.7.1.4.2.8.13.2 | Dosed |
| 1.2.398.7.1.4.2.8.13.3 | Regional |
| 14. | 1.2.398.7.1.4.2.8.14 | Peritoneal equilibrium test, solution | 1.2.398.7.1.4.2.8.14.1 | Urine urea |
| 1.2.398.7.1.4.2.8.14.2 | Urine creatinine |
| 1.2.398.7.1.4.2.8.14.3 | Urine glucose |
| 1.2.398.7.1.4.2.8.14.4 | Urine phosphorus |
| 1.2.398.7.1.4.2.8.14.5 | Blood urea |
| 1.2.398.7.1.4.2.8.14.6 | Blood creatinine |
| 1.2.398.7.1.4.2.8.14.7 | Blood glucose |
| 1.2.398.7.1.4.2.8.14.8 | Blood phosphorus |
| 1.2.398.7.1.4.2.8.14.9 | Blood albumin |

**Reference books used in providing surgical care**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| № s/n | Object identifier code of the reference book | Name of the reference book | Object identifier code of the reference book value | Contents |
| 1. | 1.2.398.7.1.4.2.9.1 | Type of surgery | 1.2.398.7.1.4.2.9.1.1 | Emergency |
| 1.2.398.7.1.4.2.9.1.2 | Planned |
| 2.. | 1.2.398.7.1.4.2.9.2 | Regimen after surgery, chemotherapy and others | 1.2.398.7.1.4.2.9.2.1 | Strict bed rest |
| 1.2.398.7.1.4.2.9.2.2 | Bed rest |
| 1.2.398.7.1.4.2.9.2.3 | Ward |
| 1.2.398.7.1.4.2.9.2.4 | General |
| 3. | 1.2.398.7.1.4.2.9.3 | The outcome of the operation | 1.2.398.7.1.4.2.9.3.1 | Without complications during surgery/procedure/apheresis |
| 1.2.398.7.1.4.2.9.3.2 | Other types of peritonitis |
| 1.2.398.7.1.4.2.9.3.3 | Peritonitis, unspecified |
| 1.2.398.7.1.4.2.9.3.4 | Internal bleeding |
| 1.2.398.7.1.4.2.9.3.5 | External bleeding |
| 1.2.398.7.1.4.2.9.3.6 | Anastomotic leak |
| 1.2.398.7.1.4.2.9.3.7 | Abscess of the abdominal cavity |
| 1.2.398.7.1.4.2.9.3.8 | Abscess of the pelvic cavity |
| 1.2.398.7.1.4.2.9.3.9 | Comatose state |
| 1.2.398.7.1.4.2.9.3.10 | Anaphylactic shock |
| 1.2.398.7.1.4.2.9.3.11 | Posthemorrhagic shock |
| 1.2.398.7.1.4.2.9.3.12 | Sepsis |
| 1.2.398.7.1.4.2.9.3.13 | Postoperative pancreatitis |
| 1.2.398.7.1.4.2.9.3.14 | Intestinal fistulas |
| 1.2.398.7.1.4.2.9.3.15 | Biliary fistulas |
| 1.2.398.7.1.4.2.9.3.16 | Vesicovaginal fistula |
| 1.2.398.7.1.4.2.9.3.17 | Vesicointestinal fistula |
| 1.2.398.7.1.4.2.9.3.18 | Vesicoureteral fistula |
| 1.2.398.7.1.4.2.9.3.19 | Urethral fistula |
| 1.2.398.7.1.4.2.9.3.20 | Bronchial fistula |
| 1.2.398.7.1.4.2.9.3.21 | Duodenal fistula |
| 1.2.398.7.1.4.2.9.3.22 | Uretrovaginal fistula |
| 1.2.398.7.1.4.2.9.3.23 | Rectovaginal fistula |
| 1.2.398.7.1.4.2.9.3.24 | Enterovaginal fistula |
| 1.2.398.7.1.4.2.9.3.25 | Acute and chronic crisis of transplanted organ rejection |
| 1.2.398.7.1.4.2.9.3.26 | Paracolossal abscess |
| 1.2.398.7.1.4.2.9.3.27 | Paracostomy hernia |
| 1.2.398.7.1.4.2.9.3.28 | Paraproctitis |
| 1.2.398.7.1.4.2.9.3.29 | Necrosis and retraction of the retracted intestine |
| 1.2.398.7.1.4.2.9.3.30 | Mediastenitis |
| 1.2.398.7.1.4.2.9.3.31 | Pelvic tissue phlegmon |
| 1.2.398.7.1.4.2.9.3.32 | Paranephritis |
| 1.2.398.7.1.4.2.9.3.33 | Pancreonecrosis |
| 1.2.398.7.1.4.2.9.3.34 | Wound complications |
| 1.2.398.7.1.4.2.9.3.35 | Wound divergence |
| 1.2.398.7.1.4.2.9.3.36 | Wound suppuration |
| 1.2.398.7.1.4.2.9.3.37 | Eventration |
| 1.2.398.7.1.4.2.9.3.38 | Skin flap necrosis |
| 1.2.398.7.1.4.2.9.3.39 | Postoperative suture hematoma |
| 1.2.398.7.1.4.2.9.3.40 | Hematoma suppuration |
| 1.2.398.7.1.4.2.9.3.41 | Circulatory system complications |
| 1.2.398.7.1.4.2.9.3.42 | Cerebral embolism |
| 1.2.398.7.1.4.2.9.3.43 | Myocardial infarction |
| 1.2.398.7.1.4.2.9.3.44 | Cerebral infarction |
| 1.2.398.7.1.4.2.9.3.45 | Cerebral ischemia |
| 1.2.398.7.1.4.2.9.3.46 | Cardiovascular insufficiency |
| 1.2.398.7.1.4.2.9.3.47 | Rhythm and conduction disturbances |
| 1.2.398.7.1.4.2.9.3.48 | Thromboembolism of the pulmonary artery branches |
| 1.2.398.7.1.4.2.9.3.49 | Brain hemorrhage |
| 1.2.398.7.1.4.2.9.3.50 | Pericarditis |
| 1.2.398.7.1.4.2.9.3.51 | Inflammation of the venous and lymphatic vessels |
| 1.2.398.7.1.4.2.9.3.52 | Retrothrombosis |
| 1.2.398.7.1.4.2.9.3.53 | Thrombosis of the stump |
| 1.2.398.7.1.4.2.9.3.54 | Thrombosis of the vascular anastomosis |
| 1.2.398.7.1.4.2.9.3.55 | Delayed cerebrovascular accidents |
| 1.2.398.7.1.4.2.9.3.56 | Respiratory complications |
| 1.2.398.7.1.4.2.9.3.57 | Pulmonary failure |
| 1.2.398.7.1.4.2.9.3.58 | Bronchitis |
| 1.2.398.7.1.4.2.9.3.59 | Pneumonia |
| 1.2.398.7.1.4.2.9.3.60 | Pleurisy |
| 1.2.398.7.1.4.2.9.3.61 | Pulmonary edema |
| 1.2.398.7.1.4.2.9.3.62 | Empyemas |
| 1.2.398.7.1.4.2.9.3.63 | Pulmonary atelectasis |
| 1.2.398.7.1.4.2.9.3.64 | Laryngeal edema |
| 1.2.398.7.1.4.2.9.3.65 | Pneumothorax |
| 1.2.398.7.1.4.2.9.3.66 | Complications from the central nervous system |
| 1.2.398.7.1.4.2.9.3.67 | Cerebral edema |
| 1.2.398.7.1.4.2.9.3.68 | Facial nerve paralysis |
| 1.2.398.7.1.4.2.9.3.69 | Meningitis |
| 1.2.398.7.1.4.2.9.3.70 | Other complications |
| 1.2.398.7.1.4.2.9.3.71 | Renal failure |
| 1.2.398.7.1.4.2.9.3.72 | Liver failure |
| 1.2.398.7.1.4.2.9.3.73 | Osteomyelitis |
| 1.2.398.7.1.4.2.9.3.74 | Phlegmon of the chest |
| 1.2.398.7.1.4.2.9.3.75 | Post-transfusion syndrome |
| 1.2.398.7.1.4.2.9.3.76 | Post-perfusion syndrome |
| 1.2.398.7.1.4.2.9.3.77 | Lymphostasis |
| 1.2.398.7.1.4.2.9.3.78 | Nonunion of fracture |
| 1.2.398.7.1.4.2.9.3.79 | Pseudarthrosis |
| 1.2.398.7.1.4.2.9.3.80 | Deformation of bones of upper extremities |
| 1.2.398.7.1.4.2.9.3.81 | Deformation of bones of lower extremities |
| 1.2.398.7.1.4.2.9.3.82 | Degenerative-dystrophic processes in bones |
| 1.2.398.7.1.4.2.9.3.83 | Hearing loss. deafness |
| 1.2.398.7.1.4.2.9.3.84 | Atrophy of mucous membrane of nasal cavity |
| 1.2.398.7.1.4.2.9.3.85 | Perforation of nasal septum |
| 1.2.398.7.1.4.2.9.3.86 | Scarring of nasal entrance |
| 1.2.398.7.1.4.2.9.3.87 | Cerebrospinal fluid leak from nose |
| 1.2.398.7.1.4.2.9.3.88 | Parathyroid insufficiency |
| 1.2.398.7.1.4.2.9.3.89 | Lymphorrhoea |
| 1.2.398.7.1.4.2.9.3.90 | Suture failure |
| 1.2.398.7.1.4.2.9.3.91 | Expulsive hemorrhage |
| 1.2.398.7.1.4.2.9.3.92 | Keratopathy |
| 1.2.398.7.1.4.2.9.3.93 | Hemophthalmos |
| 1.2.398.7.1.4.2.9.3.94 | Endophthalmitis |
| 1.2.398.7.1.4.2.9.3.95 | Remnants of lens masses |
| 1.2.398.7.1.4.2.9.3.96 | Small chamber syndrome |
| 1.2.398.7.1.4.2.9.3.97 | Compression syndrome of the eyeball |
| 1.2.398.7.1.4.2.9.3.98 | Detachment of the vascular membrane |
| 1.2.398.7.1.4.2.9.3.99 | Uterine perforation |
| 1.2.398.7.1.4.2.9.3.100 | Remains of a fetal egg |
| 1.2.398.7.1.4.2.9.3.101 | Vomiting after surgery on the gastrointestinal tract |
| 1.2.398.7.1.4.2.9.3.102 | Syndromes of the operated stomach |
| 1.2.398.7.1.4.2.9.3.103 | Malabsorption after surgery, not classified elsewhere |
| 1.2.398.7.1.4.2.9.3.104 | Postoperative intestinal obstruction |
| 1.2.398.7.1.4.2.9.3.105 | Dysfunction after colostomy and enterostomy |
| 1.2.398.7.1.4.2.9.3.106 | Postcholecystectomy syndrome |
| 1.2.398.7.1.4.2.9.3.107 | Other digestive disorders after medical procedures, not classified elsewhere |
| 1.2.398.7.1.4.2.9.3.108 | Digestive disorders after medical procedures, unspecified |
| 1.2.398.7.1.4.2.9.3.109 | Postoperative urethral stricture |
| 1.2.398.7.1.4.2.9.3.110 | Postoperative vaginal adhesions |
| 1.2.398.7.1.4.2.9.3.111 | Prolapse of the vaginal arch after uterine extirpation |
| 1.2.398.7.1.4.2.9.3.112 | Postoperative adhesions in the pelvis in women |
| 1.2.398.7.1.4.2.9.3.113 | Dysfunction of the external urinary tract stoma |
| 1.2.398.7.1.4.2.9.3.114 | Other disorders of the genitourinary system after medical procedures |
| 1.2.398.7.1.4.2.9.3.115 | Violation of the genitourinary system after medical procedures, unspecified |
| 1.2.398.7.1.4.2.9.3.116 | Postcardiotomy syndrome |
| 1.2.398.7.1.4.2.9.3.117 | Other functional disorders after heart surgery |
| 1.2.398.7.1.4.2.9.3.118 | Postmastectomy lymphatic edema syndrome |
| 1.2.398.7.1.4.2.9.3.119 | Other disorders of the circulatory system after medical procedures, not classified elsewhere |
| 1.2.398.7.1.4.2.9.3.120 | Circulatory system disorders after medical procedures, unspecified |
| 4. | 1.2.398.7.1.4.2.9.4 | Instructions after the operation | 1.2.398.7.1.4.2.9.4.1 | Postoperative wound care |
| 1.2.398.7.1.4.2.9.4.2 | Cold on the wound |
| 1.2.398.7.1.4.2.9.4.3 | Fall prevention |
| 1.2.398.7.1.4.2.9.4.4 | Accompany with movement |
| 1.2.398.7.1.4.2.9.4.5 | Care of catheters, drains, stoma, tube |
| 1.2.398.7.1.4.2.9.4.6 | Take measures to reduce pain |
| 1.2.398.7.1.4.2.9.4.7 | Assist with eating |
| 1.2.398.7.1.4.2.9.4.8 | Provide a bedpan |

**Ambulance and Air Ambulance Directory**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Item No. | Object identifier code of the directory | Name of the directory | Value object identifier code of the directory | Content |
| 1. | 1.2.398.7.1.4.2.10.1 | Fracture shape | 1.2.398.7.1.4.2.10.1.1 | Linear |
| 1.2.398.7.1.4.2.10.1.2 | Irregular |
| 1.2.398.7.1.4.2.10.1.3 | Multifragmentary |
| 2. | 1.2.398.7.1.4.2.10.2 | Direction of fracture lines | 1.2.398.7.1.4.2.10.2.1 | Vertical |
| 1.2.398.7.1.4.2.10.2.2 | Horizontal |
| 1.2.398.7.1.4.2.10.2.3 | Oblique-vertical in the direction from top to bottom, left to right |
| 3. | 1.2.398.7.1.4.2.10.3 | Damage shape | 1.2.398.7.1.4.2.10.3.1 | Linear |
| 1.2.398.7.1.4.2.10.3.2 | Rounded |
| 1.2.398.7.1.4.2.10.3.3 | Oval |
| 1.2.398.7.1.4.2.10.3.4 | Irregular oval |
| 1.2.398.7.1.4.2.10.3.5 | Triangular |
| 4. | 1.2.398.7.1.4.2.10.4 | Direction of physical damage | 1.2.398.7.1.4.2.10.4.1 | Vertical |
| 1.2.398.7.1.4.2.10.4.2 | Horizontal |
| 1.2.398.7.1.4.2.10.4.3 | Oblique-vertical in the direction from top to bottom, left to right |
| 5. | 1.2.398.7.1.4.2.10.5 | Condition of the bottom or covering crust | 1.2.398.7.1.4.2.10.5.1 | Moist, sunken in relation to the level of the surrounding skin |
| 1.2.398.7.1.4.2.10.5.2 | At the level of the surrounding skin, above the level of the surrounding skin, falls off peripherally |
| 1.2.398.7.1.4.2.10.5.3 | Area of ​​hyperpigmentation |
| 1.2.398.7.1.4.2.10.5.4 | Area of ​​hypopigmentation |
| 6. | 1.2.398.7.1.4.2.10.6 | Peculiarities of the condition of the surrounding soft tissues | 1.2.398.7.1.4.2.10.6.1 | Inflation |
| 1.2.398.7.1.4.2.10.6.2 | Hyperemic. |
| 1.2.398.7.1.4.2.10.6.3 | With overlapping blood, soil |
| 7. | 1.2.398.7.1.4.2.10.7 | Color of bruise | 1.2.398.7.1.4.2.10.7.1 | Reddish-bagroic |
| 1.2.398.7.1.4.2.10.7.2 | Livid purple |
| 1.2.398.7.1.4.2.10.7.3 | Brown |
| 1.2.398.7.1.4.2.10.7.4 | Greenish |
| 1.2.398.7.1.4.2.10.7.5 | Yellow |
| 8. | 1.2.398.7.1.4.2.10.8 | Shape and size of the wound at gaping and converging edges | 1.2.398.7.1.4.2.10.8.1 | Linear |
| 1.2.398.7.1.4.2.10.8.2 | Rope-shaped |
| 9. | 1.2.398.7.1.4.2.10.9 | Features of the wound edges | 1.2.398.7.1.4.2.10.9.1 | Sedimentation |
| 1.2.398.7.1.4.2.10.9.2 | Bruising |
| 1.2.398.7.1.4.2.10.9.3 | Detachment |
| 1.2.398.7.1.4.2.10.9.4 | Contamination |
| 1.2.398.7.1.4.2.10.9.5 | Foreign inclusions |
| 10. | 1.2.398.7.1.4.2.10.10 | Relief of beveling of the wound walls | 1.2.398.7.1.4.2.10.10.1 | Even |
| 1.2.398.7.1.4.2.10.10.2 | Smooth |
| 1.2.398.7.1.4.2.10.10.3 | Located vertically |
| 1.2.398.7.1.4.2.10.10.4 | One wall is beveled and the other is undermined |
| 11. | 1.2.398.7.1.4.2.10.11 | Features of the wound bottom | 1.2.398.7.1.4.2.10.11.1 | Presence of interstitial connective tissue bridges |
| 1.2.398.7.1.4.2.10.11.2 | Muscle damage |
| 1.2.398.7.1.4.2.10.11.3 | Bone injuries |
| 12. | 1.2.398.7.1.4.2.10.12 | Features of hair damage in the area of the wound | 1.2.398.7.1.4.2.10.12.1 | Transversely crossed in the initial and middle thirds of the wound |
| 1.2.398.7.1.4.2.10.12.2 | Crossed obliquely in the initial and middle thirds of the wound |
| 1.2.398.7.1.4.2.10.12.3 | In the terminal segment of the hair. |
| 1.2.398.7.1.4.2.10.12.4 | With the bulbs dislodged. |
| 13. | 1.2.398.7.1.4.2.10.13 | Features of microrelief on the plane of cut, cutting, sawing of cartilage, bone | 1.2.398.7.1.4.2.10.13.1 | Even |
| 1.2.398.7.1.4.2.10.13.2 | Irregular |
| 1.2.398.7.1.4.2.10.13.3 | Serrated |
| 14. | 1.2.398.7.1.4.2.10.14 | Behavior | 1.2.398.7.1.4.2.10.14.1 | Adequate |
| 1.2.398.7.1.4.2.10.14.2 | Passive, inhibited |
| 1.2.398.7.1.4.2.10.14.3 | Numbness |
| 1.2.398.7.1.4.2.10.14.4 | Excited |
| 1.2.398.7.1.4.2.10.14.5 | Fearful |
| 1.2.398.7.1.4.2.10.14.6 | Tearful |
| 15. | 1.2.398.7.1.4.2.10.15 | Reason for calling an ambulance team | 1.2.398.7.1.4.2.10.15.1 | Loss of consciousness (of any genesis) |
| 1.2.398.7.1.4.2.10.15.2 | Respiratory arrest |
| 1.2.398.7.1.4.2.10.15.3 | Cardiac arrest |
| 1.2.398.7.1.4.2.10.15.4 | Foreign body in the respiratory tract |
| 1.2.398.7.1.4.2.10.15.5 | Shock |
| 1.2.398.7.1.4.2.10.15.6 | Convulsions |
| 1.2.398.7.1.4.2.10.15.7 | Chest pain |
| 1.2.398.7.1.4.2.10.15.8 | Paresis and plegia (newly occurring) |
| 1.2.398.7.1.4.2.10.15.9 | Multiple injuries and wounds with bleeding |
| 1.2.398.7.1.4.2.10.15.10 | Wounds with bleeding |
| 1.2.398.7.1.4.2.10.15.11 | Isolated injury (head, neck) with bleeding |
| 1.2.398.7.1.4.2.10.15.12 | Extensive burns and frostbite |
| 1.2.398.7.1.4.2.10.15.13 | Animal and insect bites (stings) (risk of developing anaphylactic shock) |
| 1.2.398.7.1.4.2.10.15.14 | Electrical injury |
| 1.2.398.7.1.4.2.10.15.15 | Vomiting with blood |
| 1.2.398.7.1.4.2.10.15.16 | Childbirth with complications |
| 1.2.398.7.1.4.2.10.15.17 | Transportation of tissue (part of tissue), organs (part of organs) for subsequent transplantation |
| 1.2.398.7.1.4.2.10.15.18 | Emergencies |
| 1.2.398.7.1.4.2.10.15.19 | Consciousness is impaired, with a tendency to further depression |
| 1.2.398.7.1.4.2.10.15.20 | Severe disturbances of external respiration |
| 1.2.398.7.1.4.2.10.15.21 | Heart rhythm disturbances |
| 1.2.398.7.1.4.2.10.15.22 | Hemodynamics are unstable, high risk of developing shock, complicated crisis |
| 1.2.398.7.1.4.2.10.15.23 | Rash against the background of high temperature |
| 1.2.398.7.1.4.2.10.15.24 | Isolated trauma with bleeding |
| 1.2.398.7.1.4.2.10.15.25 | Toxic poisoning |
| 1.2.398.7.1.4.2.10.15.26 | Atypical pain (suspected acute coronary syndrome) |
| 1.2.398.7.1.4.2.10.15.27 | Headache in pregnant women |
| 1.2.398.7.1.4.2.10.15.28 | Psychosis of various etiologies |
| 1.2.398.7.1.4.2.10.15.29 | Isolated trauma without bleeding |
| 1.2.398.7.1.4.2.10.15.30 | Abdominal pain (acute abdomen) |
| 1.2.398.7.1.4.2.10.15.31 | High temperature above 38º C in children under 3 years of age and in pregnant women |
| 1.2.398.7.1.4.2.10.15.32 | Physiological birth |
| 1.2.398.7.1.4.2.10.15.33 | Abdominal pain in pregnant women (threat of miscarriage) |
| 1.2.398.7.1.4.2.10.15.34 | Limited burns and frostbite in children |
| 1.2.398.7.1.4.2.10.15.35 | Vomition plus loose stools with mild signs of dehydration |
| 1.2.398.7.1.4.2.10.15.36 | Acute diseases or exacerbations of chronic diseases, without obvious signs of a threat to life |
| 1.2.398.7.1.4.2.10.15.37 | Acute inflammatory and allergic diseases of the skin and subcutaneous tissue |
| 1.2.398.7.1.4.2.10.15.38 | Minor injuries (shallow wounds, burns, bruises, abrasions) |
| 1.2.398.7.1.4.2.10.15.39 | Pain syndrome caused by a chronic disease |
| 1.2.398.7.1.4.2.10.15.40 | Voming in pregnant women (up to 12 weeks) |
| 1.2.398.7.1.4.2.10.15.41 | Acute urinary retention caused by chronic diseases of the urinary system |
| 1.2.398.7.1.4.2.10.15.42 | Urine with blood |
| 1.2.398.7.1.4.2.10.15.43 | Inflammatory diseases after childbirth, abortions |
| 1.2.398.7.1.4.2.10.15.44 | Foreign bodies, except for the respiratory tract |
| 1.2.398.7.1.4.2.10.15.45 | Conditions requiring medical procedures in primary health care or hospital settings |
| 1.2.398.7.1.4.2.10.15.46 | Animal and insect bites (stings) |
| 1.2.398.7.1.4.2.10.15.47 | Arterial hypertension (without complicated crisis) |
| 1.2.398.7.1.4.2.10.15.48 | High temperature that does not subside on its own |
| 16. | 1.2.398.7.1.4.2.10.16 | Ambulance call category | 1.2.398.7.1.4.2.10.16.1 | Urgency category 1 (team arrival time - up to 10 minutes) |
| 1.2.398.7.1.4.2.10.16.2 | Urgency category 2 (team arrival time up to 15 minutes) |
| 1.2.398.7.1.4.2.10.16.3 | Urgency category 3 (team arrival time up to 30 minutes) |
| 1.2.398.7.1.4.2.10.16.4 | Urgency category 4 (team arrival time up to 60 minutes) |
| 17. | 1.2.398.7.1.4.2.10.17 | Orientation in space | 1.2.398.7.1.4.2.10.17.1 | In time |
| 1.2.398.7.1.4.2.10.17.2 | In place |
| 1.2.398.7.1.4.2.10.17.3 | In one's own personality |
| 18. | 1.2.398.7.1.4.2.10.18 | Result of ambulance team call | 1.2.398.7.1.4.2.10.18.1 | Transportation of the patient to a medical organization providing inpatient care |
| 1.2.398.7.1.4.2.10.18.2 | The patient is left at the call site |
| 1.2.398.7.1.4.2.10.18.3 | The patient is left at home (at the place of residence) |
| 19. | 1.2.398.7.1.4.2.10.19 | Pulse | 1.2.398.7.1.4.2.10.19.1 | Satisfactory |
| 1.2.398.7.1.4.2.10.19.2 | Rhythmic |
| 1.2.398.7.1.4.2.10.19.3 | Arrhythmic |
| 1.2.398.7.1.4.2.10.19.4 | Tense |
| 1.2.398.7.1.4.2.10.19.5 | Weak filling |
| 1.2.398.7.1.4.2.10.19.6 | Absent |
| 20. | 1.2.398.7.1.4.2.10.20 | Chest excursion | 1.2.398.7.1.4.2.10.20.1 | Normal |
| 1.2.398.7.1.4.2.10.20.2 | Reduced Right |
| 1.2.398.7.1.4.2.10.20.3 | Reduced Left |
| 1.2.398.7.1.4.2.10.20.4 | Pathological |
| 1.2.398.7.1.4.2.10.20.5 | No breathing |
| 21. | 1.2.398.7.1.4.2.10.21 | Percussion sound | 1.2.398.7.1.4.2.10.21.1 | Clear pulmonary |
| 1.2.398.7.1.4.2.10.21.2 | Dull (or blunt) |
| 1.2.398.7.1.4.2.10.21.3 | Tympanic |
| 1.2.398.7.1.4.2.10.21.4 | Hyperresonant |
| 22. | 1.2.398.7.1.4.2.10.22 | Auscultatory breathing | 1.2.398.7.1.4.2.10.22.1 | Vesicular |
| 1.2.398.7.1.4.2.10.22.2 | Puerile |
| 1.2.398.7.1.4.2.10.22.3 | Rigid |
| 1.2.398.7.1.4.2.10.22.4 | Weakened Right |
| 1.2.398.7.1.4.2.10.22.5 | Weakened Left |
| 1.2.398.7.1.4.2.10.22.6 | Bronchorrhea |
| 23. | 1.2.398.7.1.4.2.10.23 | Rale | 1.2.398.7.1.4.2.10.23.1 | No |
| 1.2.398.7.1.4.2.10.23.2 | Dry |
| 1.2.398.7.1.4.2.10.23.3 | Wet |
| 24. | 1.2.398.7.1.4.2.10.24 | Dyspnea | 1.2.398.7.1.4.2.10.24.1 | No |
| 1.2.398.7.1.4.2.10.24.2 | Expiratory |
| 1.2.398.7.1.4.2.10.24.3 | Inspiratory |
| 1.2.398.7.1.4.2.10.24.4 | Mixed |
| 25. | 1.2.398.7.1.4.2.10.25 | Meningeal symptoms  Eyeballs | 1.2.398.7.1.4.2.10.25.1 | Rigidity of the occipital muscles |
| 1.2.398.7.1.4.2.10.25.2 | Kernig's symptom (+-) |
| 1.2.398.7.1.4.2.10.25.3 | Brudzinski's symptom (+-) |
| 26. | 1.2.398.7.1.4.2.10.26 | Meningeal symptoms | 1.2.398.7.1.4.2.10.26.1 | Gaze paresis Right |
| 1.2.398.7.1.4.2.10.26.2 | Gaze paresis Left |
| 1.2.398.7.1.4.2.10.26.3 | Horizontal nystagmus |
| 1.2.398.7.1.4.2.10.26.4 | Vertical nystagmus |
| 27. | 1.2.398.7.1.4.2.10.27 | Eyeballs | 1.2.398.7.1.4.2.10.27.1 | Ptosis Right |
| 1.2.398.7.1.4.2.10.27.2 | Ptosis Left |
| 1.2.398.7.1.4.2.10.27.3 | Nasolabial fold, smoothed swallowing disorders |
| 1.2.398.7.1.4.2.10.27.4 | Tongue deviation Right |
| 1.2.398.7.1.4.2.10.27.5 | Tongue deviation Left |
| 1.2.398.7.1.4.2.10.27.6 | Corner of mouth drooping |
| 28. | 1.2.398.7.1.4.2.10.28 | Tendon reflexes | 1.2.398.7.1.4.2.10.28.1 | Normal |
| 1.2.398.7.1.4.2.10.28.2 | Symmetrically decreased |
| 1.2.398.7.1.4.2.10.28.3 | Right increased |
| 1.2.398.7.1.4.2.10.28.4 | Left increased |
| 1.2.398.7.1.4.2.10.28.5 | Upper increased |
| 1.2.398.7.1.4.2.10.28.6 | Lower increased |
| 1.2.398.7.1.4.2.10.28.7 | Right absent |
| 1.2.398.7.1.4.2.10.28.8 | Left absent |
| 1.2.398.7.1.4.2.10.28.9 | Upper absent |
| 1.2.398.7.1.4.2.10.28.10 | Lower absent |
| 1.2.398.7.1.4.2.10.28.11 | Absent |
| 29. | 1.2.398.7.1.4.2.10.29 | Kinetic sphere | 1.2.398.7.1.4.2.10.29.1 | Paresis |
| 1.2.398.7.1.4.2.10.29.2 | Plegia |
| 1.2.398.7.1.4.2.10.29.3 | Right muscle tone increased |
| 1.2.398.7.1.4.2.10.29.4 | Left muscle tone increased |
| 1.2.398.7.1.4.2.10.29.5 | Upper muscle tone increased |
| 1.2.398.7.1.4.2.10.29.6 | Lower muscle tone increased |
| 1.2.398.7.1.4.2.10.29.7 | Right muscle tone decreased |
| 1.2.398.7.1.4.2.10.29.8 | Left muscle tone decreased |
| 1.2.398.7.1.4.2.10.29.9 | Upper muscle tone decreased |
| 1.2.398.7.1.4.2.10.29.10 | Lower muscle tone decreased |
| 30. | 1.2.398.7.1.4.2.10.30 | Pain sensitivity | 1.2.398.7.1.4.2.10.30.1 | Decreased Right |
| 1.2.398.7.1.4.2.10.30.2 | Decreased Left |
| 1.2.398.7.1.4.2.10.30.3 | Upper Decreased |
| 1.2.398.7.1.4.2.10.30.4 | Lower Decreased |
| 1.2.398.7.1.4.2.10.30.5 | Increased Right |
| 1.2.398.7.1.4.2.10.30.6 | Increased Left |
| 1.2.398.7.1.4.2.10.30.7 | Increased Lower |
| 1.2.398.7.1.4.2.10.30.8 | Increased Upper |
| 31. | 1.2.398.7.1.4.2.10.31 | Aphasia | 1.2.398.7.1.4.2.10.31.1 | Motor |
| 1.2.398.7.1.4.2.10.31.2 | Sensor |
| 1.2.398.7.1.4.2.10.31.3 | Total |
| 32. | 1.2.398.7.1.4.2.10.32 | Babinski's Symptom | 1.2.398.7.1.4.2.10.32.1 | Right side |
| 1.2.398.7.1.4.2.10.32.2 | Left side |
| 33. | 1.2.398.7.1.4.2.10.33 | Oppenheim's Symptom | 1.2.398.7.1.4.2.10.33.1 | Right side |
| 1.2.398.7.1.4.2.10.33.2 | Left side |
| 34. | 1.2.398.7.1.4.2.10.34 | Oropharynx | 1.2.398.7.1.4.2.10.34.1 | Balanced |
| 1.2.398.7.1.4.2.10.34.2 | Hyperemia |
| 1.2.398.7.1.4.2.10.34.3 | Swelling |
| 35. | 1.2.398.7.1.4.2.10.35 | Tonsils | 1.2.398.7.1.4.2.10.35.1 | Enlarged |
| 1.2.398.7.1.4.2.10.35.2 | Loose |
| 1.2.398.7.1.4.2.10.35.3 | Tonsil stones |
| 36. | 1.2.398.7.1.4.2.10.36 | Tongue | 1.2.398.7.1.4.2.10.36.1 | Clean |
| 1.2.398.7.1.4.2.10.36.2 | Wet |
| 1.2.398.7.1.4.2.10.36.3 | Dry |
| 1.2.398.7.1.4.2.10.36.4 | Coated with plaque |
| 37. | 1.2.398.7.1.4.2.10.37 | Condition of the abdomen | 1.2.398.7.1.4.2.10.37.1 | Soft |
| 1.2.398.7.1.4.2.10.37.2 | Painless |
| 1.2.398.7.1.4.2.10.37.3 | Painful |
| 1.2.398.7.1.4.2.10.37.4 | Tense |
| 1.2.398.7.1.4.2.10.37.5 | Swollen |
| 38. | 1.2.398.7.1.4.2.10.38 | Density of parenchymatous organs | 1.2.398.7.1.4.2.10.38.1 | Normal |
| 1.2.398.7.1.4.2.10.38.2 | Enlarged |
| 1.2.398.7.1.4.2.10.38.3 | Dense |
| 1.2.398.7.1.4.2.10.38.4 | Painful |
| 39. | 1.2.398.7.1.4.2.10.39 | Urine flow | 1.2.398.7.1.4.2.10.39.1 | Normal |
| 1.2.398.7.1.4.2.10.39.2 | Dysuria |
| 40. | 1.2.398.7.1.4.2.10.40 | Abdomen shape | 1.2.398.7.1.4.2.10.40.1 | Ovoid |
| 1.2.398.7.1.4.2.10.40.2 | Rounded |
| 41. | 1.2.398.7.1.4.2.10.41 | Uterine tone | 1.2.398.7.1.4.2.10.41.1 | Norm |
| 1.2.398.7.1.4.2.10.41.2 | Contractions |
| 42. | 1.2.398.7.1.4.2.10.42 | Peripheral edema | 1.2.398.7.1.4.2.10.42.1 | Absent |
| 1.2.398.7.1.4.2.10.42.2 | Pastosity |
| 1.2.398.7.1.4.2.10.42.3 | Swelling |
| 43. | 1.2.398.7.1.4.2.10.43 | Uterine tone | 1.2.398.7.1.4.2.10.43.1 | Without violations |
| 1.2.398.7.1.4.2.10.43.2 | With violations |
| 44. | 1.2.398.7.1.4.2.10.44 | Body type | 1.2.398.7.1.4.2.10.44.1 | Asthenic |
| 1.2.398.7.1.4.2.10.44.2 | Normsthenic |
| 1.2.398.7.1.4.2.10.44.3 | Hypersthenic |
| 45. | 1.2.398.7.1.4.2.10.45 | Consciousness | 1.2.398.7.1.4.2.10.45.1 | Clear |
| 1.2.398.7.1.4.2.10.45.2 | 1st degree stupefaction |
| 1.2.398.7.1.4.2.10.45.3 | 2nd degree stupefaction |
| 1.2.398.7.1.4.2.10.45.4 | Stupor |
| 1.2.398.7.1.4.2.10.45.5 | 1st degree coma |
| 1.2.398.7.1.4.2.10.45.6 | 2nd degree coma |
| 1.2.398.7.1.4.2.10.45.7 | 3rd degree coma |
| 1.2.398.7.1.4.2.10.45.8 | Absent |
| 46. | 1.2.398.7.1.4.2.10.46 | Glasgow coma scale | 1.2.398.7.1.4.2.10.46.1 | 1 |
| 1.2.398.7.1.4.2.10.46.2 | 2 |
| 1.2.398.7.1.4.2.10.46.3 | 3 |
| 1.2.398.7.1.4.2.10.46.4 | 4 |
| 1.2.398.7.1.4.2.10.46.5 | 5 |
| 1.2.398.7.1.4.2.10.46.6 | 6 |
| 1.2.398.7.1.4.2.10.46.7 | 7 |
| 1.2.398.7.1.4.2.10.46.8 | 8 |
| 1.2.398.7.1.4.2.10.46.9 | 9 |
| 1.2.398.7.1.4.2.10.46.10 | 10 |
| 1.2.398.7.1.4.2.10.46.11 | 11 |
| 1.2.398.7.1.4.2.10.46.12 | 12 |
| 1.2.398.7.1.4.2.10.46.13 | 13 |
| 1.2.398.7.1.4.2.10.46.14 | 14 |
| 1.2.398.7.1.4.2.10.46.15 | 15 |
| 47. | 1.2.398.7.1.4.2.10.47 | Pupils | 1.2.398.7.1.4.2.10.47.1 | Normal |
| 1.2.398.7.1.4.2.10.47.2 | Miosis |
| 1.2.398.7.1.4.2.10.47.3 | Mydriasis |
| 48. | 1.2.398.7.1.4.2.10.48 | Reaction to light | 1.2.398.7.1.4.2.10.48.1 | Lively |
| 1.2.398.7.1.4.2.10.48.2 | Weakened |
| 1.2.398.7.1.4.2.10.48.3 | Absent |
| 1.2.398.7.1.4.2.10.48.4 | Anisocoria DS |
| 49. | 1.2.398.7.1.4.2.10.49 | Heart tones | 1.2.398.7.1.4.2.10.49.1 | Clear |
| 1.2.398.7.1.4.2.10.49.2 | Muffled |
| 1.2.398.7.1.4.2.10.49.3 | Dull |
| 50. | 1.2.398.7.1.4.2.10.50 | Heart murmurs | 1.2.398.7.1.4.2.10.50.1 | None |
| 1.2.398.7.1.4.2.10.50.2 | Systolic |
| 1.2.398.7.1.4.2.10.50.3 | Diastolic |

**Rehabilitation Service Directories**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Item No. | Object identifier code of the directory | Name of the directory | Value object identifier code of the directory | Content |
| 1. | 1.2.398.7.1.4.2.11.1 | Rehabilitation Route Scale | 1.2.398.7.1.4.2.11.1.1 | Very high potential |
| 1.2.398.7.1.4.2.11.1.2 | High potential |
| 1.2.398.7.1.4.2.11.1.3 | Average potential |
| 1.2.398.7.1.4.2.11.1.4 | Below average potential |
| 1.2.398.7.1.4.2.11.1.5 | Low potential |
| 2. | 1.2.398.7.1.4.2.11.2 | Rehabilitation Potential Assessment Scale | 1.2.398.7.1.4.2.11.2.1 | Anatomical limitations (motor, sensory) |
| 1.2.398.7.1.4.2.11.2.2 | Cognitive and speech impairments (speech impairments, cognitive impairments, communication level) |
| 1.2.398.7.1.4.2.11.2.3 | Social adaptation scale scores (dependency scale/degree) |
| 3. | 1.2.398.7.1.4.2.11.3 | Rehabilitation stage | 1.2.398.7.1.4.2.11.3.1 | First stage |
| 1.2.398.7.1.4.2.11.3.2 | Second stage |
| 1.2.398.7.1.4.2.11.3.3 | Third stage |
| 4. | 1.2.398.7.1.4.2.11.4 | Rehabilitation plan | 1.2.398.7.1.4.2.11.4.1 | Medical rehabilitation activities |
| 1.2.398.7.1.4.2.11.4.2 | Provision of prosthetic and orthopedic devices |
| 1.2.398.7.1.4.2.11.4.3 | Provision of deaf technical devices |
| 1.2.398.7.1.4.2.11.4.4 | Provision of typhlotechnical devices |
| 1.2.398.7.1.4.2.11.4.5 | Provision of special means of transportation |
| 1.2.398.7.1.4.2.11.4.6 | Provision of mandatory hygiene products |
| 1.2.398.7.1.4.2.11.4.7 | Provision of personal assistant services |
| 1.2.398.7.1.4.2.11.4.8 | Provision of sign language specialist services |
| 1.2.398.7.1.4.2.11.4.9 | Sanatorium and resort treatment |
| 1.2.398.7.1.4.2.11.4.10 | Provision of special social services |
| 1.2.398.7.1.4.2.11.4.11 | Assistance in employment |
| 1.2.398.7.1.4.2.11.4.12 | Assistance in training/retraining |
| 5. | 1.2.398.7.1.4.2.11.5 | Patient rehabilitation profile | 1.2.398.7.1.4.2.11.5.1 | Neurological |
| 1.2.398.7.1.4.2.11.5.2 | Neurosurgical |
| 1.2.398.7.1.4.2.11.5.3 | Cardiological |
| 1.2.398.7.1.4.2.11.5.4 | Cardiac surgery |
| 1.2.398.7.1.4.2.11.5.5 | Traumatological |
| 1.2.398.7.1.4.2.11.5.6 | Orthopedic |
| 1.2.398.7.1.4.2.11.5.7 | Other |
| 6. | 1.2.398.7.1.4.2.11.6 | Efficiency of medical rehabilitation | 1.2.398.7.1.4.2.11.6.1 | R2 <1 – unsatisfactory efficiency |
| 1.2.398.7.1.4.2.11.6.2 | 1<1.5 – satisfactory |
| 1.2.398.7.1.4.2.11.6.3 | 1.5–2.0 – good |
| 1.2.398.7.1.4.2.11.6.4 | >2.0 – significant |
| 7. | 1.2.398.7.1.4.2.11.7 | Achieving the rehabilitation goal of the current treatment | 1.2.398.7.1.4.2.11.7.1 | Achieved |
| 1.2.398.7.1.4.2.11.7.2 | Not achieved |
| 1.2.398.7.1.4.2.11.7.3 | Partially achieved |
| 8. | 1.2.398.7.1.4.2.11.8 | Rehabilitation prognosis | 1.2.398.7.1.4.2.11.8.1 | Favorable |
| 1.2.398.7.1.4.2.11.8.2 | Relatively favorable |
| 1.2.398.7.1.4.2.11.8.3 | Doubtful |
| 1.2.398.7.1.4.2.11.8.4 | Unfavorable |
| 9. | 1.2.398.7.1.4.2.11.9 | Rehabilitation level | 1.2.398.7.1.4.2.11.9.1 | Outpatient |
| 1.2.398.7.1.4.2.11.9.2 | Inpatient |
| 10. | 1.2.398.7.1.4.2.11.10 | Rehabilitation type | 1.2.398.7.1.4.2.11.10.1 | Physical rehabilitation |
| 1.2.398.7.1.4.2.11.10.2 | Physiotherapy |
| 1.2.398.7.1.4.2.11.10.3 | Psychocorrection |
| 1.2.398.7.1.4.2.11.10.4 | Egotherapy |
| 1.2.398.7.1.4.2.11.10.5 | Social worker consultation |
| 1.2.398.7.1.4.2.11.10.6 | Patient education |
| 1.2.398.7.1.4.2.11.10.7 | Reconstructive surgery |
| 1.2.398.7.1.4.2.11.10.8 | Rehabilitation in day hospitals |
| 1.2.398.7.1.4.2.11.10.9 | Rehabilitation in 24-hour hospitals |
| 1.2.398.7.1.4.2.11.10.10 | Rehabilitation in rehabilitation centers |
| 1.2.398.7.1.4.2.11.10.11 | Rehabilitation in hospitals at home |
| 1.2.398.7.1.4.2.11.10.12 | Rehabilitation in outpatient clinics |
| 1.2.398.7.1.4.2.11.10.13 | Sanatorium and resort treatment |
| 1.2.398.7.1.4.2.11.10.14 | Additional services |
| 11. | 1.2.398.7.1.4.2.11.11 | Evaluation of the results of medical rehabilitation | 1.2.398.7.1.4.2.11.11.1 | Full recovery of impaired functions |
| 1.2.398.7.1.4.2.11.11.2 | Partial restoration of impaired functions |
| 1.2.398.7.1.4.2.11.11.3 | Full compensation of disturbed functions |
| 1.2.398.7.1.4.2.11.11.4 | Partial compensation of disturbed functions |
| 1.2.398.7.1.4.2.11.11.5 | No positive result |
| 12. | 1.2.398.7.1.4.2.11.12 | Rehabilitation potential | 1.2.398.7.1.4.2.11.12.1 | High |
| 1.2.398.7.1.4.2.11.12.2 | Medium |
| 1.2.398.7.1.4.2.11.12.3 | Low |
| 1.2.398.7.1.4.2.11.12.4 | None |

**Oncology Service Directories**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Item No. | Object identifier code of the directory | Name of the directory | Value object identifier code of the directory | Content |
| 1. | 1.2.398.7.1.4.2.12.1 | Method for detecting malignant neoplasms | 1.2.398.7.1.4.2.12.1.1 | Self-referral |
| 1.2.398.7.1.4.2.12.1.2 | Preventive examination |
| 1.2.398.7.1.4.2.12.1.3 | Screening |
| 2. | 1.2.398.7.1.4.2.12.2 | Stage of tumor process | 1.2.398.7.1.4.2.12.2.1 | I |
| 1.2.398.7.1.4.2.12.2.2 | Ia |
| 1.2.398.7.1.4.2.12.2.3 | Ib |
| 1.2.398.7.1.4.2.12.2.4 | Ic |
| 1.2.398.7.1.4.2.12.2.5 | II |
| 1.2.398.7.1.4.2.12.2.6 | IIa |
| 1.2.398.7.1.4.2.12.2.7 | IIb |
| 1.2.398.7.1.4.2.12.2.8 | IIc |
| 1.2.398.7.1.4.2.12.2.9 | III |
| 1.2.398.7.1.4.2.12.2.10 | IIIa |
| 1.2.398.7.1.4.2.12.2.11 | IIIb |
| 1.2.398.7.1.4.2.12.2.12 | IIIc |
| 1.2.398.7.1.4.2.12.2.13 | IV |
| 1.2.398.7.1.4.2.12.2.14 | IVa |
| 1.2.398.7.1.4.2.12.2.15 | IVb |
| 1.2.398.7.1.4.2.12.2.16 | IVc |
| 1.2.398.7.1.4.2.12.2.17 | In situ |
| 1.2.398.7.1.4.2.12.2.18 | Not applicable |
| 1.2.398.7.1.4.2.12.2.19 | Unknown |
| 1.2.398.7.1.4.2.12.2.20 | Other |
| 3. | 1.2.398.7.1.4.2.12.3 | Treatment type | 1.2.398.7.1.4.2.12.3.1 | Radiation therapy |
| 1.2.398.7.1.4.2.12.3.2 | Surgical |
| 1.2.398.7.1.4.2.12.3.3 | Chemotherapeutic treatment |
| 1.2.398.7.1.4.2.12.3.4 | Targeted therapy |
| 1.2.398.7.1.4.2.12.3.5 | Symptomatic treatment |
| 1.2.398.7.1.4.2.12.3.6 | Immuno-oncological therapy |
| 1.2.398.7.1.4.2.12.3.7 | Palliative |
| 1.2.398.7.1.4.2.12.3.8 | Rehabilitation |
| 1.2.398.7.1.4.2.12.3.9 | Radionuclide therapy |
| 1.2.398.7.1.4.2.12.3.10 | Radiosurgical treatment |
| 1.2.398.7.1.4.2.12.3.11 | Hormonal therapy |
| 1.2.398.7.1.4.2.12.3.12 | Photodynamic therapy |
| 1.2.398.7.1.4.2.12.3.13 | Bone resorption inhibitors |
| 1.2.398.7.1.4.2.12.3.14 | Cryotherapy |
| 1.2.398.7.1.4.2.12.3.15 | Combination treatment |
| 1.2.398.7.1.4.2.12.3.16 | Chemoradiation |
| 1.2.398.7.1.4.2.12.3.17 | Laser therapy |
| 1.2.398.7.1.4.2.12.3.18 | Proton therapy |

**Classification in the field of digital health**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Item No. | Object identifier code of the directory | Name of the classification | Value object identifier code of the directory | Content |
| 1. | 1.2.398.7.1.4.3.1 | Classification of body parts | 1.2.398.7.1.4.3.1.1 | Left |
| 1.2.398.7.1.4.3.1.2 | Right |
| 1.2.398.7.1.4.3.1.3 | Head areas |
| 1.2.398.7.1.4.3.1.4 | Frontal area |
| 1.2.398.7.1.4.3.1.5 | Parietal region |
| 1.2.398.7.1.4.3.1.6 | Temporal region |
| 1.2.398.7.1.4.3.1.7 | Occipital region |
| 1.2.398.7.1.4.3.1.8 | Mastoid region |
| 1.2.398.7.1.4.3.1.9 | Ocular region |
| 1.2.398.7.1.4.3.1.10 | Suborbital region |
| 1.2.398.7.1.4.3.1.11 | Cheekbone region |
| 1.2.398.7.1.4.3.1.12 | Nasal region |
| 1.2.398.7.1.4.3.1.13 | Mouth area |
| 1.2.398.7.1.4.3.1.14 | Chin area |
| 1.2.398.7.1.4.3.1.15 | Cheek area |
| 1.2.398.7.1.4.3.1.16 | Peri-mandibular region |
| 1.2.398.7.1.4.3.1.17 | Neck areas |
| 1.2.398.7.1.4.3.1.18 | Large supraclavicular fossa (scapuloclavicular triangle) |
| 1.2.398.7.1.4.3.1.19 | Jugular notch of the sternum |
| 1.2.398.7.1.4.3.1.20 | Small supraclavicular fossa |
| 1.2.398.7.1.4.3.1.21 | Area of the sternoclavicular-papillary muscle |
| 1.2.398.7.1.4.3.1.22 | Anterior triangle of the neck area (scapulotracheal triangle) |
| 1.2.398.7.1.4.3.1.23 | Malgaigne's triangle |
| 1.2.398.7.1.4.3.1.24 | Posterior triangle of the neck (scapulotrapezoid triangle) |
| 1.2.398.7.1.4.3.1.25 | Submandibular triangle |
| 1.2.398.7.1.4.3.1.26 | Subchondral triangle |
| 1.2.398.7.1.4.3.1.27 | Posterior surface of the neck |
| 1.2.398.7.1.4.3.1.28 | Chest areas |
| 1.2.398.7.1.4.3.1.29 | Pre-chest area |
| 1.2.398.7.1.4.3.1.30 | Chest area |
| 1.2.398.7.1.4.3.1.31 | Subpectoral region |
| 1.2.398.7.1.4.3.1.32 | Axillary area |
| 1.2.398.7.1.4.3.1.33 | Back areas |
| 1.2.398.7.1.4.3.1.34 | Scapular region |
| 1.2.398.7.1.4.3.1.35 | Subscapular region |
| 1.2.398.7.1.4.3.1.36 | Vertebral region |
| 1.2.398.7.1.4.3.1.37 | Lumbar region |
| 1.2.398.7.1.4.3.1.38 | Sacral region |
| 1.2.398.7.1.4.3.1.39 | Abdominal areas |
| 1.2.398.7.1.4.3.1.40 | Epigastric region |
| 1.2.398.7.1.4.3.1.41 | Left subcostal region |
| 1.2.398.7.1.4.3.1.42 | Right subcostal region |
| 1.2.398.7.1.4.3.1.43 | Umbilical region |
| 1.2.398.7.1.4.3.1.44 | Lateral abdominal region |
| 1.2.398.7.1.4.3.1.45 | Hypogastric (suprapubic) region |
| 1.2.398.7.1.4.3.1.46 | Left iliac (inguinal) region |
| 1.2.398.7.1.4.3.1.47 | Right iliac (inguinal) region |
| 1.2.398.7.1.4.3.1.48 | Perineum |
| 1.2.398.7.1.4.3.1.49 | Female perineum |
| 1.2.398.7.1.4.3.1.50 | Male perineum |
| 1.2.398.7.1.4.3.1.51 | Perianal superficial area |
| 1.2.398.7.1.4.3.1.52 | Upper extremity areas |
| 1.2.398.7.1.4.3.1.53 | Left upper extremity |
| 1.2.398.7.1.4.3.1.54 | Right upper extremity |
| 1.2.398.7.1.4.3.1.55 | Deltoid region |
| 1.2.398.7.1.4.3.1.56 | Anterior surface of the shoulder |
| 1.2.398.7.1.4.3.1.57 | Posterior surface of the shoulder |
| 1.2.398.7.1.4.3.1.58 | Anterior surface of the elbow |
| 1.2.398.7.1.4.3.1.59 | Posterior surface of the elbow |
| 1.2.398.7.1.4.3.1.60 | Anterior surface of the forearm |
| 1.2.398.7.1.4.3.1.61 | Posterior surface of the forearm |
| 1.2.398.7.1.4.3.1.62 | Dorsal surface of the wrist |
| 1.2.398.7.1.4.3.1.63 | Flexor surface of the wrist |
| 1.2.398.7.1.4.3.1.64 | Dorsal (back) surface of the hand |
| 1.2.398.7.1.4.3.1.65 | Hypotener area |
| 1.2.398.7.1.4.3.1.66 | Palmar surface of the hand |
| 1.2.398.7.1.4.3.1.67 | Tener area |
| 1.2.398.7.1.4.3.1.68 | Finger of the hand |
| 1.2.398.7.1.4.3.1.69 | Finger of the left hand |
| 1.2.398.7.1.4.3.1.70 | Thumb of the left hand |
| 1.2.398.7.1.4.3.1.71 | Index finger of the left hand |
| 1.2.398.7.1.4.3.1.72 | Middle finger of the left hand |
| 1.2.398.7.1.4.3.1.73 | Ring finger of the left hand |
| 1.2.398.7.1.4.3.1.74 | Little finger of the left hand |
| 1.2.398.7.1.4.3.1.75 | Finger of the right hand |
| 1.2.398.7.1.4.3.1.76 | Thumb of the right hand |
| 1.2.398.7.1.4.3.1.77 | Index finger of the right hand |
| 1.2.398.7.1.4.3.1.78 | Middle finger of the right hand |
| 1.2.398.7.1.4.3.1.79 | Ring finger of the right hand |
| 1.2.398.7.1.4.3.1.80 | Little finger of the right hand |
| 1.2.398.7.1.4.3.1.81 | Phalanx of the hand |
| 1.2.398.7.1.4.3.1.82 | Distal phalanx of the hand |
| 1.2.398.7.1.4.3.1.83 | Middle phalanx of the hand |
| 1.2.398.7.1.4.3.1.84 | Proximal phalanx of the hand |
| 1.2.398.7.1.4.3.1.85 | Lower limb regions |
| 1.2.398.7.1.4.3.1.86 | Left lower limb |
| 1.2.398.7.1.4.3.1.87 | Right lower limb |
| 1.2.398.7.1.4.3.1.88 | Gluteal region |
| 1.2.398.7.1.4.3.1.89 | Lateral surface of the thigh |
| 1.2.398.7.1.4.3.1.90 | Anterior surface of the thigh |
| 1.2.398.7.1.4.3.1.91 | Back surface of the thigh |
| 1.2.398.7.1.4.3.1.92 | Anterior surface of the knee |
| 1.2.398.7.1.4.3.1.93 | Lateral surface of the knee |
| 1.2.398.7.1.4.3.1.94 | Medial surface of the knee |
| 1.2.398.7.1.4.3.1.95 | Populitic surface |
| 1.2.398.7.1.4.3.1.96 | Anterior surface of the leg |
| 1.2.398.7.1.4.3.1.97 | Posterior surface of the leg |
| 1.2.398.7.1.4.3.1.98 | Anterior surface of the ankle |
| 1.2.398.7.1.4.3.1.99 | Lateral surface of the ankle |
| 1.2.398.7.1.4.3.1.100 | Medial surface of the ankle |
| 1.2.398.7.1.4.3.1.101 | Posterior surface of the ankle |
| 1.2.398.7.1.4.3.1.102 | Dorsal (back) surface of the foot |
| 1.2.398.7.1.4.3.1.103 | Lateral surface of the foot |
| 1.2.398.7.1.4.3.1.104 | Medial surface of the foot |
| 1.2.398.7.1.4.3.1.105 | Heel surface of the foot |
| 1.2.398.7.1.4.3.1.106 | Plantar surface of the foot |
| 1.2.398.7.1.4.3.1.107 | Toe of the foot |
| 1.2.398.7.1.4.3.1.108 | Toe of the left foot |
| 1.2.398.7.1.4.3.1.109 | Toe of the right foot |
| 1.2.398.7.1.4.3.1.110 | Big toe of the foot |
| 1.2.398.7.1.4.3.1.111 | Index toe of the foot |
| 1.2.398.7.1.4.3.1.112 | Middle toe of the foot |
| 1.2.398.7.1.4.3.1.113 | Ring toe |
| 1.2.398.7.1.4.3.1.114 | Little toe |
| 1.2.398.7.1.4.3.1.115 | Phalanx of the foot |
| 1.2.398.7.1.4.3.1.116 | Distal phalanx of the foot |
| 1.2.398.7.1.4.3.1.117 | Middle phalanx of the foot |
| 1.2.398.7.1.4.3.1.118 | Proximal phalanx of the foot |
| 1.2.398.7.1.4.3.1.119 | Joints |
| 1.2.398.7.1.4.3.1.120 | Left shoulder joint |
| 1.2.398.7.1.4.3.1.121 | Right shoulder joint |
| 1.2.398.7.1.4.3.1.122 | Left elbow joint |
| 1.2.398.7.1.4.3.1.123 | Right elbow joint |
| 1.2.398.7.1.4.3.1.124 | Left wrist joint |
| 1.2.398.7.1.4.3.1.125 | Right wrist joint |
| 1.2.398.7.1.4.3.1.126 | Left hip joint |
| 1.2.398.7.1.4.3.1.127 | Right hip joint |
| 1.2.398.7.1.4.3.1.128 | Left knee joint |
| 1.2.398.7.1.4.3.1.129 | Right knee joint |
| 1.2.398.7.1.4.3.1.130 | Left ankle joint |
| 1.2.398.7.1.4.3.1.131 | Right ankle joint |

© 2012. «Institute of legislation and legal information of the Republic of Kazakhstan» of the Ministry of Justice of the Republic of Kazakhstan